---
document_datetime: 2023-09-21 22:25:14
document_pages: 144
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/adakveo-epar-public-assessment-report_en.pdf
document_name: adakveo-epar-public-assessment-report_en.pdf
version: success
processing_time: 90.7609534
conversion_datetime: 2025-12-28 03:19:25.290146
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

23 July 2020 EMA/427120/2020 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report Adakveo International non-proprietary name: crizanlizumab Procedure No. EMEA/H/C/004874/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

Administrative information Name of the medicinal product: Adakveo Applicant: Active substance: crizanlizumab International Non-proprietary Name: crizanlizumab Pharmaco-therapeutic group (ATC Code): B06AX01 Therapeutic indication: Adakveo is indicated for the prevention of recurrent vaso-occlusive crises (VOCs) in sickle cell disease patients aged 16 years and older. It can be given as an add-on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate. Pharmaceutical form: Concentrate for solution for infusion Strength: 10 mg/ml Route of administration: Intravenous use Packaging: vial (glass) Package size: 1 vial Medicinal product no longer authorised

Novartis Europharm Limited

Vista Building

Elm Park

Merrion Road

Dublin 4

IRELAND

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure............................................                                            | 13 authorised                                                                                            |
|-----------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier ...................................................................................                | 13                                                                                                       |
| 1.2. Steps taken for the assessment of the product                                                                                | ...................................................... 14                                                |
| 2. Scientific discussion..............................................................................                            | 16                                                                                                       |
| 2.1. Problem statement.............................................................................................               | 16                                                                                                       |
| 2.1.1. Disease or condition                                                                                                       | ........................................................................................ 16              |
| 2.1.2. Epidemiology                                                                                                               | .................................................................................................. 16    |
| 2.1.3. Aetiology and pathogenesis ..............................................................................                  | 16                                                                                                       |
| 2.1.4. Clinical presentation, diagnosis and prognosis.....................................................                        | 17                                                                                                       |
| 2.1.5. Management...................................................................................................              | 17                                                                                                       |
| 2.2. Quality aspects ..................................................................................................           | 20                                                                                                       |
| 2.2.1. Introduction....................................................................................................           | 20                                                                                                       |
| 2.2.2. Active Substance.............................................................................................              | 20                                                                                                       |
| 2.2.3. Finished Medicinal Product................................................................................                 | 26                                                                                                       |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects.............................. longer                         | 32                                                                                                       |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects no                                                      | ...................... 33                                                                                |
| 2.2.6. Recommendations for future quality development                                                                             | ............................................... 33                                                       |
| 2.3. Non-clinical aspects............................................................................................             | 33                                                                                                       |
| 2.3.1. Introduction....................................................................................................           | 33                                                                                                       |
| 2.3.2. Pharmacology .................................................................................................             | 33                                                                                                       |
| 2.3.3. Pharmacokinetics                                                                                                           | ............................................................................................ 36          |
| 2.3.4. Toxicology......................................................................................................           | 37                                                                                                       |
| 2.3.5. Ecotoxicity/environmental risk assessment.........................................................                         | 40                                                                                                       |
| 2.3.6. Discussion on non-clinical aspects .....................................................................                   | 40                                                                                                       |
| 2.3.7. Conclusion on the non-clinical aspects product                                                                             | ............................................................... 43                                       |
| 2.4. Clinical aspects ..................................................................................................          | 43                                                                                                       |
| 2.4.1. Introduction....................................................................................................           | 43                                                                                                       |
| 2.4.2. Pharmacokinetics ............................................................................................              | 44                                                                                                       |
| 2.4.3. Pharmacodynamics..........................................................................................                 | 53                                                                                                       |
| 2.4.4. Discussion on clinical pharmacology...................................................................                     | 58                                                                                                       |
| 2.4.5. Conclusions on clinical pharmacology.................................................................                      | 60                                                                                                       |
| 2.5. Clinical efficacy                                                                                                            | .................................................................................................. 61    |
| 2.5.1. Dose response study........................................................................................                | 61                                                                                                       |
| 2.5.2. Main study ..................................................................................................... Medicinal | 61                                                                                                       |
| Ancillary analyses ........................................................ Error! Bookmark not defined.                          | Ancillary analyses ........................................................ Error! Bookmark not defined. |
| 2.5.3. Discussion on clinical efficacy............................................................................                | 92                                                                                                       |
| 2.5.4. Conclusions on the clinical efficacy ....................................................................                  | 97                                                                                                       |
| 2.6. Clinical safety                                                                                                              | .................................................................................................... 97  |
| 2.6.1. Discussion on clinical safety............................................................................                  | 118                                                                                                      |
| 2.6.2. Conclusions on the clinical safety                                                                                         | .................................................................... 122                                 |

<div style=\"page-break-after: always\"></div>

| 2.7. Risk Management Plan...................................................................................... 123            |
|--------------------------------------------------------------------------------------------------------------------------------|
| 2.8. Pharmacovigilance ........................................................................................... 125         |
| 2.9. New Active Substance ...................................................................................... 126           |
| 2.10. Significance of paediatric studies...................................................................... 126             |
| 2.11. Product information ........................................................................................ 126         |
| 2.11.1. User consultation......................................................................................... 126         |
| 2.11.2. Additional monitoring................................................................................... 126           |
| 3. Benefit-Risk Balance ........................................................................... 127                        |
| 3.1. Therapeutic Context ......................................................................................... 127         |
| 3.1.1. Disease or condition ...................................................................................... 127         |
| 3.1.2. Available therapies and unmet medical need..................................................... 127 authorised          |
| 3.1.3. Main clinical studies....................................................................................... 127        |
| 3.2. Favourable effects............................................................................................ 128 longer |
| 3.3. Uncertainties and limitations about favourable effects........................................... 129                     |
| 3.4. Unfavourable effects......................................................................................... 130         |
| 3.5. Uncertainties and limitations about unfavourable effects ....................................... 132                      |
| 3.6. Effects Table.................................................................................................... 134     |
| 3.7. Benefit-risk assessment and discussion............................................................... 137                 |
| 3.7.1. Importance of favourable and unfavourable effects............................................ 137 no                    |
| 3.7.2. Balance of benefits and risks .......................................................................... 139            |
| 3.7.3. Additional considerations on the benefit-risk balance ......................................... 140                     |
| 3.8. Conclusions ..................................................................................................... 142     |

Medicinal product no longer authorised

## List of abbreviations Quality Aa Amino acid ADCC Antibody dependent cellular cytotoxicity AET Analytical evaluation threshold AEX Anion exchange chromatography AF4 Asymmetrical flow field-flow fractionation ALC Affinity ligand chromatography AUC Analytical ultracentrifugation BET Bacterial endotoxin test BI Bioindicator ByPV Bovine Polyomavirus C1q Subcomponent of the first complement factor CCIT Container closure integrity test CCS Container closure system CD Circular dichroism CDC Complement dependent cytotoxicity CDR1 Complementarity-determining region 1 CEC Cation exchange chromatography (drug substance manufacturing process) CE-SDS Capillary electrophoresis sodium dodecyl sulphate CFU Colony-forming units CHO Chinese hamster ovary (cells) CIP Clean in place CPP(s) Critical process parameter(s) CQA Critical quality attribute CR Characterisation range CRF Cell removal and filtration (drug substance manufacturing step) CZE Capillary zone electrophoresis DMSO Dimethyl sulfoxide DNA Deoxyribonucleic acid DLS Differential light scattering DoE Design of experiments DP Drug product DS Drug substance DSC Differential scanning calorimetry EAC Equivalence acceptance criterion ECB Extended cell bank ELISA Enzyme-linked immunosorbent assay ESI-MS Electrospray ionization-mass spectrometry ETFE Ethylene tetrafluoroethylene EU Endotoxin units Fab Fragment antigen binding Fc Fragment crystallisable Fc  R(s) Fc gamma receptor(s) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

<!-- image -->

FcRn Neonatal Fc receptor GMP Good manufacturing practices HC Heavy chain HCP Host cell protein HDPE High density polyethylene ICH International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use icIEF Imaged capillary isoelectric focussing IgG Immunoglobulin G IPC(s) In-process control(s) KPP(s) Key process parameter(s) LC Light chain LC-UV Liquid chromatography with UV absorption detection LIVCA Limit of in vitro cell age LOQ Limit of quantitation mAb Monoclonal antibody MAC Multimodal anion exchange chromatography (drug substance manufacturing process) MCB Master cell bank MDI Maximum daily intake MET Microbial enumeration test MFI Micro flow imaging MIA Manufacturing authorisation MO Major objection MVM Minute virus of mice NA Not applicable NKPP Non-key process parameter OC Other concern PAR Proven acceptable range PC Process characterisation PCR Polymerase chain reaction PET Polyethylene terephthalate Ph. Eur. European pharmacopoeia PI Performance indicator pI Isoelectric point PK Pharmacokinetics pO2 Partial pressure of oxygen PP(s) Process parameter(s) PS80 Polysorbate 80 PSGL-1 P-selectin glycoprotein ligand 1 PSL Primary seed lot QA Quality attribute QTPP Quality target product profile Raji Human lymphoblastoid cell line RT Reverse transcriptase rRT Relative retention time RP-HPLC Reversed phase-high performance liquid chromatography Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

SCD Sickle cell disease SCT Safety concern threshold SD Standard deviation SDS-PAGE   Sodium dodecyl sulphate polyacrylamide gel electrophoresis SEC Size exclusion chromatography SEC-MALLS Size exclusion chromatography multi angle laser light scattering SEG101 Laboratory code for Crizanlizumab (Novartis) SelG1 Laboratory code for Crizanlizumab (Reprixys) SPR Surface plasmon resonance SST System suitability test TEM Transmission electron microscopy TAMC Total aerobic microbial count TI Tolerance interval TOR Time out of refrigerator TYMC Total combined yeast/moulds count UF/DF Ultrafiltration/Diafiltration UFT Ultrafiltration (drug substance manufacturing process) USP United States pharmacopoeia UV Ultraviolet VCD Viable cell density VIN Virus inactivation by low pH treatment (drug substance manufacturing process) VOC Vaso-occlusive crisis VRF Virus removal filtration (drug substance manufacturing process) WCB Working cell bank Non-clinical CYP Cytochrome P450 enzyme ELISA Enzyme-linked immunosorbent assay GLP Good Laboratory Practice KO mouse knock-out mouse mAb Monoclonal antibody MSD Meso Scale Discovery NOAEL No observed adverse effect level PPD Postpartum day SPR Surface Plasmon Resonance TMDD Target-mediated drug disposition TK Toxicokinetic(s) UGT Uridine 5'-diphospho-glucuronosyltransferase (UDP-glucuronosyltransferase) Clinical Medicinal product no longer authorised

ACS Acute chest syndrome ADA Anti-drug antibodies ADL activities of daily living AE Adverse event AESI Adverse event of special interest ALT Alanine aminotransferase

<div style=\"page-break-after: always\"></div>

| Anti-HAV                             | hepatitis A virus antibody                               |
|--------------------------------------|----------------------------------------------------------|
| Anti-HBc                             | hepatitis B core antibody                                |
| Anti-HCV                             | hepatitis C virus antibody                               |
| aPTT                                 | Activated partial thromboplastin time                    |
| AST                                  | Aspartate aminotransferase                               |
| AUC                                  | Area under the curve                                     |
| BLQ                                  | Below limit of quantification authorised                 |
| BMI                                  | Body mass index                                          |
| BPI                                  | Brief Pain Inventory Questionnaire                       |
| bpm                                  | beats per minute                                         |
| BSA                                  | Body surface area                                        |
| BUN                                  | Blood urea nitrogen                                      |
| CBC                                  | Complete blood count                                     |
| CDR                                  | complementarity-determining region                       |
| CFR                                  | Code of Federal Regulations                              |
| CI(s)                                | Confidence interval(s)                                   |
| CKD-EPI                              | Chronic Kidney Disease-Epidemiology Collaboration longer |
| CL                                   | Clearance                                                |
| Clast                                | Last observed concentration                              |
| Cmax                                 | maximum observed concentration no                        |
| CO2                                  | Carbon dioxide                                           |
| CRC                                  | Crisis Review Committee                                  |
| CRF                                  | Case Report Form                                         |
| CRO                                  | Contract Research Organisation                           |
| CRP                                  | C-reactive protein                                       |
| CRU                                  | clinical research unit                                   |
| CSPD                                 | Clinical Summary Preparation Document                    |
| CSR                                  | Clinical study report                                    |
| Ct                                   | last measurable concentration                            |
| CTCAE                                | Common Terminology Criteria for Adverse Events product   |
| Ctrough                              | Minimum drug concentration or pre-dose concentration     |
| CV%                                  | coefficient of variation                                 |
| DBILI                                | Direct bilirubin                                         |
| DI                                   | Dose intensity                                           |
| DMC                                  | Data Monitoring Committee                                |
| ECG                                  | Electrocardiogram                                        |
| ECOG                                 | Eastern Cooperative Oncology Group                       |
| eCRF                                 | Electronic case report form                              |
| EENT Eyes/ears/nose/throat Medicinal | EENT Eyes/ears/nose/throat Medicinal                     |
| eGFR                                 | Estimated glomerular filtration rate                     |
| EOT                                  | End of treatment                                         |
| ER                                   | Emergency room                                           |
| FAS                                  | Full analysis set                                        |
| FcRn                                 | Neonatal Fc receptor                                     |
| FDA                                  | Food and Drug Administration                             |
| FSH                                  | follicle stimulating hormone                             |

<div style=\"page-break-after: always\"></div>

GCP Good Clinical Practice GGT gamma glutamyl transferase GGT Gamma-glutamyl transpeptidase GLP Good Laboratory Practice GMR Geometric mean ratio HAHA human anti-human antibody Hb Haemoglobin HbS Haemoglobin S HBsAg hepatitis B surface antigen HbSC Heterozygous sickle Haemoglobin C disease (haemoglobin SC disease) HbSS Homozygous sickle cell disease (haemoglobin SS disease) HbSβ Heterozygotes with one copy of the HbS gene and a β -thalassemia variant (β0 or β+) HbSβ+ -thal   Sickle cell disease -Sβ+ Thalassemia HbSβ0 -thal  Sickle cell disease -Sβo Thalassemia Hct Haematocrit HCV Hepatitis C virus HDYF? How do you feel? HED human equivalent dose Hep hepatitis HIV Human Immunodeficiency Virus HR Hazard ratio HU/HC Hydroxyurea/Hydroxycarbamide IB Investigator's Brochure ICF Informed Consent Form ICH International Council for Harmonisation IEC Independent Ethics Committee IFN Interferon IIV Inter-individual variance IL Interleukin IND investigational new drug INN International nonproprietary name INR International Normalized Ratio IRB Institutional Review Board ITT Intent-To-Treat IUD intrauterine device IV Intravenous IWRES individually weighted residuals IXRS Integrated Interactive Voice/Web Response System K3EDTA tripotassium ethylenediaminetetraacetate Kd Dissociation rate constant keDT Elimination rate constant for drug-target complex KM Kaplan-Meier Lambda\\_z   Smallest (slowest) disposition (hybrid) rate constant (time-1) LDH Lactate dehydrogenase LLOQ lower limit of quantification ln natural logarithm Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

```
LOQ limit of quantitation LS Least squares mAB Monoclonal antibody Max Maximum MCH Mean corpuscular haemoglobin MCHC Mean corpuscular haemoglobin concentration MCV Mean corpuscular volume MDV Missing dependent variable Med median MedDRA Medical Dictionary for Regulatory Activities Min Minimum mITT Modified Intent-to-Treat mM millimolar MMRM Mixed linear model with repeated measures MPV mean platelet volume N number NC not calculated NCA non-compartmental analysis NM ID NONMEM identification nM nanomolar NOAEL no observed adverse effect level NONMEM Nonlinear Mixed Effects Modeling software NPDE normalized prediction distribution error NR no result NSAID Non-steroidal anti-inflammatory drug PAS PK analysis set PCP Phencyclidine PD Pharmacodynamics PDI Planned dose intensity PDS PD analysis set PE Physical examination pH hydrogen ion concentration PI Principal Investigator PK Pharmacokinetics PP Per-Protocol PR Beginning of P wave to the beginning of the next QRS PRO Patient reported outcomes PSGL-1 P-selectin glycoprotein ligand-1 PT Preferred term PT prothrombin time PTTYP Patient or population type Q Intercompartmental clearance QC quality control QRS Beginning of Q to the end of the S wave QT Beginning of QRS to end of T wave QTc corrected QT interval Medicinal product no longer authorised
```

<div style=\"page-break-after: always\"></div>

QTcB Bazett's corrected QT interval QTcF Fridericia's corrected QT interval RBC Red blood cell RDI Relative dose intensity RDW red blood cell distribution width RSE relative Standard Error SAE Serious adverse event SAP Statistical Analysis Plan SAS Statistical Analysis Software SCD Sickle cell disease SCPC Sickle cell-related pain crises SD Standard deviation SDTM Study Data Tabulation Model SE Standard error SF-36 Short Form 36-Question Health Survey SI Standard international SOC System Organ Class SOPs Standard operating procedures T0 Initial target concentration t1/2 Terminal phase half-life TB tuberculosis TBD to be determined TBILI Total bilirubin TEAE treatment emergent adverse event tmax Time to maximum concentration TMDD target-mediated drug disposition Ttot,ss Total target concentration at steady state TVP Typical value of parameter UA urinalysis ULN Upper limit of normal ULQ Upper limit of quantification US United States V Volume of distribution V/V Volume to volume ratio VC Volume of central compartment VCAM Vascular cell adhesion molecule VOC Vaso-occlusive crisis VP Volume of peripheral compartment VPC Visual predictive check Vss Volume of distribution at steady state WBC White blood cell WebSDM Web Submission Data Manager WHO World Health Organization WHO-DD World Health Organization Drug Dictionary β slopes λZ apparent terminal phase elimination rate constant Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

<!-- image -->

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

1.1. Submission of the dossier The applicant Novartis Europharm Limited submitted on 29 May 2019 an application for marketing authorisation to the European Medicines Agency (EMA) for Adakveo, through the centralised procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004. Adakveo, was designated as an orphan medicinal product EU/3/12/1034 on 09 August 2012 in the following condition: Treatment of sickle cell disease. The applicant applied for the following indication : ' Adakveo is indicated for the prevention of vaso-occlusive crises in sickle cell disease patients aged 16 years and over' . Following the CHMP positive opinion on this marketing authorisation, the Committee for Orphan Medicinal Products (COMP) reviewed the designation of Adakveo as an orphan medicinal product in the approved indication. More information on the COMP's review can be found in the Orphan maintenance assessment report published under the 'Assessment history' tab on the Agency's website: https://www.ema.europa.eu/en/medicines/human/EPAR/Adakveo. The legal basis for this application refers to: Article 8.3 of Directive 2001/83/EC - complete and independent application The application submitted is composed of administrative information, complete quality data, non-clinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies). Information on Paediatric requirements Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0060/2019 on the agreement of a paediatric investigation plan (PIP). At the time of submission of the application, the PIP EMEA-002141-PIP01-17 was not yet completed as some measures were deferred. Information relating to orphan market exclusivity Similarity Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Applicant's request(s) for consideration

<!-- image -->

<!-- image -->

Conditional marketing authorisation The applicant requested consideration of its application for a Conditional marketing authorisation in accordance with Article 14-a of Regulation (EC) No 726/2004. New active Substance status The applicant requested the active substance crizanlizumab contained in the above medicinal product to be considered as a new active substance, as the applicant claims that it is not a constituent of a medicinal product previously authorised within the European Union. Protocol assistance The applicant received the following Protocol assistance on the development relevant for the indication subject to the present application: SAWP co-ordinators 26 April 2018 Dr Caroline Auriche, Prof. Markku Pasanen and Dr Armando Magrelli The applicant received Protocol Assistance on 26 April 2018 (EMEA/H/SA/3763/1/2018/PA/II) for the development programme targeting prevention of vaso-occlusive crises in sickle cell disease. The Scientific Advice pertained to the following clinical aspects: · Adequacy of a proposed clinical study (A2301) to generate sufficient evidence on long-term efficacy and safety, dose optimisation and subgroup coherence to support full marketing authorisation: principle design features, evaluation of two doses (7.5mg/kg vs. 5mg/kg), study population, primary and secondary efficacy endpoints, definition of vaso-occlusive crisis (VOC), statistical considerations (sample size estimation, primary and key secondary analysis, handling of missing data), adequacy of evidence to be generated to support conversion of a potential conditional marketing authorisation to a full marketing authorisation, patient reported outcomes (PROs) and activity monitoring device, · Adequacy of the envisaged clinical evidence base to support 'significant benefit' in the context of the maintenance of the orphan medicine designation at the time of initial marketing authorisation. 1.2. Steps taken for the assessment of the product The Rapporteur and Co-Rapporteur appointed by the CHMP were: Medicinal product no longer authorised

| Date          | Reference                      | SAWP co-ordinators                                                |
|---------------|--------------------------------|-------------------------------------------------------------------|
| 26 April 2018 | EMEA/H/SA/3763/1/2018/PA/II no | Dr Caroline Auriche, Prof. Markku Pasanen and Dr Armando Magrelli |

Rapporteur: Milena Stain

Co-Rapporteur:  Tuomo Lapveteläinen

CHMP Peer reviewer(s): Paula Boudewina van Hennik

<div style=\"page-break-after: always\"></div>

| The application was received by the EMA on                                                                                                                                                                                     | 29 May 2019                 |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|
| The procedure started on                                                                                                                                                                                                       | 20 June 2019                |
| The Rapporteur's first Assessment Report was circulated to all CHMP members on                                                                                                                                                 | 9 September 2019 authorised |
| The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on                                                                                                                                              | 9 September 2019            |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on                                                                                                                                            | 20 September 2019           |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                                                                                                        | 17 October 2019             |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                                                                                                            | 25 February 2020            |
| The following GCP inspection(s) were requested by the CHMP and their outcome taken into consideration as part of the Quality/Safety/Efficacy assessment of the product: longer                                                 |                             |
| - A GCP inspection at 1 clinical investigator site in Jamaica, 1 clinical investigator site in USA and 1 sponsor in the USA between 4 November and 13 December 2019 The outcome of the inspection carried out was issued on no | 3 February 2020             |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Questions to all CHMP members on product                                                                                                | 06 April 2020               |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                                                       | 17 April 2020               |
| The CHMP agreed on a list of outstanding issues to be sent to the applicant on                                                                                                                                                 | 30 April 2020               |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                                                                | 18 June 2020                |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP members on                                                                                               | 08 July 2020                |
| The outstanding issues were addressed by the applicant during an oral explanation before the CHMP during the meeting on Medicinal                                                                                              | N/A                         |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Adakveo on                                        | 23 July 2020                |

<div style=\"page-break-after: always\"></div>

<!-- image -->

Sickle cell disease signifies a group of rare genetic blood disorders caused by a single missense mutation in the β -globin gene. The autosomal recessive SCD trait is determined by combinations of two abnormal alleles of the β -globin gene among which at least one carries the GLU6Val mutation HbS.

2. Scientific discussion 2.1. Problem statement 2.1.1. Disease or condition Adakveo is intended for the treatment of sickle cell disease (SCD). Sickle cell disease is a genetic disorder. In patients with SCD, haemoglobin is altered causing deformation of erythrocytes and subsequent vaso-occlusive events and chronic haemolytic anaemia. The main manifestations of SCD include painful crises including chest, back and joints, organ damage and varying degrees of anaemia and related symptoms. The applicant initially applied for the following indication: Adakveo is indicated for the 'prevention of vasoocclusive crises in sickle cell disease patients aged 16 years and over'. 2.1.2. Epidemiology Sickle cell disease (SCD) is a heritable disease mainly prevalent in sub-Saharan Africa due to a protective effect for malaria of the heterozygous form. The numbers of patients with sickle cell disease however is steadily increasing in the EU due to migration (Hickman et al 1999, Gulbis et al 2006, Modell et al 2007, Roberts et al 2007, Colombatti et al 2016). The prevalence in the EU is currently estimated to be ≤ 2.1 per 10000 individuals in the EU. SCD genotypes include HbSS, HbSC, HbSβ0 -thalassemia, HbSβ+ -thalassemia, and others. The homozygous variant of HbSS is the most common form of SCD worldwide and in the European Union (about 90% of SCD patients in the EU). The second most common form in the EU is sickle β -thalassemia (~10%) which can occur in two forms (Hb S/β+ -thalassemia and H b S/β° -thalassemia); rarer forms exist but not in Europe so far. Clinical manifestations are extremely variable between individuals and occur at different times. The majority consists of pain in varying locations caused by vaso- occlusive events causing ischemic events (and sometimes infarction). Over the course of time this causes increased organ and tissue damage. Additionally, anaemia and bacterial infections are very common. Life expectancy is decreased in patients with SCD to 42 - 53 years for men and 48 - 58 years for women (Platt et al 1994, Wierenga et al 2001, Lanzkron et al 2013). Early diagnosis, education and intervention before symptoms or organ damage manifest drastically improved mortality in children over the last decades. 2.1.3. Aetiology and pathogenesis Medicinal product no longer authorised

SCD genotypes include HbSS, HbSC, HbSβ0 -thalassemia, HbSβ+ -thalassemia, and others. Although these disorders vary in the second beta globin variant, they all result in abnormal polymerisation of haemoglobin. The

<div style=\"page-break-after: always\"></div>

mutant haemoglobin in SCD, known as sickle haemoglobin (HbS), is less soluble and prone to polymerisation upon deoxygenation, causing red blood cell sickling and associated sequelae. In SCD, both the circulating blood cells and the endothelium are activated in a chronic pro-inflammatory state. In this environment, sickled red cells, leukocytes, and platelets adhere to the vascular endothelium resulting in vaso-occlusion, one of the most serious complications of SCD. VOCs are a clinical hallmark of SCD, cause considerable acute and chronic morbidity, and mortality. The deformed erythrocytes are furthermore metabolised resulting in anaemia and related symptoms. 2.1.4. Clinical presentation, diagnosis and prognosis Clinical presentation: Sickle cell disease usually manifests for the first time in infants at the age of about 3-6 months, when foetal haemoglobin is replaced by HbS. Symptoms of sickle cell disease vary between patients but are generally caused by intermittent vaso-occlusive events and chronic haemolytic anaemia. Vaso-occlusive events result in tissue ischemia leading to acute and chronic pain mainly located in the chest, back, hands, feet and joints. These events cause also organ damage affecting any organ system including the bones, spleen, liver, brain, lungs, kidneys, and joints. Acute chest syndrome is a major cause of mortality in SCD. Often the earliest manifestation of SCD is dactylitis (pain and/or swelling of the hands or feet). In children, the spleen is of major concern as it is particularly vulnerable to infarction. The majority of untreated patients with SCD become functionally asplenic in early childhood, increasing their risk for certain types of bacterial infections. Chronic haemolysis can result in varying degrees of anaemia, jaundice, cholelithiasis, and delayed growth and sexual maturation. Individuals with the highest rates of haemolysis are predisposed to pulmonary artery hypertension, priapism, and leg ulcers. Diagnosis: Sickle cell disease usually manifests for the first time with symptoms and deformed erythrocytes in infants at the age of about 6 months when foetal haemoglobin is replaced by HbS. However, SCD can be diagnosed earlier via newborn screening or even genetic testing during pregnancy, which has been established in the US and several European counties (see review in Colombatti et al 2016). Otherwise the diagnosis of SCD is established via molecular genetic testing to identification of significant quantities of HbS (Bender 2017). Prognosis: Life expectancy is decreased in patients with SCD, to 42 - 53 years for men and 48 - 58 years for women (Platt et al 1994, Wierenga et al 2001, Lanzkron et al 2013). Vaso-occlusive events like cardiac arrest, thrombosis or stroke and organ failure are major causes of mortality in SCD. 2.1.5. Management Medicinal product no longer authorised

The management of SCD includes mainly the treatment of clinical manifestations and preventive measures including early education of patients and parents.

The treatment of clinical manifestations consists mainly of the management of pain episodes (hydration, anti-inflammatory agents, pain medication, massage etc.). Fever and suspected infection are treated with

<div style=\"page-break-after: always\"></div>

appropriate antibiotics. Life-threatening or severe complications (e.g., severe acute chest syndrome or stroke) often require red blood cell transfusions. Splenectomy may be necessary for splenic sequestration. The most frequently used pharmacologic therapy for the reduction of pain crises is hydroxyurea (HU). Hydroxyurea can decrease the frequency and severity of vaso-occlusive crises and reduce transfusion needs. Nonetheless, not all eligible SCD patients receive HU, are willing to take it or able to tolerate it. Moreover, despite current treatment many patients with SCD still experience VOC. Thus, there remains a significant unmet medical need in this patient population. The only curative option for SCD is haematopoietic stem cell transplantation (HSCT) following a myeloablative conditioning regimen. HSCT is an option in selected individuals, however, primarily limited to children and adolescents with a matched sibling donor. Although the best results are obtained with a matched sibling donor, matched unrelated and haploidentical donors are alternative methods used recently but are not the standard of care. Preventive measures include maintaining hydration and avoiding climate extremes, physical exhaustion, extremely high altitude and other unfavourable environmental factors. Other preventive measures include management of fevers, prophylactic antibiotics, immunisations, folic acid supplementation; and iron chelation therapy for those with iron overload. Chronic red blood cell transfusion is used in children at risk for stroke and individuals with pulmonary hypertension, chronic renal failure, recurrent acute chest syndrome, and severe end-organ damage. An essential part of the management of SCD is periodic monitoring of significant parameter: comprehensive medical and social evaluation, mental health and neurocognitive assessment, and routine dental care, annual CBC and reticulocyte count, assessment of iron status, liver and renal function tests, urinalysis, LDH, and vitamin D level. It also includes annual transcranial Doppler to determine risk of stroke in all children with HbS/S and HbS/β° -thalassemia and ophthalmologic evaluation in all with sickling disorders. Evaluation of organ damage is performed as indicated via chest x-ray, ECG, abdominal ultrasound, and iron overload. Due to the high frequency and severity of cardiopulmonary complications, patients are frequently subject to an echocardiogram, pulmonary function tests and sleep study. Close monitoring is required for women with SCD during pregnancy. Women with sickle cell disease have an increased risk of adverse pregnancy outcomes for the mother and the foetus. Pregnant women are at greater risk for VOCs, pre-eclampsia, eclampsia, and maternal mortality. For the foetus, there is an increased risk for intrauterine growth restriction, preterm delivery, low birth weight, and perinatal mortality.  Hydroxyurea should be discontinued during pregnancy. About the product Crizanlizumab is a selective humanised IgG2 kappa monoclonal antibody (mAb) which binds to its target P-selectin with high affinity blocking its interaction with its ligands, including P-selectin glycoprotein ligand 1 (PSGL-1). Medicinal product no longer authorised

P-selectin is an adhesion molecule expressed on activated vascular endothelial cells and platelets and is a key molecule involved in the initiation of leukocyte extravasation to underlying tissues during inflammation. P-selectin has been found to be expressed at higher levels in SCD patients. The binding to P-selectin is postulated to inhibit the P-selectin mediated cellular adhesive interactions that are a key factor in the pathogenesis of VOC.

<div style=\"page-break-after: always\"></div>

The recommended dose of crizanlizumab is 5 mg/kg administered over a period of 30 minutes by intravenous (IV) infusion at Week 0, Week 2, and every 4 weeks thereafter. The initial applied indication applied was: prevention of VOCs in SCD patients aged 16 years and over. The CHMP agreed with the following indication: ' Adakveo is indicated for the prevention of recurrent vaso occlusive crises (VOCs) in sickle cell disease patients aged 16 years and older. It can be given as an add on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate. ' According to the new mechanism of action, the World Health Organisation created a new 4 th  ATC level (B06AX -other haematological agent) and assigned the B06AX01 ATC code to crizanlizumab. Type of Application and aspects on development The applicant requested consideration of its application for a Conditional Marketing Authorisation in accordance with Article 14-a of the Regulation (EC) No 726/2004, based on the following criteria: Scope for Conditional Marketing Authorisation · Medicines for human use are eligible if they are aimed at treating, preventing or diagnosing seriously debilitating or life-threatening diseases. SCD is debilitating, life-threatening and systemic disease regardless of patient age. It is still associated with decreased life expectancy in SCD patients, although the current SoC improved the overall quality of life and life expectancy in the last decades. Further, crizanlizumab was designated as an orphan medicinal product EU/3/12/1034 on 09. Aug 2012 in the following condition: Treatment of sickle cell disease. Requirements for Conditional Marketing Authorisation · The benefit-risk balance is positive. · It is likely that the applicant will be able to provide comprehensive data. The applicant plans to generate comprehensive safety and efficacy data with a phase III study A2301. This multicentre, placebo-controlled, parallel, double blind clinical study in patients of 12 years and older started in 2019 and the results of the primary analysis are planned to be available in 2025. The design was adapted based on advice from the SAWP/CHMP: 240 patients (including at least 48 adolescents) will be randomised 1:1:1 to treatment with crizanlizumab 5 mg/kg, 7.5 mg/kg or placebo The blinded period for primary analysis is planned for one year per patient, with an open label extension (up to 5 years on study treatment). Stratification factors, inclusion and exclusion criteria are similar to study A2201. In addition to confirming the efficacy and safety of crizanlizumab 5 mg/kg, this study should assess whether a higher dose (7.5 mg/kg) of crizanlizumab could further reduce the frequency of VOCs. The primary objective is to compare the efficacy based on the annualised rate of VOC leading to a healthcare visit, in addition to standard of care. The key secondary objective is to compare the efficacy based on the annualised rate of all VOCs (whether managed at home or leading to healthcare visit). Medicinal product no longer authorised

- Unmet medical needs will be addressed.

SCD is debilitating, life-threatening and a systemic disease with limited treatment options and high unmet medical need, regardless of patient age. A significant unmet medical need exists in SCD for more effective

<div style=\"page-break-after: always\"></div>

<!-- image -->

The active substance of Adakveo (INN: crizanlizumab) is a recombinant IgG2a kappa humanised monoclonal antibody directed against human P-selectin. Binding of Adakveo to P-selectin blocks interaction of P-selectin with its ligand P-selectin glycoprotein ligand 1 (PSGL-1). Adakveo is produced from a mammalian Chinese hamster ovarian cell line. It consists of 2 heavy chains (HC) of the lgG2a subclass (448 aa) and 2 light chains (LC) of the kappa subclass (218 aa) connected by intra- and interchain disulphide bonds. The N-glycosylation site is located at amino acid position Asn298 on the heavy chain. The theoretical molecular mass of the fully assembled antibody is 146,232 Da.

treatments. Current treatment is preventive, symptomatically, limited to a few eligible patients or not well tolerated/accepted. Further, despite current treatment many patients with SCD still experience VOC. Thus, there remains a significant unmet medical need in this patient population. Crizanlizumab exhibits a new mode of action compared to existing treatments offering an alternative or add-on treatment option. · The benefits to public health of the immediate availability outweigh the risks inherent in the fact that additional data are still required. The applicant claims that SCD patients have a high unmet medical need and few therapeutic options. Therefore, the immediate availability of treatment alternatives has the potential to reduce the existing disease burden (VOCs) and has the potential to reduce the incidence of acute complications and consequently, extend life expectancy and quality of life of SCD patients. A conditional marketing authorisation would enable SCD patients to get access to crizanlizumab well in advance compared to when the drug would become available after submission of the phase III data from study A2301 (with results of the primary analysis planned to be available in 2025). Adakveo has a favourable safety profile and the sole important identified risk for crizanlizumab of infusion-related reaction can be adequately addressed via routine risk minimisation measure (i.e. appropriate labelling). Therefore, making crizanlizumab available to patients while collecting comprehensive efficacy and safety data in the ongoing phase 3 study A2301 is not expected to represent a risk to public health. 2.2. Quality aspects 2.2.1. Introduction The finished product is presented as concentrate for solution for infusion containing 100 mg/10 mL (10 mg/mL) of crizanlizumab as active substance. Other ingredients are: citrate, sucrose, polysorbate 80 and water for injections (WFI). The product is available in a colourless Type I glass vial (10 mL) closed with a coated chlorobutyl rubber stopper and sealed with an aluminium cap with a plastic flip-off disk. 2.2.2. Active Substance General Information Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Manufacture, process controls and characterisation

The construction of the expression vector and its genetic elements are described in sufficient detail. The origin of the original antibody sequence and sequence modifications that have been introduced during early development are briefly described; equivalence of the amino acid sequence of the commercial antibody and the antibody used in early development was confirmed. The information provided on the origin and history of the parental cell line and generation of the final production clone is acceptable. The applicant has established a two-tiered cell bank system with Master Cell Bank (MCB) and Working Cell Bank (WCB). Cell banking procedures are adequately described. An acceptable protocol for manufacture and qualification of future WCB has been submitted upon request. However, the applicant has chosen not to register the protocol in 3.2.S.2.3 and will consequently submit a variation for implementation of a new WCB. The expression construct and cell substrate including MCB, WCB, and ECB (extended cell banks generated from cells propagated beyond the limit of in vitro

Manufacturers Novartis Pharma AG, Basel, Switzerland manufactures crizanlizumab active substance in accordance with good manufacturing practices (GMP). Manufacturing Process and Controls Crizanlizumab is expressed in a CHO cell line using a fed-batch process. Manufacture of a batch starts from a single vial of the working cell bank (WCB); multiple active substance batches may result from a single WCB vial thaw (multi-batch mode). The cells are expanded under controlled conditions to obtain sufficient cells for inoculation of the main stage bioreactor. Crizanlizumab is purified by column chromatography steps. Product fractions from several chromatography cycles may be pooled. The manufacturing process includes two dedicated, orthogonal virus clearance steps as well as a diafiltration/ultrafiltration step prior to filling into polyethylene terephthalate (PET) bottles. Reprocessing is currently not foreseen. The established hold times for the process intermediate pools are adequately justified by physico-chemical and microbial hold time studies. The manufacturing process is described in sufficient detail. The process parameters, classified into critical process parameters (CPP), key process parameters (KPP) and non-key process parameters (NKPP) are based on enhanced knowledge gained by process experience throughout development, experience with similar processes and process characterisation at small scale. The classification of the parameters and proposed limits are adequately justified. In-process controls (IPCs) with action or acceptance limits are established to ensure that the active substance and resulting finished product will meet quality requirements. The IPCs and their limits have been derived from process understanding and under consideration of safety aspects. Overall, the process parameters and IPCs in combination with the other control measures appear sufficient to ensure quality and safety of crizanlizumab and to monitor process consistency. Control of Materials Raw materials are of compendial quality or adequate in-house specifications have been established. Composition and preparation of cell culture media and buffer solutions as well as relevant processing materials are described. Except recombinant Protein A and the cell banks, no materials of animal, human or recombinant origin are used for manufacture of crizanlizumab active substance. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

cell age) were characterised in line with ICH guidelines Q5A, Q5B and Q5D using state-of-the-art analytical methods. Process Validation A traditional approach was chosen to verify process performance at commercial scale. The prospective process validation encompassed manufacture of three consecutive process validation batches at the intended commercial manufacturing site and scale. Confirmation of the maximum in vitro cell age, the multi-batch mode, removal of process- and product related impurities, and of the hold times for process intermediates were part of the validation activities. The validation results, which were all within their specified acceptance criteria, demonstrate that the process performs consistently (up to the final mixing step) and delivers active substance complying with the release specifications under commercial operating conditions. In one of the corresponding finished product batches faint translucent swirls (`striae´) consisting of crizanlizumab were observed. A major objection was raised in this regard. With the responses, characterisation data and a risk assessment addressing a potential risk for the patients have been submitted. An in-depth investigation conducted by the applicant compellingly identified the root cause triggering formation of striae in the finished product. Consequently, the applicant tightened the respective parameters and manufactured three verification batches (active substance and corresponding finished product batches) to confirm the effectiveness of the implemented measures. The three verification batches complied with all IPCs and release criteria specified for active substance and finished product. Considering the nature of the striae and the implemented corrective measures the risk for the patients is low. With the additional data, the full active substance manufacturing process is considered successfully validated. Studies evaluating re-use and cleaning of the chromatography resins were carried-out at small scale; confirmatory studies at large-scale have been completed (ALC) or are ongoing (MAC, CEC); the corresponding validation protocol is registered in 3.2.S. Re-use of the UF/DF membrane is concurrently validated at large scale; a validation protocol for membrane re-use is registered in 3.2.S. Based on a risk assessment and further evaluation considering prior knowledge, extraction studies were performed for polymeric materials. The concentration of any of the detected extractables was well below the analytical evaluation threshold (AET) and the materials can be considered safe from a leaching perspective. Transportation of active substance from the active substance to the finished product manufacturing site has been sufficiently qualified. Process Development Crizanlizumab active substance was manufactured according to four different process variants (i.e. Process A, B, C, and D). Crizanlizumab was initially developed on behalf of Reprixys, USA. A manufacturing process at 100 L, 200 L and 1000 L scale was used for manufacture of material for Phase 1/2 clinical trials including the pivotal SUSTAIN/SEG101A2201 Phase 2 trial, non-clinical studies, stability studies, and for production of reference standard (Process A). Medicinal product no longer authorised

Upon acquisition of Reprixys, process development was continued by Novartis Pharma AG, Switzerland. A new production cell line was generated using a Novartis CHO cell line, and the process was considerably changed (change of cell culture process and media, adaptation of the harvesting and purification process change of the active substance formulation and storage condition). In addition, the process was scaled up (Process B). Process

<div style=\"page-break-after: always\"></div>

B material was used for clinical development (studies SEG101A2102 and pivotal study CSEG101A2202), stability studies, and production of reference standard. For Process C (material used for non-clinical studies and registration stability studies), the cell culture and purification process remained unchanged but the formulation was slightly changed. Subsequently, the intended commercial Process D was developed; Process D material is/was used for further Phase 2 and Phase 3 studies, stability studies and to produce reference standards. Based on process characterisation studies, changes were introduced at several downstream processing steps. Prior to validation of the active substance manufacturing process, two additional changes were implemented at the main stage bioreactor step. Following process validation, the final mixing step of the active substance manufacturing process was subject to refinement (changed classification of parameters and tightening of parameters ranges). In accordance with ICH Q5E analytical comparability of the active substance obtained from the different processes and scales has been demonstrated in three comparability studies. Comparability across the different scales of Process A was assessed by Reprixys. Two comparability studies were conducted by Novartis; the first study compared one batch of Process A active substance with two batches manufactured according to Process B, the second study evaluated comparability across Process B, C, and D (two, one, and four active substance batches, respectively, were used). Both comparability exercises included in-process control tests, routine release tests, and additional characterisation tests using orthogonal state-of-the-art analytical procedures. In addition, stability under long-term (&lt; - 60 °C), accelerated (5 °C) and stress conditions (25 °C, 40 °C) was compared. Formal comparability studies to demonstrate comparability of active substance batches manufactured according to the optimised Process D (modification of addition of antifoam and Feed 2) or the post validation Process D (tightened parameters prior to filling) with the previous process variants were not performed. Considering the design of the first comparability study (Process A vs Process B), where only a single batch of Process A active substance was included and comparability was assessed against release criteria, the observed analytical differences, and different performance in the comparative PK/PD study, a major objection was raised to address the uncertainties about the comparability of Process A and B. Due to the indirect bridging approach to the intended commercial Process D (i.e. Process A, Process B, and the final commercial Process D were not directly compared but Process A was compared to Process B and a second comparability study was performed for Process B, Process C, and the non-optimised Process D), this uncertainty also comprised the intended commercial Process D. Analytical differences are evident for the distribution of charge variants, lower levels of aggregates (Process B), quantitative changes in distribution of disulphide isoforms), and changed distribution of glycoforms. In addition, active substance from Process B shows a slightly improved stability profile under stress conditions (as intended by the formulation change). However, lower levels of aggregates and an improved stability profile do not preclude comparability. Furthermore, as demonstrated by the applicant, the qualitative differences in glycoform distribution and other observed differences have no impact on biological function. Overall, it appears unlikely that the observed analytical differences affect the clinical performance of the product. optimisation of process D that was implemented after demonstration of comparability has no impact on product Medicinal product no longer authorised

Analytical comparability of active substance produced according to Process B, Process C, and non-optimised process D has been sufficiently demonstrated. The observed minor differences in glycoform distribution are considered unlikely to affect the clinical performance of the product. Additional data demonstrate that the quality.

<div style=\"page-break-after: always\"></div>

The applicant followed an enhanced development approach using existing knowledge on crizanlizumab and other monoclonal antibodies, process development and manufacturing experience, risk assessment tools, and process characterisation studies to define a control strategy as outlined in ICH Q11 and EMA/CHMP/BWP/187338/2014. Development data and process characterisation studies were used to systematically evaluate process parameters with regard to their impact on process performance and product quality and inform prediction models. Qualified small-scale models were established for univariate and/or multivariate process characterisation studies. The small-scale models for the production bioreactor and the purification chromatography steps are sufficiently described and the qualification approach appears reasonable. The design and results of the process characterisation studies are adequately summarised and support the classification of process parameters and their defined ranges. A comprehensive set of product variants, process related impurities and general quality attributes, which cover the relevant attributes of crizanlizumab, was assessed and an impact score based on impact on efficacy/biological activity, PK/PD, immunogenicity and safety was assigned to each quality attribute (QA). The criticality score was calculated from the impact score and the uncertainty score using a full-factorial equation. Quality attributes with moderate, high, or very high criticality score were classified as critical quality attributes (CQA). Criticality ratings and their justification appear reasonable. Each CQA is addressed by multiple control elements which include process control elements (design control, process control, raw material control, in-process testing, process development/process characterisation, process validation, release testing) and stability capability which guide the testing strategy (in-process, release, and stability testing) for each CQA. For each CQA the different control elements applied are described and adequately justified. The proposed control strategy appears adequate to ensure a consistent product quality. Characterisation The applicant comprehensively characterised the structure and biological properties of crizanlizumab using orthogonal, state-of-the art analytical methods. The molecular mass of the intact, the deglycosylated, and the reduced molecule was determined. The amino acid sequence of crizanlizumab was experimentally confirmed by peptide mapping with 100% sequence coverage. Presence of C- and N-terminal variants (pyroglutamate, Lys-clipping, prolinamide), oxidation, deamidation, succinimide formation, isomerisation and glycation was assessed and disulphide bonds, IgG2 disulphide isoforms as well as free sulfhydryl groups were determined. Glycoanalysis comprised the identification of the oligosaccharide pattern and site occupancy. Charge and size variants were extensively determined using multiple analytical methods. The higher order structure was evaluated. The biological characterisation included binding to the target P-selectin (by ELISA and SPR), binding to Fc receptors and C1q (ELISA) as well as functional activity in a cell-based assay. In addition, absence of Fc effector functions (ADCC and CDC) was confirmed in cell-based assays. Characterisation was done using three batches that have been manufactured according to the intended commercial process. Extensive forced degradation studies were conducted to identify the degradation pathways of crizanlizumab and confirm the stability indicating capability of analytical methods. The stress conditions comprised freeze/thaw stress, oxidative stress, pH stress, tumbling stress, excessive light exposure, and thermal stress Product-related variants and impurities have been identified and thoroughly characterised using batches originating from all four process variants. Medicinal product no longer authorised

Data presented for the three process validation runs performed at the intended scale in combination with batch analyses data of all clinical and several other development batches manufactured according to Process B, C, or D demonstrate that the process consistently and effectively removes HCP, host cell DNA, and residual protein A to very low levels. In addition, consistent reduction of host cell DNA and Protein A has been demonstrated in

<div style=\"page-break-after: always\"></div>

small-scale spiking experiments. Levels of process-related impurities introduced as raw materials were below the limit of quantitation (LOQ) of the analytical method. Specification, analytical procedures, reference standards, batch analysis, and container closure The proposed set of QAs included in the specifications for release and stability testing of crizanlizumab active substance complies with ICH Q6B, Ph. Eur. 2031, and EMA/CHMP/BWP/532517/2008. The specifications for crizanlizumab active substance are: appearance (turbidimetry, color, pH), identity (CZE, inhibition of P-selectin mediated cell adhesion), purity and impurities (SEC, CZE, CE-SDS, ELISA), potency (Cell Based Assay), microbiology (bioburden and endotoxin), and quantity (UV). Potency is determined by a relevant cell-based assay that measures inhibition of adhesion of P-selectin expressing cells to recombinant PSGL-1. Quantity is based on protein content determined by UV-spectrometry under denaturing conditions. Most of the proposed specification limits are based on tolerance intervals (TI) with 99.9% coverage and 95% confidence for results of release and stability testing of active substance lots manufactured according to Process B, C, and D. For several parameters, results for active substance and finished product were pooled to calculate the tolerance interval if no stability trend is present and equivalence between the active substance and finished product dataset was demonstrated. In addition to the batch data, the applicant took into account regulatory requirements from the Ph. Eur. and relevant guidelines. In summary, the proposed specification limits are agreeable. The applicant is recommended to re-evaluate the specification limits after data for a sufficient number of commercial batches is available (by December 2025) (See 'Recommendations for future quality development'). Analytical Methods Overall, the analytical methods are sufficiently described and appear adequate. The methods are clearly identified by internal method identifiers in the specification list. If applicable, a reference to the compendial monograph is provided. The implemented system suitability tests (SST) and sample acceptance criteria appear suitable to provide adequate control over analytical method performance. The presented validations and verifications of the analytical methods are adequate and demonstrate the suitability of the analytical procedures for their intended use. The relevant analytical method parameters have been assessed in accordance with ICH Q2(R1). Robustness data requested for SEC, CZE, reduced CE-SDS, HCP ELISA, and inhibition of adhesion of P-selectin expressing cells demonstrate the robustness of the non-compendial release methods. Batch Analyses Medicinal product no longer authorised

Batch release data are presented for active substance batches manufactured according to Process A at 100 L, 200 L or 1,000 L scale, batches produced with Process B, Process C, and batches manufactured at the intended commercial site Novartis Pharma AG using Process D. The batches were used in clinical and non-clinical studies, stability studies as well as for preparation of reference standards and for process validation purposes. During the procedure, batch release data were provided for verification batches and further batches manufactured according to the commercial process at Novartis Pharma AG. The presented results demonstrate that the manufacturing process reliably delivers crizanlizumab active substance with consistent quality.

<div style=\"page-break-after: always\"></div>

## Reference materials

Commitments to complete the currently ongoing stability studies are given by the applicant.

The history of the five reference standards used throughout development of crizanlizumab, which were manufactured from active substance lots representative for the respective development stage, is presented. The reference materials were sufficiently qualified according to the development phase using release and additional characterisation tests. An acceptable protocol for stability of the reference standard is in place. A two-tiered system with primary reference standard and working reference standard has been implemented. The proposed (re)qualification procedure for future reference standards is appropriate. Container closure Crizanlizumab bulk active substance is stored in 5 L PET bottles with high density polyethylene (HDPE) screw on caps. The components of the PET bottles and the HDPE caps are compliant with the regulations and compendial monographs (Ph. Eur. and USP). Extractable studies demonstrate that the containers can be considered safe from a leachable perspective. Compatibility has been demonstrated by stability studies. Stability A shelf life of 18 months at below -60 °C protected from light is proposed by the applicant. The ongoing registration stability studies are conducted at recommended storage conditions (&lt; -60 °C) as well as under accelerated (5 °C ± 3 °C) and stressed conditions (25 °C ± 2 °C) using three clinical crizanlizumab active substance batches that were manufactured according to the intended commercial manufacturing process (not including the pre- and post-validation adaptations of Process D) at the commercial site. Commitment stability studies at recommended, accelerated, and stress conditions with the three process validation batches are ongoing as well. In addition, supportive developmental stability data are presented for two technical batches manufactured at scale, one according to Process C and one according to Process D (without pre- and post-validation adaptations), at the intended commercial manufacturing site. The design of the stability studies is generally in accordance with ICH Q5C and ICH Q1A; statistical evaluations were performed according to ICH Q1E. For the all stability studies, samples are stored in containers representative for the commercial container closure system. The analytical program follows the proposed active substance specifications and includes stability indicating methods. For the three registration stability batches, 18 months real-time data are available, whereas for the three process validation batches (commitment stability) and the two development batches 12 months real-time data are presented. Furthermore, 12 months real-time data are available for one of the registration batches that has been subject to four freeze/thaw cycles prior to storage at long-term conditions. At long-term conditions, all results comply with the acceptance criteria for the current studies as well as the proposed commercial specification limits and do not show any relevant trends. Under accelerated conditions after 6 months all results comply with the specifications. The presented data support the proposed shelf life of 18 months at &lt; - 60 °C, protected from light in the container closure system defined in Module 3.2.S.6. The supportive statistical evaluation confirms the proposed shelf life. Medicinal product no longer authorised

## 2.2.3. Finished Medicinal Product

<div style=\"page-break-after: always\"></div>

## Description of the product and Pharmaceutical Development

<!-- image -->

To support formulation changes from Formulation 1 (manufacturing process I/II) to Formulation 2 (process III) and from Formulation 2 to Formulation 3 (process IV), in vitro analytical comparability studies have been performed. The first study assessed comparability of Formulation 1 (SelG1/Reprixys CMO, two batches), Formulation 1 (SEG101/Novartis Pharma Stein AG, one batch) and Formulation 2 (SEG101/Novartis Pharma Stein AG, one batch). Overall, the comparability study design is considered adequate (i.e. appropriate methods covering relevant CQAs). All analysed finished product batches fulfilled specifications during release testing.

Description and composition Crizanlizumab 100 mg/10 mL (10 mg/mL) finished product is a sterile, single-use, preservative-free, colourless to slightly brownish-yellow concentrate for solution for infusion. The active substance is formulated in citrate, sucrose, polysorbate 80 and water for injections (WFI); the pH is approximately 6.0. The excipients used serve as buffering and stabilizing agents and are of Ph. Eur. quality. They were selected based on formulation development studies. Each vial contains an overfill that allows withdrawal of the labelled amount (i.e. 10 mL) of finished product. Pharmaceutical development CQAs Criticality of quality attributes was defined for both active substance and finished product using an approach according to ICH Q9, which assesses each attribute regarding efficacy / biological activity, PK / PD, immunogenicity, and safety. The ranking is determined by the impact and level of uncertainty of the impact. The adequacy of CQAs for the active substance is discussed in the respective active substance section. For the finished product, the following quality attributes are considered as critical (i.e. have a criticality ranking of moderate to very high): container closure integrity, sterility, appearance of the container, subvisible particles, visible particles, active substance concentration in the finished product, extractable volume and pH of the finished product. With the exception of the container closure integrity test, all the CQAs are controlled by the finished product release specifications. Container closure integrity is evaluated as part of stability testing. Overall, the approach for identification of CQAs and the criticality assignment appears reasonable and sufficiently justified. The control strategy of CQAs relevant for the finished product is deemed satisfactory. Formulation development To optimize the stability of the liquid finished product formulation, the applicant performed formulation screening studies using three buffer systems, three isotonising and/or stabilising agents, and two pH values. The influence of formulation on the stability of study samples was evaluated under long-term, accelerated and stressed storage conditions. As read-out, potency by binding ELISA and cell-based assay, Polysorbate 80 content, charged variants by CZE, purity by SEC, subvisible particulate matter, content by UV, turbidity, colour and pH were tested. Stability was analysed after 12 weeks storage. Based on these results, a buffer containing sucrose, sodium citrate, Polysorbate 80, at pH 6.0 was finally selected as commercial formulation, which is considered sufficiently justified. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

To assess comparability of Formulation 2 (process III) versus Formulation 3 (process IV), analytical release and additional characterisation data from batches with Formulation 2 (manufactured at the pilot plant at Novartis Pharma Stein AG, Switzerland) versus batches with Formulation 3 (commercial formulation and commercial production line at Novartis Pharma Stein AG, Switzerland) were compared. Furthermore, stability of all finished product batches was assessed at long-term, accelerated and stress storage conditions. Overall, the presented data indicate that Formulation 2 is comparable to Formulation 3. Manufacturing process development Manufacture of crizanlizumab finished product includes compounding, sterile filtration, aseptic filling into vials and packaging. The applicant has provided an overview of process changes during manufacture of clinical batches in tabular format. Studies to evaluate the appropriateness of process parameter settings were conducted for the following process steps: thawing of the active substance, manufacture of Polysorbate stock solution, compounding of excipient dilution solution, compounding of bulk finished product solution, filtration (filter size study, adsorption on filter, impact of filtration pressure on finished product quality, filter compatibility) and filling. The study to assess adsorption of protein or Polysorbate 80 to the filter used for sterile filtration indicates that Polysorbate 80 adheres to the membrane at the beginning of the filtration. The need to conduct a filter flush and the filter flush volume is indicated in the description of the manufacturing process. Compatibility with process materials has been investigated in different studies: compatibility with tubing, compatibility with stainless steel, leachables from process contact materials. According to the information provided, tubings, stainless steel vessels, and microbial and sterile filters appear compatible with the finished product. No substances of concern for patient safety are leaking into the product. Container closure system The container closure system consists of a colourless 10 mL Type I glass vial closed with a grey rubber stopper and sealed with an aluminium cap with a yellow plastic flip-off disk. The primary packaging components are of Ph. Eur. quality. The information on the suppliers of the primary packaging components is included in the dossier and respective certificates of analysis (CoA) have been provided. No substance of safety concern is leaking into the finished product as indicated by results of leachables and extractables testing. Elemental impurities were evaluated in line with ICH Q3D. No impurity of concern has been identified. Compatibility Studies were conducted to evaluate compatibility of the finished product with normal saline (0.9 % sodium chloride) and 5 % dextrose (or glucose) as diluents, as well as infusion sets consisting of representative combinations of commercially available components. In-use stability has been assessed and is reflected in the SmPC. Manufacture of the product and process controls Medicinal product no longer authorised

## Manufacture

Valid GMP certificates and/or manufacturing authorisations have been provided for all finished product manufacturing sites or are available via EudraGMDP.

<div style=\"page-break-after: always\"></div>

The manufacturing process of crizanlizumab bulk finished product includes thawing of the active substance, addition of excipient dilution solution and microbial retention filtration. For manufacture of the finished product, bulk finished product is sterile filtered in line and filled into the final containers followed by 100% visual inspection. The batch formula is adequately described. Several active substance batches may be pooled for manufacture of finished product. Process controls A detailed list of in-process controls used to control the manufacturing process has been provided, including acceptance criteria (action limits). Appropriate controls with acceptance criteria (i.e. bacterial endotoxins before microbial filtration, filter integrity after sterile filtration) have been defined for manufacturing steps, which are considered as critical. Overall, the provided information on the finished product manufacturing process is considered adequate. No reprocessing or reworking steps are defined for crizanlizumab concentrate for solution for infusion 100 mg/10 mL. Process validation Process validation was conducted with three consecutive finished product batches. The manufacturing process validation covers the entire manufacturing process and was performed applying normal operating values/ranges. For the validation batches, the process parameters operated well within the pre-defined values and ranges, and all in-process controls met the pre-defined acceptance criteria. However, for one batch, striae (i.e. faint translucent swirls) were observed. This issue was raised as a major objection, see also discussion above in the active substance section. Sterile filtration of the crizanlizumab bulk finished product was successfully validated in lab scale by applying a bacterial retention test with Brevundimonas diminuta (ATCC1946) and using worst-case conditions. Aseptic filling has been adequately validated by media fills, which are usually performed at least twice a year. The respective validation results support the proposed filling time for the commercial process. Depyrogenation and sterilisation of vials and sterilisation of (pre-depyrogenised) stoppers are performed in-house at Novartis Stein. Qualification results are included in the dossier and considered adequate. Hold times for the manufacture of crizanlizumab finished product were investigated during manufacture of pre-validation and process validation batches and are sufficiently justified. Transport of crizanlizumab finished product has been validated/qualified by several studies: temperature excursion study, qualification of the shipping container, shipping verification study (i.e. to assess protection of finished product via secondary and tertiary packaging under worst-case transport conditions) and a transport validation study. The applicant presented the results of the transport validation study, which has been finalised in 2019. According to the information provided, the transport of finished product from the Novartis distribution Site (Switzerland) to the Novartis pharmaceutical distribution site in the US and back to Switzerland can be considered as successfully validated. Medicinal product no longer authorised

## Product specification, analytical procedures, batch analysis

The specifications proposed for release and stability testing of crizanlizumab finished product comply with ICH Q6B, Ph. Eur. 2031, and EMA/CHMP/BWP/532517/2008. The specifications include tests for appearance (appearance of the container, appearance of the solution/turbidimetry, colour of the solution), general tests (i.e.

<div style=\"page-break-after: always\"></div>

pH, extractable volume, osmolality), tests for identity (identity by CZE, identity by bioassay), tests for purity/impurities (purity by SEC, subvisible particulate matter, visible particles, charge heterogeneity by CZE, purity by CE-SDS (reducing conditions), bacterial endotoxins test, sterility), potency (Inhibition of adhesion of P-selectin expressing cells to PSGL-1), and quantity (protein by UV absorption, stabilizer Polysorbate 80 by flow injection analysis). Tightness of vials is additionally assessed by dye intrusion (vacuum and overpressure) for stability testing. The proposed finished product release and shelf life specifications and the choice of analytical methods are considered appropriate. The applicant is recommended to re-evaluate the current specifications for the finished product based on commercial batches manufactured and stability data available by December 2025 (See 'Recommendations for future quality development'). The acceptance criteria can be considered as clinically qualified based on data of batches that were used in clinical studies. Despite that 'Sum of fragments by SEC' and 'Basic variants by CZE' are above the clinically qualified levels, the basic variant is not expected to affect efficacy or safety of the molecule. Overall the possible clinical impact is considered justified. Analytical procedures The following methods are used for control of active substance as well as finished product, and are described and discussed in the active substance part of Module 3: Appearance of the solution (Ratio turbidimetry), colour of the solution, pH value, identity and charge heterogeneity by CZE, identity and potency by inhibition of adhesion of P-selectin expressing Raji cells to PSGL-1, purity by SEC, purity by CE-SDS (reducing conditions), and assay of protein by UV absorption. Compendial finished productspecific test methods 'subvisible particulate matter', 'visible particles' and 'extractable volume' have not been re -validated for crizanlizumab concentrate for solution for infusion 100 mg/10 mL. This is considered acceptable. Method verification testing has been performed according to Ph. Eur. for bacterial endotoxins test and the test for sterility. Furthermore, verification testing has been performed for osmolality testing, which has been evaluated for robustness and intermediate precision. Validation of the assay for quantification of Polysorbate included testing for specificity, accuracy, precision (repeatability, intermediate precision), linearity/range and robustness in line with ICH Q2 requirements. The validation of the container closure integrity test (blue dye intrusion test) was originally conducted for water and tryptic soy broth, and subsequently re-validated using the finished product matrix (i.e. 100 mg and 0 mg crizanlizumab/in 10 mL citrate buffer). Batch analysis Batch analysis data was presented for batches manufactured according to process I (active substance process A), for batches manufactured according to process I (active substance process A) at an alternate site, for batches manufactured at Novartis Pharma Stein AG, Switzerland according to process III (active substance process B2), and for batches manufactured at Novartis Pharma Stein AG, Switzerland according to process IV. All batches complied with the pre-defined acceptance criteria valid at the time of release and confirm Medicinal product no longer authorised consistency of the manufacturing process.

## Reference materials

<div style=\"page-break-after: always\"></div>

The reference standard used for release and stability testing of crizanlizumab concentrate for solution for infusion 100 mg/10 mL is the same as for the active substance. For details, please refer to the respective active substance section. Stability of the product The applicant is proposing a finished product shelf life of 18 months when stored at 2 -8°C. Overall, the presented stability studies are considered in line with ICH Q5C and ICH Q1A requirements. The following real time stability data are currently available: 18 months for three clinical batches manufactured according to a process representative for the commercial process (i.e. active substance process D, finished product process IV); 12 months for the three process validation batches manufactured according to the commercial process; 24 months supportive data for one technical batch. All batches were manufactured at the proposed commercial manufacturing site and were packed in the primary packaging proposed for marketing. The real time stability data are well within the defined acceptance criteria Based on the data provided, the proposed finished product shelf life of 18 months when stored at 2 -8°C is considered acceptable. Up to 6 months data have also been provided for batches stored under accelerated (25°C / 60% RH), intermediate (30°C / 75% RH) and stress (40 °C/75 % RH) conditions. Photostability was tested on one batch of finished product. Results showed that intensive light exposure results in a high degradation of the product. Data also confirmed that the finished product is adequately protected from light when packed in the commercial secondary pack. This is appropriately reflected in the SmPC. Data indicating stability of the finished product when exposed to temperature and shaking stress have been provided. In-use stability has been assessed in the course of pharmaceutical development and is appropriately reflected in the SmPC as follows; 'Chemical and physical in -use stability, from the start of preparation of the diluted solution for infusion until end of infusion, has been demonstrated for up to 8 hours at room temperature (up to 25°C) and at 2°C to 8°C for up to 24 hours overall. From a microbiological point of view, the diluted solution for infusion should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, including 4.5 hours at room temperature (up to 25°C) from the start of preparation to completion of the infusion, unless dilution has taken place in controlled and validated aseptic conditions.' Adventitious agents Medicinal product no longer authorised

Overall, the risk of contamination of crizanlizumab with adventitious agents is considered very low. The applicant implemented multiple complementary measures to ensure product safety with regard to non-viral and viral adventitious agents. The measures include careful selection of materials, testing of cell banks and process

<div style=\"page-break-after: always\"></div>

intermediates, testing of microbial attributes at release, and implementation and validation of dedicated virus clearance steps and steps contributing to virus reduction. · Crizanlizumab is manufactured from a CHO cell line without any animal- or human-derived raw materials. · The production cell line, the MCB, as well as the WCB have been manufactured without using any animal- or human-derived materials. The cell banks have been extensively tested for the absence of adventitious viruses and microbial contamination. · Each unprocessed bulk harvest is routinely tested for absence of adventitious viruses and microbial contamination. · Endotoxin levels and bioburden/sterility are adequately controlled throughout the manufacturing process. · Robust and effective overall virus clearance by orthogonal manufacturing process steps has been demonstrated. The manufacturing process includes two dedicated virus clearance steps effective against enveloped and non-enveloped viruses. 2.2.4. Discussion on chemical, pharmaceutical and biological aspects Active Substance The manufacturing process has been described in sufficient detail; all raw and starting materials including the cell banks used in the manufacture of crizanlizumab are listed, identifying where each material is used in the process. Information on the quality and control of these materials has been provided. Overall, an adequate process control system seems to be in place, which ensures a consistent routine manufacture of crizanlizumab active substance. The process validation in combination with manufacture of the verification batches support the conclusion that the manufacturing process for the active substance reliably generates active substance respective finished product meeting its predetermined specifications and quality attributes. The provided batch analyses data shows consistency of active substance batches. Faint translucent swirls (`striae´) consisting of crizanlizumab were observed in one of the finished product validation batches. Detailed investigations identified the root-cause. The three verification batches that were manufactured with tightened parameters comply with all IPCs and release limits. Importantly, no striae were detected in the corresponding finished product batches. Based on the nature of the striae and the implemented measures, potential risk for the patients is deemed low. Under consideration of the additional information provided by the applicant, the major objection raised on this point is considered resolved. Medicinal product no longer authorised

Comparability of crizanlizumab active substance originating from Process B, C, and D (process variant without optimisations and post validation adaptations) has been sufficiently demonstrated. Additional data shows that the optimisation of Process D had no relevant impact on product quality. Some analytical differences were observed between material from Process A, which has been used for the pivotal Phase 2 study, and Process B. However, the observed analytical differences are unlikely to have an impact on clinical performance of the product.

The overall control strategy ensuring that material of sufficiently high quality will enter the market appears is adequate.

<div style=\"page-break-after: always\"></div>

## Finished Product

## 2.3.2. Pharmacology

Crizanlizumab concentrate for solution for infusion 100 mg/ mL contains citrate, sucrose as stabilizer and Polysorbate 80. The finished product is packaged in Type I glass vials (Ph. Eur.) closed with a grey rubber stopper (Ph. Eur.) and sealed with an aluminium cap with a yellow plastic flip-off disk. The manufacturing process of crizanlizumab finished product includes thawing of the active substance, addition of excipient dilution solution, microbial retention filtration and aseptic filling into vials, and is in principle adequately described. The definition of CQAs and overall control of the process appears reasonable. Process characterisation, process validation and batch data indicate that the manufacturing process reliably generates finished product meeting its predetermined specifications and quality attributes. Different versions of the manufacturing process (i.e. process I, II, III and IV) and formulations (i.e. 1, 2, and 3) have been used in the course of manufacturing process development. Differences on analytical level were observed when comparability of Formulations 1 (process I/II) and 2 (process III) has been assessed. However, these analytical differences are unlikely to affect the clinical performance of the product. In conclusion, information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use. 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects The quality of this product is considered to be acceptable when used in accordance with the conditions as defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. Data has been presented to give reassurance on viral/TSE safety. 2.2.6. Recommendations for future quality development In the context of the obligation of the MAHs to take due account of technical and scientific progress, the CHMP recommends the following point for investigation: · The applicant is recommended to re-evaluate the current specifications for active substance and finished product based on commercial batches manufactured and stability data available by December 2025. 2.3. Non-clinical aspects 2.3.1. Introduction Medicinal product no longer authorised

SEG101 is a recombinant humanised IgG2 kappa anti-P-selectin monoclonal antibody which is intended for the prevention of recurrent vaso-occlusive crises (VOCs) in sickle cell disease patients aged 16 years and older. It

<div style=\"page-break-after: always\"></div>

can be given as an add on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate. Originally, the human SelG1 antibody (termed crizanlizumab) was developed by Reprixys P.C. Upon acquisition of Reprixys P.C. by Novartis in 2016, several drug substance manufacturing changes were introduced, including a cell line switch, manufacturing process changes, and a formulation change, resulting in the antibody version SEG101. Primary pharmacodynamic studies The primary pharmacological data consists of literature reports describing the functional activity of the parental anti-P-selectin antibody G1, and of the studies conducted with crizanlizumab addressing the binding properties, functional activity and haemolytic potential. Primary pharmacodynamics was only studied ex vivo with SelG1 and SEG101 because of occurrence of immunological reactions and species differences in target recognition of P-selectin, which hamper animal PD studies. Accordingly, there are no preclinical in vivo studies in a sickle cell disease model or in a vaso-occlusive model with the humanised antibodies SelG1 or SEG101. The target recognition for SelG1 and SEG101 is based on an in silico primary sequence analysis of selectin isoforms and an in vitro surface plasmon resonance (SPR) binding assay, which was used to bridge between SelG1 and SEG101. P-selectin in vivo binds to PSGL-1. Here, P-selectin is substituted by P-selectin fused to immunoglobulin (PSel-Ig) and PSGL-1 by glycosulfopeptide 6 (GSP6), which represents a minimal peptide version of PSGL-1, still capable of binding PSel-Ig. Spiked PSel-Ig (P-selectin fused to immunoglobulin) is allowed to compete with therapeutic antibodies SelG1 or SEG101, which is then expressed as % inhibition PSel-Ig binding. The SPR-assay for PD analysis of SelG1 and SEG101 was a non-validated fit-for-purpose assay. In the first-in-human studies with SelG1, a validated method with the same principle was used. In addition, functional characterisation data derived from the literature with the original mouse anti-P-selectin antibody G1 isolated from hybridomas generated by immunisation of mice with a recombinant human P-selectin containing the lectin and EGF domains were provided. The literature data provide evidence for binding and functional activity of the parental P-selectin antibody G1 that are relevant for the therapeutic rationale in treatment of sickle cell disease. The published in vitro data demonstrate that crizanlizumab blocks binding of human P-selectin to its ligand PSG-1, blocks neutrophil binding to P-selectin, blocks leukocyte rolling and adhesion to human vascular endothelium under shear stress, inhibits interaction of neutrophils with stimulated platelets, and blocks binding of human sickled red cells to human endothelium under flow. Medicinal product no longer authorised

Primate anti-human antibodies (ADAs) were detected in toxicological studies in Cynomolgus monkeys, accompanied by hypersensitivity reactions in some animals. Anti-human antibodies against SelG1 were detected in 40% of all treated animals at least once throughout the observation period in a 26-week repeat-dose toxicity study. Similarly, using SEG101 in pregnant Cynomolgus monkeys and infants a dose dependent increment in anti-human antibody formation against SEG101 was observed (3/7 animals in the 10mg SEG101/ kg group; 8/9 animals in the 50mg SEG101/kg group). The significance of this observation for the evaluation of the PD target interaction in the SPR-binding assay was not addressed and might represent a source of error in calculating % inhibition of P-selectin binding. Similarly, human data obtained from the SPR binding assay might be influenced by anti-SEG101 antibodies. However, the IC50 values for SEG101 and SelG1 in normal human serum, SCD human serum, pregnant and infants Cynomolgus monkey serum gave similar results, between 4.6-6.2 µg/ml.

<div style=\"page-break-after: always\"></div>

In conclusion, all values are in good agreement and fulfil the evaluation criteria for SEG101 and SelG1 induced % inhibition to compete with P-selectin fused to immunoglobulin (PSel-Ig) and glycosulfopeptide 6 (GSP6). The natural ligand of P-selectin, PSGL-1, also binds E- and L-selectin, although with lower affinity. According to literature (Zhang et al. 2016), E-selectin is directly related to the sought indication, VOC in SCD. Related to target recognition, non-specific binding of SelG1 or SEG101 to E-selectin is not shown. PSGL-1 did not bind E-selectin, causing no evaluation of crizanlizumab in this assay. In a similar experimental setting, humanised SEG101 did not bind L-selectin so that one can exclude unselective binding to this isoform. Other cell adhesion molecules (ICAM-1, VCAM-1) potentially involved in the patho-mechanism relevant for the applied indication have not been investigated for unspecific binding and interaction with the SRP-binding assay. The antibody SEG101 was not controlled for unspecific binding in Western blots, FACS or immunohistochemistry to human tissue or patient material. Thus, off-target recognition cannot be excluded from the preclinical data provided. Neutrophil rolling on P-selectin and its blocking by SelG1 was investigated. The estimated IC50 to block neutrophil rolling was between 2.5 and 1.25 µg/ml SelG1 and therefore in good agreement with EC50 values of SelG1 to compete with GSP-6 binding (5.4 µg/ml). The SEG101 antibody was not evaluated in this experimental setting. In order to test complement activation of SelG1, surface plasmon resonance binding to immobilised C1q of the complement system was quantified and compared to two control antibodies. No CDC activity was observed. SEG101 is capable of interfering with platelet counting in EDTA and citrate blood from male healthy volunteers. SEG101 induces platelet clumping which results in decreased platelet counts when spiked ex vivo in EDTA-blood and to a lesser extent in citrated blood. This effect is time-dependent and enhanced when platelets are pre-activated with thrombin; it appears in native blood i.e., in the absence of platelet pre-activation only after 24 hours of incubation. Use of citrate blood and rapid sample processing within 4 hours are recommended. In contrast, no crizanlizumab-related effects on any of the haematology parameters including platelets were observed in the 26-week repeat dose toxicology study and the ePPND study in Cynomolgus monkeys. The difference between monkey and human platelet analyses was explained by faster analysis of monkey blood samples and the higher number of activated platelets in blood samples from SCD patients. Secondary pharmacodynamic studies Crizanlizumab species-cross reactivity was assessed by the analysis of binding capability of the antibody to platelets from human, Cynomolgus monkey, dog, and rat using a fluorescence activated cell sorting (FACS) method. The results show that SelG 1 can bind human and Cynomolgus platelets expressing P-selectin, but not platelets expressing P-selectin from dog or rat. The haemolytic potential of SelG 1 was evaluated in human blood using spectrophotometry to quantify released haemoglobin. Up to 100µg/ml SelG1 no effect was observed on the haemoglobin release. Interference with platelet counting assays Medicinal product no longer authorised

The study was conducted to assess the potential analytical interference of SEG101 on platelet count in EDTAand citrated human blood. Resting and activated platelets isolated from healthy donors were incubated ex vivo with SEG101 spiked in at 0, 10, 40, 100 and 200 μg/mL at room temperature and at 37°C. Platelet counts were performed after 2 hours, 4 hours and 24 hours incubation. The results indicated that SEG101 induces platelet clumping with related-decreased platelet count when spiked ex vivo in EDTA-blood (and to a lesser extend in

<div style=\"page-break-after: always\"></div>

citrated blood). This effect was time-dependent appearing significant after 4 hours of incubation but not after 2 hours and was enhanced when platelets are pre-activated in whole blood primed with thrombin. Safety pharmacology programme Separate safety pharmacology studies have not been conducted. Safety pharmacology endpoints were included the 4-weeks and 26-weeks repeat dose studies. No effects on cardiovascular endpoints were observed in the 4-weeks repeat-dose toxicity study. No effects on cardiovascular, CNS or respiratory function were observed in Cynomolgus monkeys in the 26-week repeat-dose toxicity study. Pharmacodynamic drug interactions Pharmacodynamic drug interaction studies have not been conducted. 2.3.3. Pharmacokinetics The pharmacokinetics of SelG1 and the current product SEG101 was compared in a separate study in Cynomolgus monkeys after a single intravenous dose. In addition, pharmacokinetic properties/ toxicokinetics of crizanlizumab were evaluated in the repeat dose toxicity studies as well as in the enhanced pre- and postnatal developmental toxicity study in Cynomolgus monkeys. SelG1 and SEG101 levels were analysed by appropriately validated methods. The analytical methods for quantification of SelG1/SEG101 serum concentrations, analysis of pharmacodynamics response and detection of anti-drug antibodies in Cynomolgus monkey serum were generally considered sufficient and appropriately qualified or validated for the purpose. Additional information was requested concerning the AlphaLisa assay. The AlphaLisa assay that was employed for detection of anti-SelG1 antibodies in the 4-week and 26-week repeat-dose toxicity studies, and the possible drug interference effect was exploratory in nature and was not validated. The cut-point for positivity was not established from the collection of normal sera but was based on pre-dose individual values. ADAs were detected but they did not have a significant impact on exposure to crizanlizumab in the toxicity studies. Therefore, the assay can be considered sufficient for detection of ADA-positive samples from monkeys, and consequently for interpretation of PK and toxicity data. A single-dose study was conducted to compare the pharmacokinetic properties of the Reprixys (SelG1) and Novartis (SEG101) variants of crizanlizumab. 5 mg/kg or 10 mg/kg of the test compounds were administered intravenously to Cynomolgus monkeys and the animals were observed for 28 days after dosing. Of note, the comparability data provided for the SEG101-batch used in this study was incomplete and lacked target binding analysis by SPR. Medicinal product no longer authorised

In general, the exposure to crizanlizumab increased in a dose-proportional manner for both variants. Exposure to SEG101 appeared to be higher at the 5 mg/kg dose, while exposures were similar for both products at the 10 mg/kg dose level. Calculation of the geometric mean ratios of the Cmax and AUC values for SEG101/SelG1 resulted in a ratio of 1.3 and 1.2 for Cmax at the doses of 5 mg/kg and 10 mg/kg and in a ratio of 1.7 and 1.1 for AUClast for 5 mg/kg and 10 mg/kg.

Tmax ranged from 0.25 to 6.0 h and t1/2 was determined to range from 57.9 to 95.8 h after a single administration.

<div style=\"page-break-after: always\"></div>

Across studies, the volume of distribution (23.5 mL/kg to 53.5 mL/kg) indicated no distribution to tissues as the blood volume of a Cynomolgus monkey was not exceeded. Metabolism and excretion were not specifically investigated within the scope of the pharmacokinetic study as the metabolism and elimination of crizanlizumab are assumed to follow common routes for immunoglobulins. Anti-drug antibodies were detected in four out of 48 serum samples obtained from a total of 16 animals. In total three animals developed ADAs after a single administration of crizanlizumab (1 animal against SEG101 and 2 animals against SELG1). The toxicokinetic parameters of crizanlizumab (SelG1) were determined in a 4-week repeat-dose toxicology study in cynomolgus monkeys, following administration of IV bolus injection every 2 weeks for a total of two doses. After IV bolus administration, the serum concentration-time profile of crizanlizumab declined in a multi-exponential manner. Crizanlizumab exhibited dose-dependent exposure with apparent lack of accumulation. Systemic exposure of crizanlizumab increased in a roughly dose-proportional manner at the tested dose range. No sex difference was observed. The TK parameters of crizanlizumab (SelG1) were determined in a 26-week repeat-dose toxicity study in Cynomolgus monkeys administered with IV bolus injection every 4 weeks for a total of seven doses, followed by a 4-week recovery phase. At Day 1, systemic exposure of crizanlizumab increased in a roughly dose-proportional manner at the tested dose range from 5 mg/kg to 50 mg/kg. No sex difference was observed. The serum concentration-time profile of crizanlizumab appeared to decline in a multi-exponential manner. The volume of distribution was dose-dependent and values indicate that crizanlizumab is not significantly distributed to the tissues. In contrast, clearance did not appear to be dose-dependent. After repeated dosing, TK parameters were only represented graphically as only 4 samples were collected. Such a low number of samples does not enable adequate characterisation of absorption and elimination phase for estimation of Cmax and AUC TK parameters.  ADA positive animals were initially removed from the TK analysis although not all of them consistently showed lower exposure. Recalculated TK parameter summaries for Cmax and AUC after including also the ADA positive animals appeared consistent with the earlier reported TK parameters. Due to the nature of the product, pharmacokinetic drug interactions studies were not conducted. 2.3.4. Toxicology During the development of crizanlizumab, drug substance manufacturing changes were introduced. The preclinical safety profile of crizanlizumab was mostly characterised using the previous CHO-K1-derived material (SelG1) in Cynomolgus monkeys. The current crizanlizumab SEG101 was tested in the enhanced pre- and postnatal developmental toxicity study. Medicinal product no longer authorised

In line with the ICH 6 (R1) Preclinical safety evaluation of biotechnology-derived pharmaceuticals, a focused toxicology program including a single dose toxicity, 4-week and 26-week repeat-dose toxicity studies, an enhanced pre- and postnatal developmental toxicity study and tissue cross-reactivity study was conducted. The Cynomolgus monkey was chosen as a relevant species as anti-P-selectin antibodies were demonstrated not to bind to murine P-selectin but to monkey P-selectin.

<div style=\"page-break-after: always\"></div>

## Single dose toxicity

In line with the ICH S6 (R1) guideline for the preclinical safety evaluation of biotechnology-derived pharmaceuticals, carcinogenicity studies with crizanlizumab have not been conducted. Instead, a comprehensive risk assessment including feasibility assessment of available animal models for carcinogenicity testing was performed. Based on the weight of evidence the risk of carcinogenicity can be considered low. P-selectin is known to have immune modulatory function and thus, its inhibition may influence the immune

In a non-GLP single dose toxicity study, crizanlizumab SelG1 was well tolerated following administration of a single intravenous bolus dose in Cynomolgus monkeys at doses up to 13.7 mg/kg followed by a 28-day observation period. Toxicokinetic analysis revealed dose dependent exposure up to 14 days at the highest dose level. In the 28-day repeat-dose toxicity study two doses of 2, 5 or 25.2 mg/kg SelG1 were administered every other week to male and female Cynomolgus monkeys. No test article-related changes as compared to controls were observed in this study. Thus, the NOAEL was determined at the highest dose administered, i.e. 25.2 mg/kg/dose corresponding to a total dose of 50.4 mg/kg administered over a time-period of 4 weeks. Repeat dose toxicity A 26-week repeat-dose toxicity study with a total of seven administrations of 5, 25 or 50 mg/kg/dose SelG1 including a 4-week recovery period was performed in male and female Cynomolgus monkeys. Toxicology, toxicokinetics, immunogenicity and PD endpoints were evaluated. In the majority of the animals no treatment-related adverse events were observed. Treatment-related vascular inflammation was observed in various organs of two female animals in the high-dose group. The death of one male animal of the high-dose group after dosing at day 141 was attributed to the consequences of a potential hypersensitivity reaction mediated by anti-drug antibodies. The safety margin to the human dose is given as approximately 16-fold for the high dose animals and, thus, not exorbitantly high. It is acknowledged the adverse events (death, vasculitis) were only observed in very few animals and that similar observations are commonly made in Cynomolgus monkeys treated with humanised antibodies. In general, the clinical relevance of such events is considered low due to the immunogenicity intrinsic to humanised antibodies in foreign species. Primate anti-human antibodies were detected in 40% of all treated animals at least once throughout the observation period. The significance of this observation for patients is limited as an immune reaction to humanised antibodies is expected to occur in cynomolgus monkeys. Based on the findings the NOAEL was determined to be 25 mg/kg/dose. Genotoxicity In line with the ICH S6 (R1) guideline for the preclinical safety evaluation of biotechnology-derived pharmaceuticals, genotoxicity studies have not been conducted for crizanlizumab. Carcinogenicity Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

Moreover, the applicant reviewed the literature regarding the potential influence of P-selectin blockade on pregnancy. It has been described that P-selectin, among other selectins, plays an important role especially in early pregnancy, in trophoblast adhesion and migration within the decidual arterioles. However, studies in P-selectin knock-out mice revealed that the lack of P-selectin does not affect fertility or normal development, which seems in contradiction to the finding that P-selectin plays an important role in early pregnancy. This might either reflect species-specific differences, i.e. human trophoblast data versus murine knock-out models, or the system. Moreover, the animal data point towards a protective effect of P-selectin deletion or blocking against metastasising of tumours. Reproduction Toxicity The reproductive and developmental toxicology program includes one study, an enhanced pre- and postnatal developmental toxicity study. No separate studies for fertility or early embryonic development were conducted. Male and female fertility assessments were evaluated in the Cynomolgus monkey in the GLP 26-week repeated dose toxicology study. There were no crizanlizumab-related effects on mean total sperm count, density, motility, morphology, or testicular measurements during the dosing or recovery phase. There were no crizanlizumab-related differences in the number or mean duration of menstrual cycles during the dosing or recovery phase. Potential effects on embryo-foetal development were assessed as part of the enhanced pre- and postnatal development study. 10 and 50 mg/kg SEG101 were administered to pregnant Cynomolgus monkeys starting from GD20-22 until parturition once every other week. No maternal toxicity or developmental effects were observed. An increased incidence of foetal/infant loss was observed in the crizanlizumab-treated groups (50% in the 10mg/kg and in the 50mg/kg groups; 12.5% in the control group). The argumentation that foetal losses were within the historical control range of the facility was not entirely agreed. In order to address a potential relation of increased cases of abortions and stillbirths in pregnant monkeys treated with 10- or 50 mg/kg crizanlizumab as compared with control animals, the applicant provided a summarised ADA status of mothers and infants as well as birth outcomes. Six abortions or stillbirths occurred in each of the treatment groups whereas one event was registered in the control group. From the data provided, no relation of ADA-positivity in mothers and stillbirths/ abortions can be observed; ADA-positive as well as ADA-negative mothers had adverse pregnancy outcomes. Placental infarctions as a cause for stillbirth and abortion were seen in both dose groups (in ADA-positive as well as in ADA-negative mothers), but not in the control group. In the present ePPND study, maternal ADA status was evaluated at GD20-22, 48, 76, 118 and 146. The ADA status given in the table reflects the status evaluated at the last scheduled time point before abortion or stillbirth. Thus, development of ADAs in the time interval between the last blood collection and end of pregnancy is conceivable. Of note, no dose-dependence of abortions and stillbirths could be detected, which would point towards an immune-related effect rather than a PD effect of crizanlizumab. Thus, an influence of a maternal immune reaction to the humanised Ab and the consequent formation of immune complexes on the pregnancy cannot be excluded, especially when considering pregnancy as a hypercoagulable state. Abortions and stillbirths in the present study have in many cases been identified as related to thromboembolic events. However, the fact that the effects on blood vessels were not observed in multiple other tissues in the 26-week repeat dose toxicity study at the dose level of 50 mg/kg, makes the conclusion questionable. In addition, as the selectivity of SEG101 with respect to other selectins was not unequivocally demonstrated, potential off-target binding might have been involved in the adverse pregnancy outcomes. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

lack of P-selectin might be compensated by other selectins involved in trophoblast migration in P-selectin knock out mice. Other data points towards an even foeto-protective effect of P-selectin-blocking by preventing Th1 cell migration to the maternal-foetal interface and, thus, inhibiting inflammation have been provided. The ePPND study, by its nature not covering early pregnancy, cannot inform on potential effects of P-selectin inhibition on trophoblast adhesion and migration, which therefore remains an uncertainty in terms of the use of crizanlizumab in pregnancy. A dose-dependent exposure to SEG101 was detected in pregnant monkeys whereby no accumulation was observed over time. SEG101 was detected in all infants with concentrations multiples of that of their mothers. It is known from literature (Pentsuk and Van der Laan, 2009) that the IgG2 class has a low placental transfer compared to IgG1, with levels in foetuses not exceeding maternal levels. Although the level of crizanlizumab in the infants was above the maternal levels when measured on PND28, these infant levels were still well below the concentrations of crizanlizumab in the maternal animals during the gestation period and reflected the reduced transfer of IgG2 antibodies across the placenta as described above. There was adequate exposure in both, maternal and infant animals and no adverse effects on maternal toxicity or embryo/foetal growth and development were identified in the ePPND study. ADAs were detected in 25% of all treated animals during the gestational phase and all maternal animals were tested positive for ADA during the study period which is expected when administering a humanised antibody to primates. The occurrence of ADA-positive animals was lower in infants. Local Tolerance Local tolerance was assessed in the context of the repeat-dose toxicity and enhanced pre- and postnatal development toxicity studies. No evidence for an irritant potential of crizanlizumab was detected. Other toxicity studies The evaluation of tissue cross-reactivity of SelG1 on a panel of human and Cynomolgus monkey tissues revealed expected binding to platelets, megakaryocytes and Weibel-Palade bodies in endothelial cells. No off-target binding was apparent from the data provided. The applicant provided a justification for the adequacy of the systemic exposure margins from preclinical to clinical studies. Inclusion or exclusion of TK parameters of ADA positive animals did not considerably influence exposure levels and margins. 2.3.5. Ecotoxicity/environmental risk assessment The applicant did not perform specific studies on the ERA but provided a justification for not providing an ERA according to Guideline CHMP/SWP/4447/00 corr 2, which states that, among others, medicinal products containing proteins due to their nature they are unlikely to result in a significant risk to the environment. Medicinal product no longer authorised

## 2.3.6. Discussion on non-clinical aspects

Pharmacology

<div style=\"page-break-after: always\"></div>

The non-clinical primary pharmacology program for crizanlizumab consisted exclusively of in vitro assessment of the target recognition (P-selectin) of the two variants, SelG1 and SEG101, by SPR and of a cell-based assay to demonstrate inhibition of neutrophil rolling. Moreover, in vitro assessment of the interaction with immobilised glycosulfopeptide-6 (GSP6) on the SPR biosensor was performed with blood samples taken from Cynomolgus monkeys treated with SelG1 and SEG101. All assays pointed towards efficient inhibition of P-selectin by SelG1 and SEG101. Additionally, functional characterisation data from the literature with the original mouse anti-P-selectin antibody G1 isolated from hybridomas generated by immunisation of mice with a recombinant human P-selectin provides supportive evidence for the therapeutic rationale in the prevention of vaso-occlusive crises in SCD patients. Nonetheless, the proposed mode of action was not covered in its whole complexity and functional evidence for efficacy in vaso-occlusive crises was not provided in vivo or in vitro . Taken together, the primary pharmacology evaluation of SEG101 (crizanlizumab) lacks firm in vitro documentation, leaving some uncertainty on specificity and off-target activity. However, the supportive functional data generated with the parental antibody SelG1 provide sufficient support for the rationale for crizanlizumab´s biological activity in the prevention of vaso-occlusive crises. SelG1 exhibited very similar EC50 values for binding to P-selectins from Cynomolgus monkeys and humans. This, together with the fact that SelG1 binds to human and Cynomolgus monkey platelets but not to rat or dog platelets indicate that the functional activity of crizanlizumab in the two species is comparable and thus, supports the selection of Cynomolgus monkeys as a pharmacologically responsive species for toxicology testing. It is appreciated that all affinities (SelG1 and SEG101) are in the same concentration range, but a tendency to higher potency of SEG101 is seen in pharmacodynamic (PD) assays for analysis of SEG101 and SelG1 in serum using Pioneer Surface Plasmon Resonance (SPR) System. This observation may reflect better target recognition of the artificial peptide, namely GSP6 and possibly also GSnP6. Thus, one may conclude that the in vivo affinity of the therapeutic antibody SEG101 is overestimated from the non-clinical evaluation, in particular from SPR binding assays. Moreover, this assay does not allow for conclusions beyond target binding. Moreover, conclusions from biological material obtained from crizanlizumab treated patients may be hampered by inhibitory autoantibodies or off-target interactions leading to errors in % P-selectin inhibition values. Crizanlizumab interferes with the ex vivo platelet counting assays in human EDTA blood (and to a lesser extent in citrated blood). The issue is described in section 4.4 of the SmPC which recommends the following measure: 'To mitigate the potential for laboratory test interference, it is recommended to run the test as soon as possible (within 4 hours of blood collection) or use citrate tubes. When needed, platelet counts can be estimated via a peripheral blood smear. ' Patients with sickle cell disease using anticoagulation treatment are likely to use crizanlizumab after marketing. Simultaneous use of crizanlizumab and anticoagulation treatment might lead to an increased risk of bleeding. Pharmacodynamic drug interaction studies with crizanlizumab have not been conducted. This is acceptable but the potential risk of additive effects need to be taken into consideration in the clinical use (please refer to the discussion of clinical safety). Pharmacokinetics Medicinal product no longer authorised

The PK of SelG1 and SEG101 was compared in a bridging study after single dose (5 mg/kg or 10 mg/kg) administration to Cynomolgus monkeys. Exposure to both antibody variants was dose-dependent and appeared to be slightly higher for SEG101 at the lower (5 mg/kg) of the two dose levels. However, the difference can be considered small and of little significance as crizanlizumab is well tolerated in long-term toxicity studies with sufficient margin of safety to clinical dose levels. No distribution to tissues or accumulation was observed for either antibody variant.

<div style=\"page-break-after: always\"></div>

In addition, pharmacokinetic/toxicokinetic properties of crizanlizumab were evaluated in the repeat dose toxicity studies as well as in the enhanced pre- and postnatal developmental toxicity study in Cynomolgus monkeys. In general, the analytical methods for quantification of SelG1/SEG101 serum concentrations, analysis of pharmacodynamics response and detection of anti-drug antibodies in Cynomolgus monkey serum were appropriately qualified for the purpose. Toxicology SelG1 serum concentrations in the single dose toxicity study appeared to be significantly lower than those measured after a single administration (Day 1) in the single-dose toxicity study as well as in the 4-weeks and the 26-weeks repeat-dose toxicity studies. Despite using the same analytical method, it remains unclear whether the SelG1 serum concentrations detected in the single dose toxicity study are correct. Nevertheless, as crizanlizumab was well tolerated in the repeat-dose toxicity studies, this issue does not raise a concern about possible undetected adverse effects due to lower systemic exposure. The current product, SEG101 was used for toxicity testing in only one of the toxicity studies, i.e. the enhanced pre- and post-natal developmental toxicity study while the other studies have been conducted using SelG1, the previous product version. This is considered appropriate from a non-clinical point of view despite the slightly higher systemic exposure level observed for SEG101, as the safety is tolerable and the generated data provides a sufficient margin of safety to the clinical dose level. Toxicity data suggests that crizanlizumab is well tolerated up to 25 mg/kg once per week intravenous administration up to 26 weeks. An inflammatory reaction in the blood vessels of several tissues was observed in two animals of the high dose of 50 mg/kg group. The applicant considers this finding as a secondary immune-complex related reaction unrelated to the pharmacology of crizanlizumab. However, the observed inflammatory response of the blood vessels could also be a direct pharmacology-related reaction at the target site endothelium. Due to the low number of animals, an inherent characteristic of primate studies, it is not possible to exclude one or the other. This could potentially be clinically relevant if it were possible that crizanlizumab might exacerbate the underlying pathophysiological condition. However, since SCD patients have increased levels of P-selectin compared to healthy animals, further exploration in healthy animals is not likely to provide clinically meaningful insight into the issue. Carcinogenicity studies with crizanlizumab have not been conducted. Instead, a comprehensive risk assessment including feasibility assessment of available animal models for carcinogenicity testing was performed. The carcinogenic risk assessment together with the available data from the toxicity studies up to 26 weeks of duration was comprehensive enough to justify the lack of carcinogenic studies. Based on the weight of evidence the risk of carcinogenicity can be considered low. P-selectin is known to have immune modulatory function and thus, its inhibition may influence the immune system. Due to species differences between mice and humans in regulation of P-selectin by cytokines, further animal studies are unlikely to provide clinically meaningful data to address the risk. With regards to the increase in foetal loss/stillbirths in animals treated with crizanlizumab observed in the ePPND immunogenicity. However, putting the mode of action of crizanlizumab, i.e. blocking of P-selectin, into context with the literature review provided by the applicant, a direct pharmacology-based effect cannot be excluded. It is suggested that P-selectin plays an essential role in trophoblast migration and adherence in early pregnancy, Medicinal product no longer authorised study, it is agreed that the placental infarctions observed in some affected animals might be related to a period that was not covered by the ePPND study starting at GD20. Contradictory data exist from P-selectin knock-out mice that appear normal in terms of reproduction and development. Above that, placental infarcts exclusively experienced in verum groups could still be caused by crizanlizumab and/or off-target binding of

<div style=\"page-break-after: always\"></div>

<!-- image -->

crizanlizumab to other selectins. It is acknowledged that the applicant implemented a survey programme to ensure that data related to pregnancies are collected post marketing. The product information adequately reflects the ePPND study results (section 5.3) and a recommendation to avoid the use of crizanlizumab in pregnancy and in woman of childbearing potential not using contraception has been included in section 4.6 of the SmPC (please refer to clinical safety section). Primate anti-human antibodies were detected in almost half of the treated animals at least once throughout the study period. However, this finding is considered of low significance for patients as it is a common observation in monkeys treated with humanised antibodies. Environmental risk assessment The applicant did not perform specific studies on the ERA but provided a justification for not providing an ERA according to Guideline CHMP/SWP/4447/00 corr 2, which states that, among others, medicinal products containing proteins due to their nature they are unlikely to result in a significant risk to the environment. This is considered acceptable. 2.3.7. Conclusion on the non-clinical aspects The primary pharmacodynamic studies provided in support of the MAA of crizanlizumab are largely limited to P-selectin inhibition and are considered quite restricted in terms of demonstrating an effect in the prevention of vaso-occlusive events. However, the functional data generated with the parental P-selectin antibody G1 with identical target binding domain as crizanlizumab, provides supporting evidence for biological activity relevant for prevention of vaso-occlusive crisis. 2.4. Clinical aspects 2.4.1. Introduction GCP The Clinical trials were performed in accordance with GCP as claimed by the applicant The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC. · Tabular overview of clinical studies Table 1: Clinical studies with crizanlizumab that contributed to the safety analysis Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

| authorised   |
|--------------|

At the time of submission of the application for marketing authorisation, two studies with crizanlizumab were ongoing: A2202 and B2201 . Safety data for A2202 was included in the initial submission until the cut-off date: 19-Oct-2018. An update was submitted in the course of the procedure containing data up to 1-Mar-2019. Another update was provided with the responses to the D180 LooI up to 04-Oct-2019. B2201 is a study in paediatric patients and part of the paediatric investigation plan submitted by the applicant. Submission is not intended as part of this application procedure. Further, a phase III confirmatory study will provide the comprehensive data required for the conditional marketing approval: Study A2301 is multicentre, placebo-controlled, double blind study in adult and adolescent SCD patients to assess efficacy and safety of 5 and 7.5 mg/kg in 240 patients, of which at least 48 are adolescents. The study has started to enrol patients in H2 2019 and the results of the primary analysis are planned to be available in 2025. 2.4.2. Pharmacokinetics Crizanlizumab PK and PD have been characterised in healthy subjects as well as in patients with SCD in four clinical studies: Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

The PK parameters were derived using individual serum concentration-time profiles by non-compartmental analysis as well as a compartmental modelling approach, described by a population PK model. The population PK model was developed using all available crizanlizumab PK data that were collected from four different clinical studies. PK data in a total of 251 subjects or patients (87 healthy subjects, 164 patients with SCD) from four clinical studies (A2101, A2102, A2201, and A2202) were analysed to characterise crizanlizumab PK based on population PK approach.

Reprixys Pharmaceuticals Corporation initially developed crizanlizumab until Novartis acquired the company on 18-Nov-2016. Up to the time of acquisition, all pre-clinical and clinical studies used the Reprixys-manufactured crizanlizumab (SelG1). Novartis has since continued technical development and production of crizanlizumab under the code SEG101, using an optimis ed process that leverages Novartis' proprietary Chinese hamster ovary (CHO) cell line in combination with an optimised manufacturing process. Novartis-manufactured crizanlizumab (SEG101) is planned for commercialisation. Study A2102 was conducted to assess the comparability of the Novartis-manufactured crizanlizumab SEG101 and Reprixys-manufactured SelG1. Study A2101 and Study A2102 characterised the pharmacological properties in healthy subjects, and Study A2201 and Study A2202 in SCD subjects. Study A2101 was conducted with SelG1 at doses ranging from 0.2 mg/kg to 8.0 mg/kg and study A2102 with SelG1 and SEG101 at doses of 5 mg/kg (n=28 for SelG1; n=33 for SEG101) and 7.5 mg/kg (SEG101 only, n=7). Study A2201 (registration study) was conducted with SelG1 at doses of 2.5 mg/kg (n=66) and 5 mg/kg (n=67) and the ongoing study A2202 uses SEG101 at a dose of 5 mg/ kg (n=45). Medicinal product no longer authorised

Serial serum samples were collected to determine free and partially bound crizanlizumab levels using a validated ELISA (enzyme-linked immunosorbent assay).

<div style=\"page-break-after: always\"></div>

## Analytical methods:

PK ELISA: Quantification of SelG1/SEG1 in human serum was performed by ELISA. Two different methods were used in the course of development for clinical studies A2101/A2201, and A2102/A2202, respectively. The ELISA used for quantification of SelG1 in human serum for studies A2101 and A2201 is based on a method originally developed for Cynomolgus monkey sera. Subsequently, the method was tested for its suitability to quantify SelG1 in human serum. Verification results indicated that the method is suitable also for testing of human sera. The information on the SelG1 lot used for method verification has been provided, however the information on the reference standard used in clinical studies A2101 and A2201 is not available. Selectivity testing was not considered for assay validation. Furthermore, different versions of the assay were apparently used with different reagents that are considered as critical (i.e. according to existing different versions of SOPs). Later in development, a different ELISA method was implemented. This method is relevant for clinical studies A2102 and A2202 IA. The method validation results as well as the additional information provided (e.g. analysis of parallelism, incurrent sample analysis, cross-validation, and long-term stability) indicate that the new method is suitable for its intended purpose. PD Assay for SelG1 inhibition in human serum: The SPR-based assay was developed to measure the inhibitory effect of SelG1 in clinical trial patient blood serum samples. The effect is observed as inhibition of spiked PSel-Ig (FC-dimer, representing P-Selectin in the assay) binding to glycosulfopeptide 6 (a peptide mimic of the PSGL-1 domain which binds P-selectin). Two different versions of the assay were validated for clinical studies A2101/A2201  and A2102/A2202, respectively. Validation of method used in A2101/A2201 included testing for accuracy, intra-assay and inter-assay precision, determination of limits of quantitation (i.e. LLOQ: 6 µg/mL, ULOQ: 12 µg/mL), reproducibility, and assessment of sample stability (i.e. SelG1: room temperature for normal mixing time and after one and two freeze-thaw cycles; assessment of stability of GSP6 biosensor and PSel-Ig). Of note, certain assay parameters (e.g. long-term stability, inter-assay precision at LLOQ etc.) have not been considered for validation. Furthermore, the lot # of SelG1 reference standard used for method validation and dosing is not available. As regards method DMPK R1600631-pd, please refer to the respective discussion in the non-clinical section. A bead-based assay was used to qualify and specify anti-SelG1 antibodies against closely related structures of SLP-SelG1 Alpha LISA HAHA/MAHA assay 1&amp;2 using rabbit and human IgG to evaluate immunogenicity. This bead-based assay generally fulfilled the predefined criteria during qualification. The assay was used to determine anti-crizanlizumab antibodies in clinical studies A2101 and A2201. Information on the IL-12p70 Reference Standard was provided while detailed info on the Positive control sample was not given. Another immunogenicity assay was developed by Novartis during a later phase in the development to analyse samples in clinical studies A2102 and A2202. Appropriate acceptance criteria were defined and passed as shown by the respective report. This bridging MSD-based immunoassay makes use of an acid dissociation step to disrupt circulating ADA-drug complexes, which was not part of the initially developed assay. Medicinal product no longer authorised

<!-- image -->

In total, 4 clinical studies contributed to PK and or PD data. Furthermore, a Pop PK Analysis was conducted based on PK data from all four studies. A target-mediated drug disposition model was developed, which adequately described the underlying data. The final model included the following covariates: body weight, patient vs. healthy subjects, African-American vs. other races, baseline red blood cell count and serum

<div style=\"page-break-after: always\"></div>

creatinine. The results of the population PK analysis correspond to the results identified in the clinical studies.

<!-- image -->

In healthy subjects (Study A2102) the mean clearance was 11.7 mL/hr and the terminal elimination half-life (T1/2) was 254 h (or 10.6 days) at crizanlizumab (SEG101) dose level of 5 mg/kg.

From the data set provided, the following information can be derived: Absorption In Study A2101, the first in human single centre study, which was conducted in healthy subjects, only cohort D received SeIG1 at a dose level of 5.0 mg/kg, the dosage strength intended for MA as can be seen in the table above. The median Tmax was 4.83h. Data are only available for 6 patients. Regarding study A2102, which was also conducted in healthy subjects, the median Tmax was 2.00h following a single IV infusion of 5 mg/kg crizanlizumab. For study A2202, which was conducted in SCD subjects, only interim data is available for 39 subjects at week 1 (single initial infusion) and for 20 subjects at week 15 (steady state). Results indicate that the median Tmax following a 5 mg/kg infusion ranged between 1.58 h and 1.63 h, respectively. The Tmax seems comparable between single initial infusion and steady state. Overall, relevant PK parameters on absorption should be obtained from subjects with SCD since this represents that target population. Based on the results from study A2202, which is still ongoing, the median time to reach maximum serum concentration of crizanlizumab (Tmax) was 1.92 hours at steady state following intravenous administration of 5 mg/kg over a period of 30 minutes in sickle cell disease patients. Distribution As a monoclonal Ab, the distribution is typical of endogenous human antibodies within the vascular and extracellular spaces. No specific study was designed to determine the plasma protein binding of crizanlizumab. The distribution of crizanlizumab in healthy subjects was 4.26 L after a single 5 mg/kg intravenous infusion of crizanlizumab in healthy volunteers. The volume of distribution (the combined volumes of central and peripheral compartments at steady state) was estimated to be 4.98 L based on the population PK approach. Metabolism No specific investigations of the metabolism of crizanlizumab were performed. Antibodies are primarily eliminated via proteolysis by lysosomal enzymes in the liver to small peptides and amino acids. Elimination No mass balance or metabolism study of crizanlizumab have been performed and are not required since crizanlizumab is an IgG antibody and is degraded by proteolytic catabolism. Thus, no metabolic enzymes like CYPs or UGTs contribute to its clearance. Medicinal product no longer authorised

Results from study A2202 conducted in subjects with sickle cell disease indicate a mean apparent elimination T1/2 of 183 hours (7.6 days). Based on the mean AUCtau value (The AUC calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume1) at steady state (20400 μg × h/mL), the clearance

<div style=\"page-break-after: always\"></div>

(AUCtau divided by the dose) is estimated to be approximately 17.2 mL/h in patients with SCD weighing 70 kg. The clearance seems to be higher in SCD subjects. This finding is caused by differences in P-selectin levels between the two populations since the used ELISA PK assays quantify free and partially bound crizanlizumab. Bioequivalence Study A2102 was designed to compare crizanlizumab pharmacokinetics and pharmacodynamics when administered as SEG101 and SelG1 to healthy subjects. The study population included healthy male and female subjects aged 18-55 years. Twenty-eight (28) subjects were randomised to receive SEG101 5.0 mg/kg and 33 subjects to SelG1 5.0 mg/kg. The reference product was SelG1 (5.0 mg/kg) and the test product was SEG101 (5.0 mg/kg), which were supplied as open-label medication for intravenous infusion. Subjects received a single infusion dose of SelG1 5.0 mg/kg (reference) or SEG101 5.0 mg/kg (test) or SEG101 7.5 mg/kg (exploratory) on Day 1 and were confined to the study centre for at least 168 hours (7 days) following drug administration. Comparability between SEG101 and SelG1 on the PK level could not be demonstrated. The geometric mean ration (SEG101/Se1G1; 90% CI) of AUCinf was 1.277 (1.192 to 1.367) and for AUClast 1.276 (1.197 to 1.360); the 90% confidence intervals for both AUCinf and AUClast crossing the pre-defined comparability limits (0.80 1.25). The geometric mean AUCs (AUCinf and AUClast) were 28% higher for SEG101 than for SelG1 (AUCinf: 127.5%; AUClast: 127.58%). Only the Cmax values were comparable, with a 90% CI between 0.80 and 1.25 and a GM ratio of 1.114 (1.033 to 1.201). For AUCinf and AUClast, differences in the distribution of the values could also be observed with the geometric mean of SelG1 being near the minimum of SEG101 values. Overall, the study intended to demonstrate comparability between SelG1 and SEG101 on a PK level showed substantial differences in exposure. The crucial question was whether the PK differences between the earlier version of crizanlizumab (SelG1; used in the clinical registration study) and the final to be commercialised version (SEG101) translate into different PD behaviour. In response to CHMP´s questions, the applicant provided a reanalysis of samples from the initial pivotal registration study A2201 conducted with the new Novartis assay (Navigate PD assay). These new results were compared with the original results of study A2201 in order to better understand the origin of the observed differences in PD inhibition (%P-selectin inhibition 70% in pivotal study A2201 (SelG1), ~100% in study A2202 (SEG101)) and if these may indeed be attributed to the different PD assay versions (historical Reprixys assay and new Navigate assay). Overall, 156 samples were retested, with 105 samples meeting the acceptance criteria (18 pre-dose samples and 87 post-dose samples). The samples for reanalysis were categorised into high (ITRI (Initial Test results inhibition) 70-100%, medium (ITRI: medium 9.2-69.9%) and low inhibition groups (ITRI BLQ (&lt;9.2%). The high inhibition group is intended to evaluate the long-term sample stability. The medium inhibition group served to demonstrate assay related differences between the Sustain and A2202 study, and the low inhibition group to evaluate the improved sensitivity of current assay. Medicinal product no longer authorised

In the high inhibition group, 93.3% (42 from 45) of the samples showed comparable inhibition with less than 10% difference inhibition.

In the medium inhibition group, 2/3 (23 from 34) of the total samples showed an approximately 30% or higher inhibition.

In the low inhibition group half of the samples remained BLQ and the other half had 15% to 28% increase in PD activity, however data are obtained in only 8 patients.

<div style=\"page-break-after: always\"></div>

Pharmacokinetics in target population

Crizanlizumab was administered intravenously at the assigned dose of 5 mg/kg on Study Day 1 (Week 1 Day 1), after 2 weeks on Study Day 15 (Week 3 Day 1) and every 4 weeks ± 3 days thereafter. This dosing schedule is consistent with the recommended dosing regimen for this application. No dose change or modification was allowed in the study.

The high inhibition group (end of dosing interval) showed comparable inhibition between original and retested samples. The medium inhibition group displayed on average an about 30% higher %P-selectin inhibition in the re-tested samples. This supports the notion that the originally observed difference in %P-selectin inhibition may rather be attributed to the different assays used since the same samples tested with the Navigate assay displayed higher inhibition than with the historical Reprixys assay. Additionally, the newly fitted Emax model supports comparability between SelG1 a nd SEG101 (1.89 μg/mL vs. 1.47 μg/mL) as the EC50 estimates can be deemed comparable. Comparability also applies to the model predicted curves. Taking the totality of the available data into account (pharmacology, efficacy and safety), it can be concluded, that the observed differences in %P-selectin inhibition between SelG1 and SEG101 can most likely be attributed to differences of the historical Reprixys PD assay vs. the Navigate assay, as well as a shift in the standard titration curve. Dose proportionality and time dependencies In healthy subjects in study A2101 , Cmax increased in a more than dose proportional manner within a dose range of 0.2 - 8mg/kg, indicating non-linear PK. This is however likely not clinically relevant since nearly dose proportionality could be observed above the 5 mg/kg dose strength applied for. In study A2102 , where 5 mg/kg and 7.5 mg/kg were used, Cmax and AUC (AUClast, and AUCinf) increased in a nearly dose proportional way. The dose increased from 5 mg/kg to 7.5 mg/kg led to an increase of Cmax by around 36% and for AUC by around 57% - 63%. Results from study 2102 also indicate that the mean clearance was comparable between 5 mg/kg and 7.5 mg/kg strength, 11.7 mL/h and 10.9 mL/h respectively. Study A2201 , the registration study in SCD subjects, assessed primarily the safety and efficacy of Reprixys manufactured crizanlizumab, SelG1, with or without HU/HC therapy in patients with SCD (see also efficacy and safety sections below for further details). Pharmacokinetics and pharmacodynamics of SelG1 in patients with sickle cell disease was an exploratory endpoint. Considering the PK results from Study A2201, the systemic exposure after repeated dosing appears stable: The mean through serum concentrations obtained every 4 weeks during the course of one year of treatment seem comparable, indicating time-independent PK behavior. This also suggests that no accumulation over time seems to occur. These findings are in line with the results from study A2202, with comparable mean Cmax values at steady state between Week 15 and Week 1 (124 ± 31.6 μg/mL and 124 ± 31.6 μg/mL, respectively). Study A2202 was specifically designed to assess PK and PD of crizanlizumab in SCD subjects. The study is still ongoing and interim results as of the cut-off day 19 th  Oct.2018 are available. 45 patients were enrolled and received 5 mg/kg (at data cutoff, no patient had yet received 7.5 mg/kg). 55.6% of subjects were female and 44.4% male. All patients were of African or of mixed descent with African ancestry. The median (min-max) age at baseline was 29.0 (17-65) years. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Interim results indicate that the median Tmax at first dose and at steady state was around 1.6h. The mean apparent elimination T1/2 was 183 hours (7.6 days). The mean Cmax at first dose at week 1 was 116 ± 91.3 μg/mL and at week 15 124 ± 31.6 μg/ml indicating a lack of accumulation. After the 30-minute infusion maximum serum concentrations were achieved with steady concentrations for about 6 hours after initiation of the infusion. Based on the mean AUCtau value at steady state (Week 15; 20400 μg × h/mL), the clearance (AUCtau divided by the dose) is estimated to be approximately 17.2 mL/h in patients with SCD weighing 70 kg. Considering the mean trough concentration obtained every 4 weeks from week 7 to week 27, the values ranged from 3.78 μg/mL to 9.8 μg/mL with trough concentration obtained at week 3, two weeks after the previous infusion being 18.2 μg/mL. Special populations No dedicated study in special populations has been conducted. However, different demographic and covariates were evaluated in the population PK analysis to assess any influence on crizanlizumab PK. PK data in a total of 251 subjects or patients (87 healthy subjects, 164 patients with SCD) from four clinical studies (A2101, A2102, A2201, and A2202) were analysed to characterise crizanlizumab PK based on population PK approach. The dataset in the population PK analysis included 30 Caucasians, 213 African Americans, 1 Asian and 7 patients from other origins; 122 males and 129 females aged 16 to 65 years. Renal impairment Concerning renal impairment the PopPK analysis did not detect any relation between clearance of crizanlizumab and renal function. Further, the applicant has calculated AUC values based on raw data and plotted these across different renal function categories. No trend between renal function and AUC values appears present. Being a human IgG immunoglobulin with large molecular size (148 kDa), excretion in the urine is expected to be rather unlikely. However, the information with regards to severely impaired subject is very limited, with only three subjects included in the registration study A2201. Hepatic impairment Hepatic impairment is not expected to have an impact on the crizanlizumab PK as IgG Antibodies are eliminated via intracellular catabolism, following fluid-phase or receptor-mediated endocytosis. Based on a population pharmacokinetic analysis, no apparent gender related difference in crizanlizumab clearance were observed. This also seems to be the case for simulated exposure between non-African American, black subjects or subjects with African origin. Bodyweight Medicinal product no longer authorised

Bodyweight was identified as a clinically significant covariate on several factors including clearance in the population PK analyses and further analyses were requested. In response to questions raised in the D120 LoQ, the applicant has calculated AUC values based on raw data and plotted these as a function of bodyweight quartiles. No trend between bodyweight and AUC values appears present, and this suggests that the mg/kg dosing is appropriate.

## Age

<div style=\"page-break-after: always\"></div>

In study A2201, the age ranged from 16 to 63 years. Thus, no data from patients older than 63 years are available. Pharmacokinetic interaction studies No in vitro or in vivo Drug-Drug Interactions (DDI) study has been performed. The most common concomitant medications in SCD patients is HU/HC. The effect of a concomitant medication including HU/HC, corticosteroids and anti-inflammatory agents, was examined by a population PK approach. Concomitant medications including HU/HC had no effect on crizanlizumab PK in patients with SCD. It is unlikely that crizanlizumab could have an effect on other drugs via drug metabolising enzymes or transporters in terms of inhibition or induction. Population PK analyses A population PK model has been developed on the basis of PK data from all clinical studies. The model is mainly relevant for providing information about crizanlizumab PK in special populations, and for bringing together the PK data from individual studies. The model uses a quasi-equilibrium approximation of the full target-mediated drug disposition (TMDD) model to describe the disposition of crizanlizumab. Although longitudinal data were available of free crizanlizumab concentrations, P-selectin concentrations (study 2201) and ex vivo %P-selectin inhibition, the TMDD model was fitted only based on the crizanlizumab data. Bodyweight was implemented as a covariate of crizanlizumab clearance and volume of distribution with fixed allometric exponents of 0.75 and 1, respectively. The model with fixed allometric exponents performed statistically better than a model with no bodyweight as a covariate. Covariate screening was further performed only for the clearance parameter. Covariates were selected for further evaluation based on visual inspection of Empirical Bayes Estimates of clearance versus each of the covariates to be inspected. When covariates were highly correlated with each other, only one of the confounding covariates were evaluated. The chosen covariates were included in the population PK model by forward inclusion and backwards deletion steps with p-values of 0.05 and 0.01, respectively. Further, the inclusion of a covariate was dependent on its statistical significance and stability of the model. Model run output with reported boundary or singular matrix problems were not accepted. The following covariates were identified to be statistically significant predictors of clearance: patients vs. healthy subjects, African American vs. other races, baseline red blood cell count, baseline serum creatinine. Time-dependent covariates for red blood cell count and serum creatinine concentration were not shown to be significant when added separately to the model that already included their baseline effects. The relevance of significant covariates was evaluated through comparison of the derived secondary PK exposure parameters in virtual patient population of 500 individuals per simulation. The simulations were carried out for 5 mg/kg crizanlizumab in SCD patients from the final covariate model. The Forest plot (Figure 1) shows the 90% prediction interval and median steady-state AUC0-672h relative to or centred to the median steady-state AUC0-672h of the typical individual. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

Figure 1: Forest plot showing the median and 90% prediction interval of the steady-state area under the curve at the extreme values of significant covariates relative to the median steady-state area under the curve of the typical individual after 5 mg/kg crizanlizumab administration Renal and liver function were not shown to be significant covariates of crizanlizumab clearance. The Empirical Bayes clearance estimates from the final covariate model were plotted by renal and liver function categories in Figure 2. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Controversies and reservations with regards to the developed population PK model are discussed below.

<!-- image -->

The main PD marker utilised in the conducted studies is an ex vivo % P-selectin inhibition measured by a competitive binding assay mimicking the in vivo mechanism. The %P-selectin inhibition was measured in human serum across the clinical studies. It was considered that it was not an ideal PD marker, hence the applicant provided an additional analysis of retested samples which suggests that the differences observed in %P-selectin inhibition between studies and antibody versions [(70% inhibition in pivotal study A2201 (SelG1) versus ~100% in study A2202 (SEG101)] may be attributed to the different PD assay versions (historical Reprixys assay and new Navigate assay).

The population PK model has been fitted in such a way that the PK parameters relating to target-mediated clearance of crizanlizumab are estimated only based on a subset of the data, and it is possible that they are biased. The practical consequence is that the model may not accurately predict nonlinearity of crizanlizumab PK. However, given that crizanlizumab PK is almost linear in the clinically relevant dose range of 5 mg/kg to 7.5 mg/kg, this issue is not considered critical. Concerning the Pop-PK model, several questions were raised to address issues such as updated Visual Predictive Checks, to show the standard errors of the TMDD PK parameters, which were subsequently fixed, to clarify how the quantiles are calculated in a quantile-quantile plot of conditional weighted residuals, fitting a model where these exponents are estimated based on data, etc. The applicant could clarify several issues, but it also became apparent that the PK modelling results need to be treated with caution since none of the reported models seemed to have converged to maximum likelihood estimates; they had terminated early due to rounding errors. The applicant was therefore requested to produce a plot of crizanlizumab AUC (calculated based on raw time-concentration data) versus renal function. The requested plot showed that there were no trends in crizanlizumab AUC versus renal function. Further, the applicant showed that the presented models can converge successfully when the number of requested significant digits is reduced to four instead of the originally requested six significant digits. The parameter estimates of these new models were essentially unchanged, thus demonstrating that the models have indeed converged to maximum likelihood estimates. 2.4.3. Pharmacodynamics Mechanism of action Crizanlizumab represents a selective humanised IgG2 kappa anti-P-selectin monoclonal antibody (mAb) that binds to human P-selectin with high affinity, blocking the interaction with its ligands, including P-selectin glycoprotein ligand 1 (PSGL-1). Elevated levels of P-selectin are found in patients with SCD (Matsui et al 2001). P-selectin is a cell adhesion molecule that plays an important role in the development of vaso-occlusion and VOC. Crizanlizumab was shown to be species-specific, binding only to P-selectins from human- and related non-human primate and monkey species. When tested against P-selectin from lower species, such as rat or dog, crizanlizumab did not bind to it. Primary and Secondary pharmacology Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

Additionally, the chosen PD marker (%P-selectin inhibition) seems to correlate with higher crizanlizumab concentration and higher efficacy. The ex vivo %P-selectin inhibition seems to correlate with higher concentrations and resulting efficacy. P-selectin inhibition is expected to play a significant role in pathophysiology of SCD, but no information is available on P-selectin expression in different patient populations (for example, different genotypes), according to disease severity (patients with recurrent VOCs vs. patients with more benign phenotype), or according to activity of the disease. In response to questions raised in the day 120 LoQ, it became apparent, that neither soluble P-selectin concentration at baseline nor genotype were predictive of the number of VOCs a patient will experience over time. Only the baseline VOC count and crizanlizumab exposure were predictors of future VOC counts in study A2201. From the clinical data obtained in the phase 1 dose finding study A2101, a clear correlation between applied dose and PD response was observed. Systemic exposure and PD effect of crizanlizumab increased in a dose-dependent manner. The following figure illustrates the %P-selectin inhibition. Figure 3: Pharmacodynamics of SelG1 in normal human patients An exposure-response model was included in the submission, which contained PD data from all crizanlizumab clinical studies (from two phase I- and two phase II studies). Crizanlizumab serum concentration, P-selectin %-inhibition, dosing history and covariate data from studies A2101, A2102, A2202 and A2201 was used to develop a crizanlizumab exposure- P-selectin inhibition model. The model parameters were estimated by population approach using the SAEM algorithm implemented in software package MONOLIX (version 2018R1). A non-linear sigmoid Emax model was fitted to the pooled crizanlizumab serum concentrations. The Emax model assumes that a rapid equilibrium is obtained between crizanlizumab serum concentration and inhibition. Medicinal product no longer authorised

The factor 'assay' was added a priori to the EC 50 parameter of the model, given that methods of the PD assays (SensiQ and Navigate assay) were different between studies CSEGA2101, A2201 and CSEGA2102, A2202. Potential covariate effects on PK parameters in the model were planned to explain partially the inter-subject variability in parameters and to better understand causes of variability. Covariate identification followed the

<div style=\"page-break-after: always\"></div>

| Parameter                                                      | Estimate                         | SE                                  | RSE(%)                        |
|----------------------------------------------------------------|----------------------------------|-------------------------------------|-------------------------------|
| Emax [%] EC50 (SensiQ) [  g/mL] β(EC50,Navigate)   (EC50) A | 100.10 5.10 -1.19 2.06 0.47 8.79 | 0.233 0.214 0.072 0.042 0.027 0.115 | 0.23 4.18 6.02 2.03 5.75 1.30 |

<!-- image -->

Note: red dots indicate concentrations that were replaced by the lower level of quantification (LLOQ) of crizanlizumab serum concentrations.

principle of parsimony. The crizanlizumab serum concentration is a base covariate and included in all models. In addition, the differences between PD assays (SensiQ and Navigate assay) were considered as important prior knowledge and was, therefore, included in the base model. Table2:  Parameter  estimates  of  the  final  base  Emax  model  between  crizanlizumab  serum concentration (µg/mL) and P-selectin inhibition (%), PKPD Analysis Set. No additional factor or covariate was identified to improve the fit of the base Emax model. Figure 4 shows individual observations and predicted concentration -inhibition curve based on population parameter estimates of the final base Emax model. Medicinal product no longer authorised

Figure 4 Crizanlizumab concentration vs. inhibition (%) by assay

<div style=\"page-break-after: always\"></div>

However, uncertainties with regards to the reliability of the PD results remain in light of the very low CV% observed for the SeIG1 formulation in comparison to the SEG101 formulation, also in terms of the SeIG1 formulation displaying less variability. Furthermore, the observed coefficients of variation were substantially smaller than expected at the time of study planning. In the responses, the applicant provided a discussion to address these issues, which is deemed acceptable.

The factor assay (SensiQ or Navigate) was added a priori as a covariate of EC50. Subsequently, variant (SelG1 or SEG101) was identified as a statistically significant predictor of EC50 with an improvement of 3.35 points in Akaike Information Criterion. However, variant was not retained as a covariate due to high relative standard errors of 43%. The different variants have been analysed with the same Navigate assay only in study A2102. This was however in HV with lower P-selectin expression level. Therefore, this data is not considered sensitive enough to identify differences. At this point, it is not clear whether the assay or the variant would independently better explain the variability in EC50. In response to questions raised in the D120 LoQ, the applicant has supplied the requested information. The new model with variant as a covariate of EC50 parameter fits the data slightly less well than the original model with factor assay as a covariate of EC50. However, the parameter values are similar, here β(EC50,SEG101) has value of -1.17 and in the original report β(E C50,Navigate) had a value of -1.19. Based on the available data, factor 'assay' seems to be somewhat more likely to be the cause for differing PD results than 'variant'. In response to the Comparability MO in the D180 LooI, the applicant presented an additional Emax model using only data derived with the Novartis assay (Studies A2102, A2201 re-analysis, A2202). The model included the difference in manufacturing process (namely SelG1 vs. SEG101), but not 'assay' as in the pre vious Emax model. The new model indicates that EC50 estimates are comparable between SelG1 (1.89 μg/mL) and SEG101 (1.47 μg/mL). Model predicted curves displaying crizanlizumab serum concentration vs. ex vivo %P-selectin inhibition indicate comparable characteristics and therefore support the comparability of the results. Data from the comparative study A2102 in healthy subjects seems to indicate comparable PD behaviour for the two formulations SelG1 and SEG101 for the AUC of % P-selectin inhibition-time profile from time zero to Day 29 (AUC29days), the geometric mean ratio (90% CI) was 0.992 (0.981 to 1.00) and within pre-specified limits of the 90% confidence intervals, as can be seen in the following table. Table 3: Primary PD parameters for crizanlizumab 5.0 mg/kg treatment group (PDS) The rationale for using AUC29days was based on the fact that crizanlizumab is administered to patients every 4 weeks (=28 days) in clinical settings after the first two doses which are given at the start of treatment and Week 3. Medicinal product no longer authorised

The applicant provided the requested data for the distribution P-selection inhibition at specific time points. Based on the provided data, the sensitivity of this approach to detect differences between both crizanlizumab versions

<div style=\"page-break-after: always\"></div>

is still questionable especially since the %inhibition of both versions is close to 100% until around day 29. Later on, the ceiling effect seems less of a concern (Figure above). Therefore, another option would be to use AUC57 with the original ANOVA analysis. Results for PD-AUCD57 were presented with ANOVA covariate adjusted ratio of geometric means of 1.027 with 90% CI (0.992, 1.064) indicating similarity in mean % P selectin inhibition for SEG101. Considering the target population of SCD patients, results from study A2201 indicate that following a 2.5 mg/kg dose the mean trough % P-selectin inhibition obtained 4 weeks post-dose (from Week 6 to Week 50) ranged from 23.965% to 39.990%. Mean trough % P-selectin inhibition values obtained 2 weeks post-dose (Week 2 and Week 52) were 63.8% and 60.5%, respectively. Following the 5.0 mg/kg dose the mean trough % P-selectin inhibition obtained 4 weeks post-dose (from Week 6 to Week 50) ranged from 63.5% to 76.3%. Mean trough % P-selectin inhibition values obtained 2 weeks post-dose (Week 2 and Week 52) were 92.7% and 85.9%, respectively. With placebo the mean trough % P-selectin inhibition obtained 4 weeks post-dose (from Week 6 to Week 50) ranged from 2.8% to 6.1%. Overall consistency between PD effects with increasing dose could be observed. For the 5.0 mg/kg group trough SelG1 concentrations of ≥ 10 μ g/mL resulted in % P-selectin inhibition of ≥ 70%. Interim data (cut-off October 2018) of study A2202 indicates that the arithmetic mean and median post-dose inhibition remained above 98% at week 1 up to 360 hours post-dose and week 15 up to 360 hours post-dose. Considering the trough median and the arithmetic mean P-selectin inhibition it has to be noted, that the median trough P-selectin inhibition remained relatively stable at 100% up to Study Day 183. However, arithmetic mean P-selectin inhibition decreased over time. The applicant attributes this finding to two outliers, patients 5002002 and 5015001. These patients had a pre-dose PK concentrations drop accompanied by decrease in P-selectin inhibition; they were tested negative for ADAs. In the responses the applicant has further corroborated this assumption and provided a discussion attributing the lower than expected P-selectin inhibition to the unusually low crizanlizumab serum pre-dose concentrations as well as low pre-dose concentrations at later time points in these two patients. Immunogenicity: Immunogenicity assessment was performed in 88 healthy subjects and 175 patients with SCD. In study A2101 three subjects were tested positive for Anti-crizanlizumab antibodies. One subject had treatment induced ADAs, which were transient in nature, while two subjects had pre-existing ADAs. In study A2201 ten patients were tested positive for Anti-crizanlizumab antibodies. Two subjects had crizanlizumab-induced ADAs. Eight subjects had pre-existing ADAs. In study A2102 one subject in the SelG1 (5 mg/kg) treatment group and another subject in the exploratory SEG101 7.5 mg/kg arm tested positive for ADAs 106 days after receiving a single dose of crizanlizumab. No other subjects were tested positive for ADAs throughout the study. In study A2202, where interim data is available, no subject seems to have developed ADAs. Medicinal product no longer authorised

Overall, ADAs developed transiently in 3 out of 88 healthy subjects (3.4%). 2 out of 175 SCD subjects transiently developed ADAs. This does not give any grounds for concern since all 5 signals were detected transiently, with only 1 subject out of 111 developing transient ADAs at the dose of 5 mg/kg which represents the dosage strength intended for MA. Furthermore, when looking at the crizanlizumab concentrations of ADA positive and negative subjects, the concentration levels were mostly overlapping.

<div style=\"page-break-after: always\"></div>

The applicant also evaluated in vivo % inhibition of P-selectin binding in ADA-positive subjects or patients in relation to final base PK-inhibition model. The P-selectin inhibition values of treatment induced ADA-positive and pre-existing ADA-positive patients are distributed around the expected median curve of the base PK-inhibition model, which hints at negligible effects in both, PK and PD. In conclusion, based on the data available and the low incidence of immunogenicity, ADAs against crizanlizumab did not appear to affect PK or PD of crizanlizumab. However, uncertainties in terms of a potential underestimation of ADA responses in the registration study A2201 were identified. As crizanlizumab is a monoclonal antibody, an effect on the QT interval is not expected. 2.4.4. Discussion on clinical pharmacology Data from four clinical studies provide results to describe Crizanlizumab PK and PD. Study A2101 and Study A2102 characterised the pharmacological properties in healthy subjects, and Study A2201 and Study A2202 in SCD subjects. Furthermore, a Pop PK Analysis was conducted. From the data set provided, following information could be derived: Absorption: Relevant PK Parameters should be obtained from subjects with SCD since this represents that target population. Based on the results from study A2202, which is still ongoing, results indicate that the median time to reach maximum serum concentration of crizanlizumab (Tmax) was 1.92 hours at steady state following intravenous administration of 5 mg/kg over a period of 30 minutes in sickle cell disease patients. This reflected in section 5.2 of the SmPC and is based primarily on the result of study A2202, which is still ongoing. Since only preliminary results are available the information in the SmPC may need to be adapted when final results become available; the applicant committed to that. The final CSR for study A2202 should be available by end of 2025. Distribution: As a monoclonal antibody, the distribution is typical of endogenous human antibodies within the vascular and extracellular spaces. No specific study was designed to determine the plasma protein binding of crizanlizumab. The distribution of crizanlizumab in healthy subjects was 4.26 L. The volume of distribution (the combined volumes of central and peripheral compartments at steady state) was estimated to be 4.98 L based on the population PK approach. Metabolism: No specific investigations of the metabolism of crizanlizumab were performed. Antibodies are primarily eliminated via proteolysis by lysosomal enzymes in the liver to small peptides and amino acids. Elimination: No mass balance or metabolism study of crizanlizumab have been performed and are not required since crizanlizumab is an IgG antibody and is degraded by proteolytic catabolism. Thus, no metabolic enzymes like CYPs or UGTs contribute to its clearance. In healthy subjects (Study A2102) the mean terminal elimination half life (T½) was 10.6 days and the mean clearance was 11.7 ml/h at crizanlizumab dose level 5 mg/kg. In patients with sickle cell disease, the mean elimination T½ during the dosing interval was 7.5 days. Medicinal product no longer authorised

Results from study A2202 conducted in subjects with sickle cell disease indicate a mean apparent elimination T1/2 of 183 hours (7.5 days). Based on the mean AUCtau value (The AUC calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume1) at steady state (20400 μg × h/mL), the clearance (AUCtau divided by the dose) is estimated to be approximately 17.2 mL/h in patients with SCD weighing 70 kg.

<div style=\"page-break-after: always\"></div>

Apparently, the clearance seems to be higher in SCD subjects. The applicant attributes this finding to differences in P-selectin levels between the two populations. This may indeed be the case since the ELISA PK assays used quantify free and partially bound crizanlizumab. The main PD marker utilised in the studies conducted is an ex vivo % P-selectin inhibition measured by a competitive binding assay that mimics in vivo mechanism. The ex vivo %P-selectin inhibition, was measured using human serum across clinical studies. From the clinical data obtained in the dose finding study A2101, a clear correlation between dose and PD response is apparent. Overall, systemic exposure and PD effect of crizanlizumab increased in a dose-dependent manner. Considering the target population of sickle-cell-disease patients, results from study A2201 indicate that following the 2.5 mg/kg crizanlizumab dose, the mean trough % P-selectin inhibition obtained 4 weeks post dose (W6 to W50) ranged from approximately 24% to 40%. Mean trough % P-selectin inhibition values obtained 2 weeks post dose (W2 and W52) were 63.8% and 60.5%, respectively. Following the 5.0 mg/kg crizanlizumab dose, the mean trough % P-selectin inhibition 4 weeks post dose (W6 to W50) ranged from 63.5% to 76.3%; 2 weeks post dose (W2 and W52), the respective values were 92.7% and 85.9%. Following placebo, the mean trough % P-selectin inhibition obtained 4 weeks post dose (from W6 to W50) ranged from 2.8% to 6.05% Overall consistency between PD effects with increasing dose could be observed. For the 5.0 mg/kg group trough SelG1 concentrations of ≥ 10 μ g/mL resulted in % P-selectin inhibition of ≥ 70%. Interim data (cut-off October 2018) of study A2202 indicates, that the median post-dose % inhibition remained above 98% at week 1 and week 15 up to 360 hours post dose. Some uncertainties have been identified, which warrant a more in-depth discussion on the PK and PD of crizanlizumab. One major issue concerns the comparability between the crizanlizumab versions used in the trials. The formulation SelG1 was developed by Reprixys Pharmaceuticals Corporation. Up to the time of acquisition by Novartis in 2016, all non-clinical and clinical studies used the Reprixys-manufactured crizanlizumab (SelG1). Novartis then optimised relevant parameters and developed SEG101, which is planned for commercialisation. Study A2102 was conducted to assess the comparability of the Novartis-manufactured and Reprixys-manufactured crizanlizumab. However, results indicate that for the SEG101 formulation the geometric mean ratio of AUCinf and AUClast were 28% higher than for SelG1 (AUCinf: 127,5%; AUClast: 127,58%). The lower 90% CI bound of the AUCs was above 1.19, indicating a statistically significant difference. No firm conclusion on whether or not the analytical methods used have an impact on this observation can be drawn, since two different versions of the ELISA assay were used in the course of development. The reliability of the validation and thus, of PK data generated with the previous assay, remains questionable. The new assay can be considered as sufficiently validated and suitable for its intended purpose. No relevant new information concerning PK similarity has been provided with the responses. Consequently, reliability of the PD results remains of particular importance in this context. Medicinal product no longer authorised

The applicant conducted an exploratory reanalysis of the samples and retested samples from the initial pivotal registration study A2201 conducted with the new Novartis assay (Navigate PD assay).  This is to better understand the origin of the observed differences in PD inhibition (%P-selectin inhibition 70% in pivotal study A2201 (SelG1), ~100% in study A2202 (SEG101)) and if these may indeed be attributed to the different PD assay versions (historical Reprixys assay and new Navigate assay). Overall, test results indicate, that the

<div style=\"page-break-after: always\"></div>

original observed difference may be attributed to differences in the assay methods used along the development program, since the same samples tested with the Navigate assay displayed higher inhibition in the medium inhibition group as discussed above. Statistical methods for the analysis of PK and PD data in studies A2102 and A2201 are based on conventional approaches used in bioequivalence studies and are largely acceptable for the PK analysis. Nevertheless, there was no adjustment for important baseline covariates/stratification factors (gender, weight, age) in the PK/PD models for study A2102, although this is a parallel group study and the proportion of female subjects (54.5% vs. 39.3%) was higher in the SelG1 5.0 mg/kg treatment group. Adjusting the analysis by important baseline covariates such as gender, weight and age changed PK results only slightly, however, and comparability between SEG101 and SelG1 on a PK level could still not be demonstrated. For the PD analysis, the assumptions of normality and variance homogeneity in the ANOVA model are violated for AUC29 due to the observed ceiling effect (see above). As regards sample size planning, the expected inter-subject variability (CV=34.1%, derived from the lower dose group of study A2101) was clearly larger than observed in study A2102 (CV=3.6% in the SEG101 5.0 mg/kg, CV=0.2% SelG1 5.0 mg/kg). The CV assumption was derived from Study A2101, which had a very limited study population of 27 subjects and was a Reprixys study whereas for the Novartis Study A2202 the PD assay used was performed by SensiQ. The EC50 values, the ligand binding assays used to measure ex vivo %P-selectin inhibition for crizanlizumab in human serum, were lower in the Navigate assay than for the first assay by SensiQ. As there was high inhibition probably resulting in a ceiling effect, an increase in %P-selectin inhibition could have resulted in lower variability. The applicant based the information in section 5.2 of the SmPC primarily on the result of study A2202 since the study was designed to address the PK and PD properties of Crizanlizumab with appropriate sampling time points. However, study A2202 is still ongoing and final results will be provided as it is a specific obligation to the marketing authorisation. The applicant confirmed that relevant information in the SmPC will be updated as appropriate. Based on the Pop-PK model no influence of age on crizanlizumab CL was observed in the range 16-65 years but age was correlated to body weight. However, the PK data collected in the four clinical studies provided along the MAA, only included two subjects younger than 18 years. This very limited sample size makes it difficult to conclude on the influence on safety and efficacy in this subset of patients. However, the applicant provided a thorough discussion on the similarities between the SCD patient population aged 16 to &lt;18 years and ≥ 18 years with respect to SCD pathophysiology, the role of p-selectin, the clinical manifestations of SCD, the expected PK of crizanlizumab and the substantial unmet medical need in those patients. It can be agreed that SCD patients between 16 to 18 years have similar manifestations of SCD as young adults. Additionally, it is agreed that early treatment of SCD is essential for adolescent patients to avoid chronic complications. However, the ongoing phase III study A2301 is intended to include at least 48 SCD patients from the age of 12 years and these data are considered important in this CMA context to support the indication starting from 16 years of age. 2.4.5. Conclusions on clinical pharmacology Medicinal product no longer authorised

Analytical assays supporting crizanlizumab clinical development were developed and validated. Uncertainties remain regarding the validity of data generated with the initial PK assay (studies A2101 and A2201, SelG1), since relevant assay parameters have not been considered for assay validation and relevant information (e.g. reference standard used) cannot be provided. However, this is not further pursued since sufficient data was generated in the comparability study for both versions and in study A2202 for the to-be-marketed product SEG101. Further, additional PK data will be generated in the planned phase III study which will be provided as

<div style=\"page-break-after: always\"></div>

part of a specific obligation of the marketing authorisation.

<!-- image -->

<!-- image -->

SCD patients from 16 to 65 years of age were randomised in a 1:1:1 ratio to 5 mg/kg crizanlizumab (high dose), 2.5 mg/kg crizanlizumab (low dose) or placebo. The study included a screening phase (30 days prior randomisation), a 52-week treatment phase, and a follow-up evaluation phase for a maximum total of 58 weeks. Patients were stratified by concomitant HU use (yes/no) and by the number of past sickle cell-related pain crises (SCPC; 2-4 and 5-10 crises in the preceding 12 months).

<!-- image -->

Overall, the PK profile of crizanlizumab has been sufficiently characterised. Differences between crizanlizumab versions SelG1 and SEG101 have been observed in PK and PD with higher exposure and higher %inhibition of SEG101 compared to SelG1. The resulting uncertainties on the PD were addressed with a reanalysis of available samples indicating that the observed differences in PD inhibition [(70% %P-selectin inhibition in pivotal study A2201 (SelG1) versus ~100% in study A2202 (SEG101)] may be attributable to the different PD assays used in the development programme. Consequently, the PD results are considered comparable and the differences observed in PK exposure are not further pursued. 2.5. Clinical efficacy The efficacy evaluation of crizanlizumab for the prevention of vaso-occlusive crises in SCD patients presently relies on a single placebo-controlled phase II study (study A2201). The study was conducted with the Reprixys-manufactured crizanlizumab (SelG1), whereas the Novartis-manufactured crizanlizumab (SEG101) is intended for commercialisation. A study in healthy subjects was conducted to demonstrate PK/PD comparability of SelG1 and SEG101 (study A2102). For a detailed description of study A2102 please refer to the PK/PD section. A confirmatory Phase III trial will compare the efficacy of two doses of the Novartis-manufactured crizanlizumab SEG101 (5 mg/kg and 7.5 mg/kg) versus placebo. Results from this study should confirm the benefit of crizanlizumab 5 mg/kg and assess the efficacy of crizanlizumab at a higher dose and is a specific obligation of this conditional MA. A tabular overview of clinical studies with Crizanlizumab is provided above. 2.5.1. Dose response study There is no dedicated dose response study available for crizanlizumab in SCD patients. The investigated dosing of crizanlizumab is derived from a first-in-human study A2101 studying PK and PD in healthy subjects (please refer to the PK/PD section). 2.5.2. Main study Study A2201: A Phase II Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Study participants

•

The eligibility criteria were selected to enrol patients representative of SCD, ≥ 16 years of age. Main Inclusion Criteria · 16 to 65 years of age · Male, or female of non-childbearing potential or female compliant with appropriate birth control method · Negative serum pregnancy test at Screening and a negative urine pregnancy test (dipstick) prior to randomisation and dosing on Day 1 (for females) · Confirmed medical history or diagnosis of SCD (including HbSS, HbSC, HbSβ0 - thalassaemia, HbSβ+ -thalassaemia patients) · If receiving HU, must have been prescribed for the preceding 6 months and be dose stabilised for at least 3 months prior to Day 1 · If receiving erythropoietin, must have been prescribed for the preceding 6 months and be dosestabilised for at least 3 months prior to Day 1 · Had a history of 2 to 10 SCPC within the preceding 12 months either by patient history or as  determined by patient's recall (SCPC should have included the occurrence of appropriate symptoms, a visit to a specific medical facility and/or health care professional, and receipt of pain medication as defined for the primary endpoint) Main Exclusion Criteria · Was on a chronic transfusion program as defined by participating in a scheduled (pre-planned) series of transfusions (simple or exchange) for prophylactic purposes or the haemoglobin A was &gt; 20% of the total haemoglobin · Was planning on undergoing an exchange transfusion during the duration of the study · Haemoglobin was &lt; 4.0 g/dL · Was planning to undergo a major surgical procedure during the duration of the study · Was planning to initiate, terminate, or alter the dosing of HU while on study, other than for safety reasons · Was receiving chronic anticoagulation (e.g., warfarin, heparin) other than aspirin · Had significant active and poorly controlled (unstable) cardiovascular (including atrial or ventricular cardiac arrhythmias), neurologic, endocrine, hepatic, or renal disorders clearly unrelated to SCD identified by key laboratory abnormalities Was diagnosed with cancer (except non-melanoma skin and in situ cervical cancers) within the last 5 years Medicinal product no longer authorised

- History of a stroke within the past 2 years
- Had received active treatment in another investigational trial within 30 days prior to Day 1 or planned to participate in another investigational drug trial

<div style=\"page-break-after: always\"></div>

## Treatments

<!-- image -->

Crizanlizumab (2.5 mg/kg or 5 mg/kg) or placebo was administered over a period of 30 minutes by intravenous infusion at day 1, day 15 and every 4 weeks ± 3 days through Week 50 (final dose). Qualified personnel administered all doses of the study by IV infusion at the clinic. Patients were to be monitored for 60 minutes following each infusion. Including the loading and maintenance doses, patients who participated in all scheduled dosing visits received a total of 14 doses. Permitted concomitant medication In general, medications consistent with the standard of care in patients with SCD were allowed during this study. Patients receiving chronic anticoagulation therapy other than aspirin (e.g., warfarin, heparin) at screening were to be excluded from the study. If patients were on HU, they must have been on the drug for 6 months or more and the dose stabilised for at least 3 months, and the dosing was not to be altered or terminated throughout the 52-week study treatment period, other than for safety reasons. In patients not on HU, HU treatment was not to be initiated throughout the 52-week study treatment period. If a physician deemed it medically necessary to initiate, terminate, or alter HU treatment in a patient during the course of the study, the medical monitor was to be notified. If a patient was taking erythropoietin at screening, they must have been on the drug for 6 months or more and the dose stabilised for at least 3 months. Patients receiving transfusions on a chronic and scheduled basis were pre-emptively excluded from the study. Patients were allowed to receive occasional transfusions on an as needed basis. Objectives Primary objectives: · To investigate the clinical efficacy of crizanlizumab at high and low dose compared with placebo as assessed by the annual rate of sickle cell-related pain crises (SCPC). · To assess the safety and tolerability profile of chronic dosing of crizanlizumab at each dose level compared to placebo as assessed by the frequency and severity of adverse events (AEs) and other safety data in each arm as considered appropriate. Secondary objectives: · To investigate the clinical efficacy of crizanlizumab at high and low dose as compared with placebo as assessed by the annual rate of days hospitalised. · To evaluate additional clinical efficacy endpoints including time to first and second SCPC, annual rate of uncomplicated SCPC, annual rate of acute chest syndrome (ACS) and brief pain inventory questionnaire. Outcomes/endpoints Medicinal product no longer authorised

The primary endpoint of this trial was the annual rate of Sickle Cell-Related Pain Crises (SCPC). All SCPC had to meet all of the below criteria:

- An acute episode of pain;

<div style=\"page-break-after: always\"></div>

- No known cause for pain other than a vaso-occlusive event;

· Requiring a visit to a medical facility; and · Requiring treatment with a parenteral or oral narcotic (including opiates), or parenteral NSAIDs. Acute chest syndrome, hepatic sequestration, splenic sequestration, and priapism (requiring a visit to a medical facility), were by definition, also considered as SCPC for analysis purposes. For consistency reasons, all crisis events identified by investigators were independently adjudicated by a central review committee (CRC) comprised of 3 independent haematologists to determine whether reported sickle cell crisis meet the criteria for the primary efficacy outcome. The annual rate of SCPC calculation accounted for early dropouts or lost to follow-up by extrapolating the SCPC rate of every patient to one year. The key secondary endpoint was the annualised rate of days hospitalised. Hospitalisation data was captured in the eCRF. For annual rate of days hospitalised, the same statistical method used for the primary efficacy endpoint was utilised. Other secondary endpoints were: · Time to first and second SCPC Time-to-first SCPC is defined as number of months from the date of randomisation to the date of first/second SCPC. A patient without pain crises before the end date was censored at the time of withdrawal or completion of the study. End date is defined as the last dose plus 14 days. For patients never dosed, the end date is the end of study date. · Annual rate of uncomplicated SCPC Uncomplicated SCPC is defined as an acute episode of pain with no known cause for pain other than a vaso-occlusive event; requiring a visit to a medical facility; and requiring treatment with a parenteral or oral narcotic (including opiates), or parenteral NSAIDs; but is NOT classified as an acute chest syndrome, hepatic sequestration, splenic sequestration or priapism. For annualised rate of uncomplicated SCPC, the same statistical method used for the primary efficacy endpoint was utilised. · Annual rate of ACS Acute chest syndrome is defined on the basis of the finding of a new pulmonary infiltrate involving at least one complete lung segment that was consistent with alveolar consolidation. At least one of the following additional signs or symptoms needs to be present as well: a patient had to have reported chest pain, a temperature of more than 38.5°C, tachypnea, wheezing or cough. For annual rate of ACS, the same statistical method used for the primary efficacy endpoint was utilised. · Patient reported outcomes as measured by BPI Questionnaire Quality of life (QoL) was evaluated using the brief pain inventory (BPI). Patients completed the BPI questionnaires at pre-specified study visits. Medicinal product no longer authorised

## The exploratory endpoints were:

- Annual rate of days with SCPC
- Annual rate of packed RBC units transfused

<!-- image -->

<div style=\"page-break-after: always\"></div>

- Anaemia-related laboratory parameter: absolute change from baseline in haemoglobin

An unblinded pharmacist was responsible for the compounding of individual doses for randomised patients, all other study contacts were blinded to treatment assignment for the duration of study. Measures to mask patients and study personnel from treatment allocation appear to be appropriate, as it has been ensured that the IV solutions administered cannot be distinguished, and that the blind was maintained throughout the whole trial. The definition of patient populations and finalisation of SAP for the final clinical study were completed prior unblinding and the applicant clarified that the date of unblinding was after the finalisation date of the SAP.

· Haemolysis-related laboratory parameter: absolute change from baseline in lactate dehydrogenase · Absolute change from Baseline in number of reticulocytes · Absolute change from baseline in haptoglobin · Absolute change from Baseline in indirect bilirubin · Short form 36 version 2, question health survey (SF-36v2) and brief pain inventory (BPI) long form, 1-week recall questionnaire · Soluble P-selectin, soluble vascular cell adhesion molecule (VCAM-1), C-reactive protein (CRP), tissue factor, and D-dimer · PK and PD analyses Sample size Sample size calculations were performed based upon the following assumptions: · A 40% relative reduction (vs. placebo) in the number of SCPC with a mean placebo event rate of 3.0 and standard deviation of 1.7; and · Patients will be randomised in 1:1:1 ratio into placebo: high dose: low dose, stratified by concomitant usage of HU (yes; no) as well as by number of prior SCPC (2-4; 5-10) per year. Based on these assumptions, a total of 50 patients per arm was required for the study to have approximately 90% power to detect a 40% reduction in SCPC, using Wilcoxon's rank sum test (α=0.05). Assuming a 15% dropout rate, approximately 174 total patients were planned to be randomised into the study. The calculations were based on simulation with 5,000 repetitions (from Poisson distribution) using twosample Wilcoxon's rank sum test (2sided) and α=0.05. SAS V9.2 was used for the calculations. Randomisation The patients were randomised in a double-blind manner to receive either placebo, low-dose (2.5 mg/kg) crizanlizumab or high-dose (5.0mg/kg) crizanlizumab. Randomisation was stratified by HU use (yes or no) and SCPC history (2 to 4 or 5 to 10) resulting in 4 strata. The list that allocated randomisation numbers to patient numbers is available and shows a block randomisation with a block size of 9 and that stratification by centre was not taken into account. Blinding (masking) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Statistical methods

Statistical methodology of the primary efficacy analyses The primary analysis population was intent-to-treat (ITT) which included all randomised patients. The annual rate of SCPCs (or VOCs) = total number of SCPC x 365 / (end date - date of randomisation +1), where end date was last dose date + 14. For patients never dosed, end date was the end of study date, which was the last site contact date for these patients. This method of calculation assumes that the rate of SCPC remains the same after discontinuation of treatment for early dropouts. A stratified Wilcoxon rank-sum test, with randomisation stratification factors of HU/HC therapy (yes/no) and SCPC history (2-4 per year vs. 5-10 per year) as strata, was used for analyses of the primary efficacy endpoint. Medians, median difference, and 95% confidence interval (CI) for the median difference were estimated using the Hodges-Lehmann (HL) method. The primary efficacy analysis is based on the p-value of the stratified Wilcoxon Rank Sum Test, which is presented together with the standard median as well as one- and two-sample Hodges-Lehmann (HL) estimates. The definition of the metric and respective estimate to be considered for interpretation of clinical relevance is not obvious and was not unambiguously pre-defined. During study planning, a relative reduction of 40% in the number of VOCs was considered clinically relevant based on feedback from US expert medical advisors and the US authority.  The difference between treatment arms was significant using a stratified Wilcoxon Rank Sum Test (p=0.010), but the CI of the HL difference between medians of the annual rate of SCPC included 0. The duality between test and estimation method is not fulfilled and the properties of the HL estimate and corresponding CIs used for estimating the difference in medians of two non-symmetric distributions are questioned. More than one third of the randomised patients prematurely discontinued from the study, and thus the handling of the resulting missing values has a strong impact on the treatment effect estimates. The imputation using simple annualisation is questioned; patients will not continue receiving treatment upon study withdrawal and thus the assumption that the SCPC rate will remain constant is questionable and not substantiated. Furthermore, it cannot be easily assumed that the probability of having a missing value does not depend on the disease status or the treatment, as this cannot be excluded from reported reasons for early discontinuation. The analyses (including the sensitivity analysis) specified in the analysis plan do not address these issues appropriately. It would be more appropriate if missing periods (time from study discontinuation to 12 months) are replaced on the basis of similar patients in the control group using multiple imputation. More generally, treatment discontinuation is considered an intercurrent event, and it has been mentioned in the Scientific Advice letter (dated 26 Apr 2018) that 'CHMP considers that the treatment effect of interest in respect of treatment discontinuation is the effect over a 12 month period regardless of whether the patient does or does not adhere to treatment'. Consequently, patients should have been followed up and their SCPCs recorded (and included in the analyses) until month 12. The advice letter also mentions that 'The proposal to annualise rates after this intercurrent event (or after study discontinuation in respect of missing data handling -see below) is not accepted. The argument that VOC rate on treatment remains approximately the same over time (linearity of cumulative SCPC incidence curve in SUSTAIN) is not relevant where treatment is discontinued.' The treatment effect is planned to be quantified regardless of treatment discontinuation, intake (discontinuation and initiation) of HU/HC, analgesic use (including oral opioids) or ad-hoc transfusions. Medicinal product no longer authorised

<!-- image -->

Supplementary efficacy analyses were performed after finalisation of the study report. The analyses address some of the concerns raised on the primary efficacy analysis methods (see Section Ancillary analyses).

However, the rationale for some (sensitivity) analyses is not clear and it cannot be excluded that the choice of

<div style=\"page-break-after: always\"></div>

specific analysis options has been done in a data-driven way. This also applies to methods that were 'pre -specified' in the protoco l, but e.g. a different method for missing data handling is applied. The fact that there is no sustained treatment impact should inform the missing data handling approach. The applicant provided the primary analysis based on the negative binomial regression model with the additional imputation methods (i) by pain crises data prior to randomisation (M5) and (ii) reference based multiple imputation (M6) (see Section Ancillary analyses). Multiplicity The primary endpoint and the key secondary endpoint (annual rate of days hospitalised) were controlled for type I error using hierarchical testing, i.e., the primary endpoint served as a gatekeeper for the key secondary endpoint. The statistical analysis of other endpoints can be considered descriptive. For the p rimary endpoint (annual rate of SCPC leading to healthcare visit), α = 0.05 was utili sed to test 5 mg/kg dose versus placebo, and if significant, 2.5 mg/kg dose versus placebo was tested. This controlled the overall alpha level for the study at 0.05 for the primary efficacy endpoint. The primary endpoint also served as a gatekeeper for the key secondary endpoint. The key secondary endpoint was only to be tested if at least one dose was significant in the test of the primary endpoint, and the key secondary endpoint testing was to be restricted to the doses where the primary endpoint was significant. If both doses were successful for the primary endpoint, then for the key secondary endpoint, α = 0.05 was to be utili sed to test 5 mg/kg dose versus placebo, and if significant, 2.5 mg/kg dose versus placebo was to be tested. Hierarchical testing across the two doses is acceptable for the primary endpoint, but the familywise error rate is not controlled in the strong sense including the hypotheses for the secondary variable when proceeding to the key secondary variable 'if at least one dose is significant in the test of the primary endpoint' (though a procedure can, in principle, be constructed such that some alpha level is propagated to the secondary variable, which is however not consistent with the defined hierarchical testing of the primary variable, where explicitly the full alpha level is transferred to the test of the lower dose). Statistical methodology of the secondary efficacy analyses The following analysis was conducted for the secondary endpoints: · HL estimate for median difference between treatment arms was calculated for annual rate of days hospitalised (key secondary endpoint), annual rate of uncomplicated SCPC leading to healthcare visit, annual rate of acute chest pain, and annual rate of hospitalisation (post hoc). · Cox regression analysis was applied to time to first SCPC and time to second SCPC. · Least square means were calculated for change from baseline in the patient reported outcome (PRO). · Odd ratio with 95% CI was calculated to rate of patients with no SCPC (post hoc). The analysis methods for the secondary endpoints are not controlled for type I error, but can be considered as supportive information. The key secondary endpoint of annual rate of days hospitalised additionally measures the duration/severity of the SCPC. Its analysis consists of count data similar to the primary endpoint. The time-to-event analyses of time to first SCPC and time to second SCPC rely on the assumption of Medicinal product no longer authorised non-informative censoring.

<div style=\"page-break-after: always\"></div>

|         |    | longer   |
|---------|----|----------|
|         | no |          |
| product |    |          |

Subgroup analysis for stratification factors and genotype investigate the consistency of the treatment effect across these important subgroups (as well as with respect to other prognostic, and potentially predictive factor) (see Results). Results Participant flow The patient disposition is presented in the table below. Table 4: patient disposition and primary reason for discontinuation from study treatment -all randomised patients A total of 198 patients were randomised, with 67 patients randomised to receive 5.0 mg/kg crizanlizumab, 66 patients to 2.5 mg/kg crizanlizumab, and 65 patients to placebo. A total of 69 patients (34.8%) discontinued from the study. There was no imbalance between the treatment arms with regards to the number of patients with early discontinuation and reasons for early discontinuation from the study. Medicinal product no longer authorised

The most commonly reported reason for study drug discontinuation in all treatment arms was withdrawal by the patient/caregiver/legal guardian, reported in approximately 10% of the patients. Other important reasons for early discontinuation were lost to followup (7.1%) and other (7.1%). The 'other' category included a broad panel of reasons, the most frequent being pregnancy (2 patients in the 5 mg/kg arm and 1 each in the 2.5 mg/kg and placebo arms). Detailed listings for 'consent withdrawn' and 'other' have been provided.

<div style=\"page-break-after: always\"></div>

## Recruitment

This was a multicentre study and patients were recruited in 60 centres (51 centres in the US, 8 centres in Brazil and 1 centre in Jamaica). First patient, informed consent signed: 24 July 2013 Last patient completed: 23 March 2016 Conduct of the study The original protocol (dated 26 February 2013) was amended three times. 73 patients (36.9%) had one or more major protocol deviations. The majority of these deviations were related to either not receiving the appropriate number of planned infusions (mainly due to early discontinuation) or not completing a follow-up visit after the last dose. The minor protocol deviations consisted mostly of violated time windows for more than the allowed +/-3 days, missing laboratory tests of physical examination results from individual time points or single missed infusions. On several occasions, patients were not observed at the clinic for the required period of 1 hour post infusion to observe AEs and adverse effects reporting was not completed within the required timeframe. Some violations of the eligibility and entry criteria were identified. Two of the subjects, both in the crizanlizumab 5mg group, did not meet the inclusion criterion of 2-10 VOCs during the previous year. Three subjects had incomplete documentation of the inclusion and exclusion criteria. Baseline data Patients were recruited in 3 countries including the US, Brazil and Jamaica. The majority of patients were Black or African American (91.9%) followed by 4.5% White and 3.5% categorised as 'others'. Classification of ethnicity was divided into two groups including Hispanic/Latino and not Hispanic Latino. The majority of patients were not Hispanic/Latino (about 76%), however, the ratio Hispanic/Latino to not Hispanic/Latino was slightly imbalanced between the treatment groups with a lower rate of not Hispanic/Latino and higher rate of Hispanic/Latino in the 5 mg/kg crizanlizumab group (67.2% and 29.2%) compared to the placebo group (81.5% and 16.9%). The majority of subjects were female (55.1%). Study population was defined as 's ickle cell patients (16-65 years of age) who have experienced between 2 and 10 sickle cellrelated pain crises within preceding 12 months' in the study protocol. However, at least two subjects were included in the study with only one recorded VOC during the preceding year. The median age was 28.0 years (range 16-63 years). The number of patients between 16 and 18 years of age was limited. Of the enrolled patients, approximately 70% were diagnosed with sickle cell anaemia (HbSS), 16.2% with HbSC, 6.1% with HbSβ0 -thalassaemia and 5.1% with HbSβ+ -thalassaemia. HbSS and HbSß0-thalassemia are the most severe genotypes and patients with these genotypes might have a higher risk for disease-related complications compared to patients with the less severe SCD forms (HbSC or HbSß+-thalassemia). Medicinal product no longer authorised

<!-- image -->

Concomitant HU treatment was allowed, and approximately 2/3 of the subjects were on hydroxyurea. Prior HU/HC use and number of VOCS leading to a healthcare visit during the 12 months prior to screening were stratification factors and thus well balanced between the treatment groups.

<div style=\"page-break-after: always\"></div>

|    | longer   |
|----|----------|
| no |          |

| Medicinal   | Medicinal   |
|-------------|-------------|

Table 5: study A2201 (SUSTAIN): demographics and selected baseline characteristics (ITT population) Medicinal product no longer authorised

b A patient could select more than 1 race.

<div style=\"page-break-after: always\"></div>

## Numbers analysed

The efficacy results are presented separately for:

A total of 198 patients were randomised and included in the ITT population, with 67 patients randomised to receive crizanlizumab at 5.0 mg/kg (5.0 mg/kg arm), 66 patients to receive crizanlizumab at 2.5 mg/kg (2.5 mg/kg arm), and 65 patients to receive placebo (placebo arm). The primary efficacy analysis was performed on the all randomised patient population (ITT). Selected efficacy analyses were also performed on the mITT and per-protocol (PP) population. Outcomes and estimation The initial submission of the efficacy analyses was performed on CRC-adjudicated data using the Hodges-Lehmann (HL) estimate as well as simple annualisation for imputation of missing data. The magnitude of the clinical benefit was difficult to assess due to uncertainties in the statistical methodology with respect to the treatment effect estimation as well as the handling of missing data. Consequently, the applicant provided additional analyses of the primary efficacy endpoint, using the negative binomial regression and 3 different schemes to impute missing data: Analysis M4: For patients who discontinued early, impute the missing period · 'jump to reference' if withdrawal for a reason potentially related to treatment in the 5 mg/kg treatment arm · 'missing at random' for all other patients whatever the arm M5: for each patient who didn't complete 6 months of study, whatever the treatment am, · patient's annual rate of VOC imputed by patient's number of VOC leading to healthcare visit at baseline (per CRF) (as specified in the first study protocol) · study duration is imputed to one year. M6: For patients who discontinued early impute the missing period · 'jump to reference' for patients in the 5 mg/kg treatment arm · 'missing at random' for patients in the placebo arm (reference based multiple imputation). Additionally, supplementary analyses of the primary efficacy endpoint using adjudicated data, adjudicated data without the 2-week rule, investigator data as well as investigator data excluding one outlier patient were provided to assess the impact of the adjudication process. Furthermore, the initial submitted analysis of the key secondary endpoint included all hospitalisation days rather than hospitalisation due to SCPC. The applicant provided the requested supplementary analyses showing the annual rate of days hospitalised due to VOC using the HL model. However, as data employing the investigator identified VOC rate as well as negative binomial regression and imputation scheme M6 ('jump to reference') are considered the most appropriate to inform on the benefit of crizanlizumab, because after the discontinuation of study treatment patients will probably behave like in the placebo group. This would be the estimate more in line with the ITT principle. Requested supplementary analyses of the primary efficacy endpoint and important other endpoints combining all these methods/assumptions were provided in the response to the D180 LoOI. Medicinal product no longer authorised

- i.) Pre-specified analyses using CRC-adjudicated data, Hodges-Lehmann model, simple annualisation
- ii.) Supplementary Analyses provided in response to the D120 LoQ
- iii.) Supplementary Analyses provided in response to the D180 LoO

<div style=\"page-break-after: always\"></div>

<!-- image -->

Pre-specified analyses Primary Efficacy Endpoint: Annual rate of SCPC The primary efficacy analysis according to the SAP presents the p-value corresponding to the primary analysis (p=0.010) in the ITT population, together with the standard median as well as one- or two-sample Hodges-Lehmann (HL) estimates together with the 95% CI for the two-sample HL estimate. Crizanlizumab 5 mg/kg led to a 45.3% lower median annual rate of VOC leading to a healthcare visit compared to placebo considering the ratio of the standard median of 1.63 VOCs in 5 mg/kg crizanlizumab group compared to 2.98 VOCs in placebo. The Hodges-Lehmann median annual rate of SCPC lead to a value of 2.00 VOCs in 5 mg/kg crizanlizumab group compared to 3.49 VOCs in placebo leading to a relative reduction of 42.7%. The point estimate of the two-sample HL estimator was -1.01 (95% CI [-2.00, 0.00]). The difference was significant using a stratified Wilcoxon Rank Sum Test (p=0.010), but the CI of the HL difference between medians of the annual rate of SCPC included 0. Crizanlizumab 2.5 mg/kg led to a 32.6% lower median annual rate of VOC leading to a healthcare visit compared to placebo considering the ratio of the standard median of 2.01 VOCs in 2.5 mg/kg crizanlizumab group compared to 2.98 VOCs in placebo. The point estimate of the two-sample HL estimator was -0.69 (95% CI [-1.84, 0.02]). However, while results with the lower crizanlizumab dose compared to placebo were co-directional, a statistical significance was not reached (p=0.180). Table 15: treatment comparisons of annual rate of sickle cell related pain crises (adjudicated) -Intent to treat population Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| authorised   | authorised   |
|--------------|--------------|

The median observed days hospitalised were 4.00 in the 5 mg/kg crizanlizumab group, 6.87 days in the 2.5 mg/kg crizanlizumab group and 6.87 days in the placebo group. The point estimate of the HL estimate of the absolute difference between medians was 0.00 days for both doses of crizanlizumab. The differences were not statistically significant using a stratified Wilcoxon Rank Sum Test. Table 6 Treatment Comparisons of

Sensitivity Analyses Sensitivity analyses of the primary efficacy endpoint were performed to assess the robustness of the crizanlizumab effect. Annual rates of SCPC were analysed in the mITT and PP patient populations as well as patients who completed at least 6 months of study drug treatment. For all three sensitivity analyses, the results of the Wilcoxon Rank Sum Test for the 5 mg/kg crizanlizumab group were significant (p&lt;0.05), in the mITT population the standard median differed by 2.00 to 3.49, for the PP population by 1.90 to 2.99 and for the &gt;6 months population by 1.79 to 2.18. For the 2.5 mg/kg Crizanlizumab group, no significant reduction of VOCs was found in the mITT and PP population or when excluding patients who did not complete 6 months of treatment, but the medians were consistently lower than in the placebo group, i.e. standard median 2.03 compared to 2.99 in mITT population, 2.00 compared to 2.18 in the PP population and 2.01 compared to 2.18 in the &gt;6 months population. Key Secondary Efficacy Endpoint: Annual rate of days hospitalised Medicinal product no longer authorised

## Annual Rates of Days Hospitalised

<div style=\"page-break-after: always\"></div>

| authorised   | authorised   |
|--------------|--------------|

<!-- image -->

Secondary Efficacy Endpoint: Time to first and second SCPC The median time from randomisation to first VOC was 4.07 months in the 5 mg/kg crizanlizumab group compared to 1.38 months in the placebo group, which was found to be a statistically significant difference (p=0.001 with a hazard ratio of 0.495). The difference of median time to first VOC for the 2.5 mg/kg crizanlizumab group was also increased (2.2 months) over placebo, but did not reach statistical significance (p=0.136 with a hazard ratio of 0.752). Figure 5: Kaplan-Meier estimates of time to first sickle cell related pain crises -intent to treat population Medicinal product no longer authorised

The median time to second SCPC (measured from the beginning of the study) was significantly longer for the 5 mg/kg crizanlizumab group (10.32 months) compared with placebo (5.09 months; p= 0.022). For the lower crizanlizumab dose no statistically significant difference was found, but the time was increased over placebo (9.20 months; p= 0.100).

<div style=\"page-break-after: always\"></div>

<!-- image -->

Figure 6: Kaplan-Meier estimate of time to second sickle cell-related pain crisis -intent to treat population Annual Rates of Uncomplicated Sickle Cell-Related Pain Crises An analysis using the stratified Wilcoxon Rank Sum Test to compare the annual rates of uncomplicated SCPC between the 5.0 mg/kg crizanlizumab arm with that of the placebo arm in the ITT population showed a statistically significant reduction in the active treatment arm (p = 0.015). Comparison of the standard median annual rates of uncomplicated SCPC in the 5.0 mg/kg arm versus placebo showed a 62.9% reduction with active treatment (1.08 versus 2.91). Analysis using the stratified Wilcoxon Rank Sum Test to compare the annual rate of uncomplicated SCPC in the 2.5 mg/kg SelG1 arm with that in the placebo arm showed a 31.3% reduction (2.00 versus 2.91), but it was not statistically significant (p = 0.120). Both 95% CIs of the two-sample HL estimates include 0. Annual Rate of Acute Chest Syndrome Due to the rare occurrence of acute chest syndrome in this study, no treatment differences were observed in the median annual rates of acute chest syndrome for all treatment arms in the ITT, mITT, and PP populations. Brief Pain Inventory Questionnaire Within treatment arms, there were no observed changes from baseline in the LS means relative to other assessments (Day 15 and Weeks 14, 26, 38, and 52) in the pain severity domain. Additionally, no treatment differences was observed between the 5 mg/kg crizanlizumab arm and the placebo arm at any assessment. The questionnaire with a 1-week recall period was collected at fixed time points independently from the timing of VOC. Exploratory Efficacy Endpoints: Medicinal product no longer authorised

## Annual Rate of days with SCPC

The median of the annual rate of days with SCPC showed a 29.67% reduction in the 5 mg/kg considering the standard median of 9.79 days for the 5 mg/kg group compared to 13.92 days for placebo. The difference in HL estimates of the median annual rate of days with SCPC showed a 26.20% reduction in the 5 mg/kg considering

<div style=\"page-break-after: always\"></div>

the HL estimates of 16.65 days for the 5 mg/kg group compared to 22.56 days for placebo. The HL median absolute difference showed a difference of -4.00. There was no difference in the median annual rate of days with SCPC between the 2.5 mg/kg treatment arm and placebo. Annual rate of packed RBC transfused No treatment difference was observed in the `annual rate of packed RBC units transfused` between the treatment groups. However, patients who underwent transfusions of 10 units or more were excluded from the analysis. Laboratory parameters No significant change in haematological parameters (haemoglobin, LDH, reticulocytes, haptoglobin, indirect bilirubin, soluble VCAM-1, high-sensitivity CRP, tissue factor and D-dimer) could be found in both dose groups of crizanlizumab. The only exception was found in the change from baseline in levels of soluble p-selectin. For the 5 mg/kg crizanlizumab group a significant decrease from baseline in soluble p-selectin LS means was observed at day 15 (-28.8, p &lt; 0.001) and at Week 52 (-28.8, p &lt; 0.001). Inhibition was less pronounced at week 26 (-6.9, p=0.104). Ancillary analyses Following the acquisition of Reprixys and the completed Study A2201 (SUSTAIN) CSR, Novartis performed additional efficacy analyses related to additional endpoints (rate of patients with no VOC event leading to healthcare visit (VOC free), annual rate of hospitalisation), subgroup analyses (gender (female vs. male) and ethnicity (Hispanic-latino vs. not Hispanic-latino)) and supportive analyses of the primary endpoint (imputation methods M1-M4) that are described in the analysis plan for this SCE (SCE-CSPD analysis plan). Imputation methods In order to evaluate the impact of early dropouts, different imputations methods were applied. Four different imputation methods were presented to evaluate the robustness to departures from the assumption that discontinuations from study treatment were independent from treatment effect and disease. These are illustrated in the table below for analysis of annual rate of VOC without imputation and with imputation methods M1 and M2 using Hodges Lehmann median differences and in the table below for the negative binomial analysis on frequency of VOC without imputation and with imputation methods M3 and M4. Results for the annual rate of VOC using a stratified Wilcoxon Rank Sum test and the rate ratio by applying a negative binomial regression on the number of VOC leading to healthcare visit consistently show a significant effect. However, the rationale for some (sensitivity) analyses is not clear and it cannot be excluded that the choice of specific analysis options has been done in a data-driven way. M1-M3 are not considered appropriate because subjects who discontinue differ from completers simply by not taking the drug and may also differ with respect to factors not covered by the stratification factors. Furthermore, for M1M2 the variability of the VOC distribution is not taken into account by single imputation and a patient's VOC rate is entirely imputed ignoring the period of the actually observed rate (which may not be an efficient use of the data at hand). M3 applies multiple imputation but assumes missing at random. Medicinal product no longer authorised

M4 appears to be the only method among the four considered in the sensitivity analyses that is based on plausible and sufficiently conservative (i.e. not favouring the crizanlizumab arm) assumptions. M4 imputes according to the strategy of 'jump to reference' for patients who withdraw for a reason potentially related to treatment in the 5 mg/kg treatment arm or 'missing at random' for patie nts in the placebo arm and patients

<div style=\"page-break-after: always\"></div>

| longer   |
|----------|

<!-- image -->

who withdraw for reason not potentially related to treatment in the 5 mg/kg arm. However, few or no treatment discontinuations might be truly independent from a perceived lack of efficacy or from safety reasons, even if not formally announced by the patient. Table 7: Study A2201 (SUSTAIN): supplementary analyses of primary efficacy endpoint (annual rate of VOC leading to healthcare visit) Figure 7: Study A2201 (SUSTAIN): imputation methods for negative binomial regression of the number of VOC leading to healthcare visit (Population: ITT) In response to the questions raised in the d120 LoQ, the applicant has provided supplementary analyses to the primary efficacy variable based on negative binomial regression model. Medicinal product no longer authorised

Both additional imputation methods lead to reduced effect sizes. With M5 the rate ratio is 0.72 [0.54, 0.95], whereas the most conservative method M6 leads to a non-significant result (0.74 [0.54, 1.03]).

<div style=\"page-break-after: always\"></div>

## Subgroup analysis

<!-- image -->

The applicant provided subgroup analyses for genotype, frequency of prior VOCs and HU use. Subgroup analysis by gender and ethnicity were conducted post-CSR. Figure  8:  study  A2201  (SUSTAIN):  treatment  comparisons  of  annual  rate  of  VOC  leading  to healthcare visit in patients by subgroup (population: ITT) HU therapy Subgroup analysis for HU use (yes or no) showed reduction of the annual VOC rate with 5mg/kg crizanlizumab compared to placebo in both subgroups. In patients not receiving concomitant HU therapy (HU use= no), the median annual rate of VOC was reduced by 50.0% considering the ratio of a standard median of 1.00 VOCs in 5 mg/kg group compared to 2.00 VOCs in placebo. In patients receiving concomitant HU therapy (HU use= yes), the median annual rate of VOC was reduced by 32.1% considering the ratio of a standard median of 2.43 VOCs in 5 mg/kg group compared to 3.58 VOCs in placebo. The HL median absolute difference showed lower reductions of the annual VOC rates but showed also a more pronounced treatment effect in patients not receiving concomitant HU therapy. For the 2.5 mg/kg crizanlizumab group, a more pronounced reduction of the median annual VOC rate (44.1%) was observed in patients receiving HU therapy compared to the 5 mg/kg crizanlizumab group considering the ratio of the standard median of 2.00 VOCs for 2.5 mg/kg group compared to 3.58 VOCs for placebo. The HL median absolute difference was the same in both groups and did not show any difference of the treatment effect between the two doses in patients receiving concomitant HU therapy. Please refer to the table below. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

| longer authorised   |
|---------------------|

<!-- image -->

<!-- image -->

HU therapy categorised by VOC history Patients on HU therapy experiencing lower rate of VOCs (2-4) had a 21.2% reduction of the annual VOC rate when treated with 5 mg/kg crizanlizumab considering the standard median of 1.97 VOCs for 5 mg/kg crizanlizumab compared to 2.50 VOCs for placebo. Patients experiencing lower rate of VOCs (2-4) but did not receive HU therapy had a 1.0% reduction of the annual VOC rate when treated with 5 mg/kg crizanlizumab considering the standard median of 1.98 VOCs for 5 mg/kg crizanlizumab compared to 2.00 VOCs for placebo. Patients on HU therapy experiencing higher rate of VOCs (5-10) had a 38.9% reduction of the annual VOC rate when treated with 5 mg/kg crizanlizumab considering the standard median of 4.13 VOCs for 5 mg/kg crizanlizumab compared to 6.76 VOCs for placebo. Patients experiencing higher rate of VOCs (5-10) but did not receive HU therapy had a 82.2% reduction of the annual VOC rate when treated with 5 mg/kg crizanlizumab considering the standard median of 0.74 VOCs for 5 mg/kg crizanlizumab compared to 4.40 VOCs for placebo. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

|        | authorised   |
|--------|--------------|
| longer |              |
| no     |              |

<!-- image -->

Figure 9:  Forest plot for treatment comparisons of number of VOC leading to healthcare visit by subgroups, using negative binomial regression analysis (Population: ITT) Medicinal product no longer authorised

Estirmated rate ratio(95% confidence interval)

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Category    | Subcategory 5.0 mg/kg SelG1   | Subcategory 5.0 mg/kg SelG1   | Subcategory 5.0 mg/kg SelG1   | Placebo   | Placebo   | Odds ratio (95%CI)**   | p-valu e*   |
|-------------|-------------------------------|-------------------------------|-------------------------------|-----------|-----------|------------------------|-------------|
|             |                               | n (%)                         | Group N                       | n (%)     | Group N   |                        |             |
| Overall     |                               | 15 (22.4)                     | 67                            | 5 ( 7.7)  | 65        | 3.57 (1.20,10.63)      | 0.018       |
| HU use      | Yes                           | 9 (21.4)                      | 42                            | 4 (10.0)  | 40        | 2.45 (0.69,8.73)       | 0.159       |
|             | No                            | 6 (24.0)                      | 25                            | 1 ( 4.0)  | 25        | 7.58 (0.84,68.46)      | 0.044       |
| VOC History | 2-4 Medicinal                 | 12 (28.6)                     | 42                            | 4 ( 9.8)  | 41        | 3.70 (1.08,12.65)      | 0.031       |
|             | 5-10                          | 3 (12.0)                      | 25                            | 1 ( 4.2)  | 24        | 3.14 (0.30,32.47)      | 0.322       |
| Genotype    | HbSS                          | 10 (21.3)                     | 47                            | 3 ( 6.4)  | 47        | 3.96 (1.01,15.48)      | 0.037       |
|             | HbSß+/HbSC/ HbSß0/Others      | 5 (25.0)                      | 20                            | 2 (11.1)  | 18        | 2.67 (0.45,15.89)      | 0.277       |
| Gender      | Male                          | 8 (25.0)                      | 32                            | 4 (14.8)  | 27        | 1.92 (0.51,7.24)       | 0.337       |

A forest plot of the subgroup analyses showed that differences are not consistent when comparing crizanlizumab dose (5.0mg/kg) with placebo or crizanlizumab dose (2.5mg/kg) with placebo, except for crisis history where a slightly higher effect for the 5-10 group was observed in both comparisons. The negative binomial regression model was extended by treatment-by-stratification factor interactions, none of them was statistically significant at 10% level, therefore, no potential signal could be detected. It is important to recognise that the significance test of the treatment-by-stratification interaction generally has low power in a trial designed to detect the main effect of treatment. The treatment effect seems to be lower for older than for younger patients for both treatment groups. In conclusion, there could be an effect of crisis history and age on the treatment effect, but both effects would be quite minor. VOC-free patients (patients with no VOC event leading to healthcare visit) Patients were considered VOC-free if they completed the study with an annualised rate of VOC leading to healthcar e visit of '0'. The proportion of VOC -free patients was more than 3-fold higher in the crizanlizumab 5 mg/kg arm compared with the placebo arm (22.4% vs 7.7%, p=0.018). Similar differences were also observed across disease related subgroups (HU/HC use, number of crises at baseline, and genotype). Category Subcategory 5.0 mg/kg SelG1 Placebo n (%) Group N n (%) Group N Overall 15 (22.4) 67 5 ( 7.7) 65 HU use Yes 9 (21.4) 42 4 (10.0) 40 No 6 (24.0) 25 1 ( 4.0) 25 VOC History 2-4 12 (28.6) 42 4 ( 9.8) 41 5-10 3 (12.0) 25 1 ( 4.2) 24 Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|           | Female                 | 7 (20.0)   |   35 | 1 ( 2.6)   |   38 | 9.25 (1.08,79.56)   |   0.018 |
|-----------|------------------------|------------|------|------------|------|---------------------|---------|
| Ethnicity | Hispanic or Latino     | 6 (30.0)   |   20 | 3 (27.3)   |   11 | 1.14 (0.22,5.87)    |   0.875 |
|           | Not Hispanic or Latino | 9 (20.0)   |   45 | 2 ( 3.8)   |   53 | 6.37 (1.30,31.28)   |   0.012 |

<!-- image -->

|                                                       | Treatment Arm                 | Treatment Arm   | Ratio of predicted number of VOCs (active versus placebo)   |
|-------------------------------------------------------|-------------------------------|-----------------|-------------------------------------------------------------|
|                                                       | Crizanlizumab 5 mg/kg N=67 no | Placebo N=65    |                                                             |
| Number of observed VOC leading to healthcare visit a  | 1.81                          | 2.75            |                                                             |
| Predicted number of VOC leading to healthcare visit b | 2.43                          | 3.75            | 0.65                                                        |
| SE                                                    | 0.125                         | 3.00            | 0.164                                                       |
| 95% confidence interval                               | 1.90, 3.11                    | 2.99, 4.71      | 0.47, 0.90                                                  |
| p-value                                               |                               |                 | 0.008                                                       |

<!-- image -->

* p-value from Cochran-Mantel Haenszel test, for overall category stratified by HU/HC therapy (yes, no) and categorised crises history (2-4, 5-10) as recorded in the IXRS system. ** odds-ratio (95% Wald confidence interval) derived from logistic regression model including stratification factors HU/HC therapy (yes, no) and categorised crises history (2-4, 5-10) as recorded in the IXRS system. Supplementary analyses provided in response to the D120 LoQ Primary Efficacy Endpoint: Annual rate of SCPC Treatment comparison of VOC leading to healthcare visit (CRC-adjudicated data) using negative binomial regression analysis (Population ITT) HU = hydroxyurea; IXRS = Integrated Interactive Voice/Web Response System; LS = least squares; VOC = Vaso-occlusive crisis; SE = standard error. Note: The Number of VOC leading to healthcare visit is defined as the total number of pain crises for a patient occurring from the date of randomisation to End date. End date = last dose date + 14 days. For patients not dosed, End date = end of study date. Note: The generalised linear model includes treatment, HU therapy (yes, no), and categorised crises history (2 to 4, 5 to 10) as independent variables with negative Binomial distribution, log link, and an offset term log study duration (in years). Note: HU use and categorised crises history are presented as recorded in the IXRS system. a Observed number of VOC leading to healthcare visit is the mean of individual patients' number of VOC leading to healthcare visit based on Crisis Review Committee adjudicated data. b  Predicted number and ratios of VOC leading to healthcare visit are the inverse of the link function of the LS Mean from the model. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

Imputation methods for negative binomial regression of the number of VOC leading to healthcare visit (CRC-adjudicated data) LCL: Lower confidence limit, UCL: Upper confidence limit Impact of the adjudication process and outlier patient on the results of the primary efficacy endpoint Hodges-Lehmann model Supplementary analyses of primary efficacy endpoint (annual rate of VOC leading to healthcare visit) with Hodges-Lehmann method ITT: Intend to treat; LCL: Lower confidence limit, UCL: Upper confidence limit Medicinal product no longer authorised

## Negative binomial model

Supplementary analyses of primary efficacy endpoint (annual rate of VOC leading to healthcare visit) with negative binomial model

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

ITT: Intend to treat; LCL: Lower confidence limit, UCL: Upper confidence limit Key Secondary Efficacy Endpoint: Annual rate of days hospitalised due to VOC The standard median annual rate is 60% lower on crizanlizumab 5 mg/kg than on placebo, however the HodgesLehman median difference between treatment arms remains 0.00 days (95% CI: -3.00, 0.00; Wilcoxon rank sum test: p=0.716)). a  Medians, median differences, and CI for the median differences are calculated using Hodges-Lehmann method. The Hodges-Lehmann median is a non-parametric estimator of the location parameter. Medicinal product no longer authorised

|                                                                                               | Treatment Arm              | Treatment Arm   | Treatment arm comparison   |
|-----------------------------------------------------------------------------------------------|----------------------------|-----------------|----------------------------|
| product                                                                                       | Crizanlizumab 5 mg/kg N=67 | Placebo N=65    |                            |
| Hodges-Lehmann median annual rate of days hospitalised due to VOC leading to healthcare visit | 8.18                       | 7.55            | 0.00                       |
| 95% CI a                                                                                      |                            |                 | -3.00, 0.00                |
| p-value b                                                                                     |                            |                 | 0.716                      |
| Mean (± SD)                                                                                   | 12.39 (18.710)             | 18.64 (44.051)  |                            |
| Median c                                                                                      | 2.01                       | 5.03            |                            |
| Change from placebo (%)                                                                       |                            |                 | -60.0                      |
| Minimum, maximum                                                                              | 0.0, 81.7                  | 0.0, 307.4      |                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

| longer   |
|----------|

Treatment Arm Treatment arm The annual rate of days hospitalised is defined as the total number of days hospitalised for a patient occurring from the date of randomisation to the End date x 365 divided by the number of days during that same time period. End date = last dose date + 14 days. For patients not dosed, End date = end of study date. Supplementary analyses provided in response to the D180 LoOI Primary Efficacy Endpoint: Annual rate of SCPC Treatment comparison of VOC leading to healthcare visit as per investigator using negative binomial regression analysis, imputation method M6, without one outlier patient Key Secondary Efficacy Endpoint: Annual rate of days hospitalised Treatment comparison of days hospitalised using investigator data, negative binomial regression analysis and imputation method M6 (without one outlier patient) Annual rate of days hospitalised due to VOC Treatment comparison of days hospitalised due to VOC using investigator data, negative binomial regression analysis and imputation method M6 (without outlier patient) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

| no   |
|------|

| NumberofdayswithVoc ImputationM6   | 24.31(35.356)   | 33.17 (49.470)   | RR=0.80 (0.48,1.33)   |
|------------------------------------|-----------------|------------------|-----------------------|

Secondary Efficacy Endpoint The main secondary endpoints related to VOC (VOC-free, time to first VOC and annualised rate of uncomplicated VOCs) were also re-analysed using investigator data, negative binomial regression (when applicable) and imputation method M6 (without one outlier patient). Exploratory Efficacy Endpoint Treatment comparison number of days with VOC leading to healthcare visit per investigator using negative binomial regression analysis and imputation method M6 (without outlier patient) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

| longer   |
|----------|
| no       |

| Study identifier   | A2201   |
|--------------------|---------|

VOC leading to healthcare visit before and after randomisation per investigator (Population ITT) Summary of main study The following table summarises the pre-specified efficacy results as well as requested supplementary analyses from the main study. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections). Table 8:  Summary of efficacy for trial A2201 Title: A Phase II Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises. Study identifier A2201 CSEG101A2201 SUSTAIN Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Annual rate of SCPC                            | Treatment group                                                                                                    | 5 mg/kg crizanlizumab                                                                                              | 2.5 mg/kg crizanlizumab                                                                                            | Placebo                                                                                                            |
|------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|
|                                                | Number of subjects                                                                                                 | 67                                                                                                                 | 66                                                                                                                 | 65                                                                                                                 |
|                                                | Hodges-Lehmann (HL) median                                                                                         | 2.00                                                                                                               | 2.50                                                                                                               | 3.49                                                                                                               |
|                                                | Treatment arm comparison (active versus placebo) 95% CI p-value Mean (SD)                                          | -1.01 -2.00, 0.00 0.010 2.89                                                                                       | -0.69 -1.84, 0.02 0.180 3.04 authorised                                                                            | 4.43 (4.861)                                                                                                       |
|                                                | Standard median                                                                                                    | (4.196) 1.63                                                                                                       | (3.607) 2.01                                                                                                       | 2.98                                                                                                               |
|                                                | Min, Max                                                                                                           | 0.0, 24.3                                                                                                          | 0.0, 24.3                                                                                                          | 0.0, 24.3                                                                                                          |
| Notes                                          | Study outcomes are difficult to interpret due to applied statistical test and the handling of missing data. longer | Study outcomes are difficult to interpret due to applied statistical test and the handling of missing data. longer | Study outcomes are difficult to interpret due to applied statistical test and the handling of missing data. longer | Study outcomes are difficult to interpret due to applied statistical test and the handling of missing data. longer |
| Analysis description                           | Secondary Analysis no                                                                                              | Secondary Analysis no                                                                                              | Secondary Analysis no                                                                                              | Secondary Analysis no                                                                                              |
| Analysis population and time point description | Intent to treat 52 weeks                                                                                           | Intent to treat 52 weeks                                                                                           | Intent to treat 52 weeks                                                                                           | Intent to treat 52 weeks                                                                                           |
| Annual rate of days hospitalised               | Treatment group product                                                                                            | 5 mg/kg crizanlizumab                                                                                              | 2.5 mg/kg crizanlizumab                                                                                            | Placebo                                                                                                            |
| Medicinal                                      | Number of subjects                                                                                                 | 67                                                                                                                 | 66                                                                                                                 | 65                                                                                                                 |
| Medicinal                                      | Hodges-Lehmann median                                                                                              | 12.48                                                                                                              | 9.01                                                                                                               | 13.00                                                                                                              |
| Medicinal                                      | Treatment arm comparison (active versus placebo)                                                                   | 0.00                                                                                                               | 0.00                                                                                                               |                                                                                                                    |
| Medicinal                                      | 95% CI p-value                                                                                                     | -4.36, 0.00 0.450                                                                                                  | -3.90, 2.61 0.837                                                                                                  | 24.97 (50.160)                                                                                                     |
| Medicinal                                      | Mean (SD)                                                                                                          | 16.03 (24.021)                                                                                                     | 16.61 (28.989)                                                                                                     |                                                                                                                    |
| Medicinal                                      | Standard median                                                                                                    | 4.00                                                                                                               | 6.87                                                                                                               | 6.87                                                                                                               |
| Medicinal                                      | Min, Max                                                                                                           | 0.0, 130.7                                                                                                         | 0.0, 151.0                                                                                                         | 0.0, 307.4                                                                                                         |

<div style=\"page-break-after: always\"></div>

<!-- image -->

Annual rate of days hospitalised due to

VOC

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Annual rate of days hospitalised   | Treatment group                                                                        | 5 mg/kg crizanlizumab   | Placebo                   |
|------------------------------------|----------------------------------------------------------------------------------------|-------------------------|---------------------------|
| Annual rate of days hospitalised   | Number of subjects                                                                     | 66                      | 65                        |
| Annual rate of days hospitalised   | Mean (across imputation) (±SD)                                                         | 17.31 (32.936)          | 24.41 (47.370) authorised |
| Annual rate of days hospitalised   | Treatment difference estimate (active versus placebo) RR (predicted rate ratio) 95% CI | 0.72 0.36, 1.45 longer  |                           |

|                       |   Age 65-74 (Older subjects number /total number) |   Age 75-84 (Older subjects number /total number) |   Age 85+ (Older subjects number /total number) |
|-----------------------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------------|
| Controlled Trials     |                                                 0 |                                                 0 |                                               0 |
| Non-Controlled Trials |                                                 1 |                                                 0 |                                               0 |

At the moment the only study available with efficacy data in patients treated with crizanlizumab derives from study A2201.

Analysis performed across trials (pooled analyses and meta-analysis) Not applicable. Clinical studies in special populations In study A2201, the age ranged from 16 to 63 years. Thus, no data from patients older than 63 years are available from this study. Preliminary efficacy data were provided for the ongoing phase II study A2202. In Study A2202, the age ranged from 17 to 65 years. Supportive study Medicinal product no longer authorised

Preliminary descriptive analyses of the efficacy data were provided for the ongoing phase II study A2202.

<div style=\"page-break-after: always\"></div>

## 2.5.3. Discussion on clinical efficacy

<!-- image -->

In addition, in some patients who started HU treatment during the baseline period, a significant number of the VOCs occurred before the initiation of HU. The applicant clarified that there seems to be no trend indicating that initiating HU/HC during the year preceding randomisation had a major impact on the occurrence of VOCs in the 31 concerned patients.

Design and conduct of clinical studies Efficacy data for the prevention of vaso-occlusive crises in SCD patients aged 16 years and above is derived from a single phase II study, in SCD patients with a history of 2 to 10 sickle cell related pain crises in the preceding 12 months. The pivotal study A2201 was a multicentre, randomised, double-blind, parallel-group, placebo-controlled study evaluating the efficacy (and safety) of two doses of crizanlizumab (5 mg/kg and 2.5 mg/kg) in SCD patients (any genotype) with or without concomitant hydroxyurea/hydroxycarbamide treatment. As this study was conducted with the Reprixys-manufactured crizanlizumab (SelG1) whereas the Novartis-manufactured crizanlizumab (SEG101) is intended for commercialisation, the applicant has conducted a phase I study in healthy subjects (study A2102) to demonstrate PK/PD comparability of SelG1 and SEG101. The study showed substantial differences in exposure and the crucial question was whether the PK differences between the earlier (SelG1) and the to-be commercialised version (SEG101) translate into different PD behaviour. The applicant provided a re-analysis of samples from study A2201 conducted with the new Novartis assay and compared results with the original data. The reanalysis indicates that the observed differences may be rather attributed to differences in the two PD assays used (see PK/PD section). Additionally, the applicant provided preliminary efficacy data from the ongoing single-arm open-label phase II study A2202, conducted with SEG101. The provided efficacy data until the cut-off date of 04-Oct-2019 (n=45) on the annualised VOC rate show comparable effect between study A2202 and study A2201 (conducted with the Reprixys-manufactured SelG1). In study A2201, 198 patients were randomised in a 1:1:1 ratio to 5 mg/kg crizanlizumab, 2.5 mg/kg crizanlizumab or placebo. Randomisation was stratified by concomitant use of hydroxyurea (HU) (yes/no) and number of vaso-occlusive crises in the year preceding study start. The study had a 30-day screening period, a 52-week treatment period and a follow-up evaluation phase for a maximum total duration of 58 weeks. Concomitant medication consistent with standard care of patients with SCD was permitted during the course of the study. For the concomitant use of HU and erythropoietin, patients must have been on the drug for 6 months and the dose stable for at least 3 months. If a physician deemed it medically necessary initiation, termination or alteration of HU treatment was allowed. The applicant clarified that HU/HC use during the study was relatively stable among the treatment groups. Dose modifications/ interruptions were reported in 6 patients in the placebo group, 6 patients in the 2.5 mg/kg crizanlizumab and 4 patients in the 5 mg/kg crizanlizumab group. Termination of HU/HC was reported in 1 patient in the placebo and 2 patients in the 5 mg/kg crizanlizumab group and initiation of HU/HC after start of study treatment was reported in 1 patient in the placebo arm. The rationale for modification of HU use was not collected in the CRF. Nevertheless, changes in HU/HC treatment during the study were well balanced between treatment arms and thus, the initial concern that these changes might have had an impact on the efficacy or safety results has been resolved. Medicinal product no longer authorised

Furthermore, patients receiving chronic anticoagulant therapy other than aspirin (e.g. warfarin, heparin) were excluded from the study. Concomitant heparin use was more prevalent in the placebo group than in the

<div style=\"page-break-after: always\"></div>

crizanlizumab groups, but an impact on the primary efficacy outcome cannot be entirely excluded since differences in the length of heparin treatment, ranging from 1 to &gt;100 days, were seen. The applicant provided comparative data on heparin and enoxaparin use during the study. The number of patients receiving heparin/enoxaparin, the event incidence (number of records) and number of patients who received a heparin dose &gt;3000 IU was relatively balanced between the placebo and 2.5 mg/kg crizanlizumab arm and slightly lower in the 5 mg/kg crizanlizumab arm. The majority of these events were of short duration and comparable between the treatment arms. The number of patients who received heparin to manage a VOC was slightly higher in the 5 mg/kg treatment arm, but duration of administration was longer in the placebo arm. The initial concern that concomitant heparin/enoxaparin use might have biased the primary efficacy results has been resolved. Patients on a chronic transfusion programme or planning an exchange transfusion during the study were excluded. However, occasional transfusions as needed were allowed. The applicant clarified that blood products were administered in a balanced way between the treatment arms. However, 3 patients were excluded from the analysis for having transfusions of 10 or more units (2 patients in the 2.5 mg/kg arm and one patient in the 5 mg/kg arm). The applicant assumes that these patients were part of a chronic transfusion programme. With regards to an impact of ad hoc transfusions on the efficacy analysis, the applicant clarified that there were only few samples or patients with a PK sample collected within 5 days of blood transfusions, preventing a reliable assessment of the potential impact of blood transfusions on PK/PD and VOCs in SCD patients. However, in the ongoing phase III study A2301 the protocols advise to collect PK/PD samples before and after the administration of an ad hoc transfusion. Patients were recruited in 51 centres in the US, Brazil and Jamaica. The majority of patients were Black or African Americans (about 90% in all groups). The study population consisted of patients with sickle cell disease of any genotype (HbSS, HbSC, HbSβ 0 thalassaemia and HbSβ + -thalassaemia). Patient age ranged from 16 to 63 years of age and was balanced between the treatment groups. The number of enrolled patients 16-18 years of age was very limited in this study and the applicant was asked to discuss whether the results from adults can be extrapolated to patients 16 to 18 years of age. The applicant provided a thorough discussion on the similarities between the SCD patient population aged 16 to &lt;18 years and ≥ 18 years with respect to SCD pathophysiology, the role of P-selectin, the clinical manifestations of SCD, the expected PK of crizanlizumab and the substantial unmet medical need in those patients. The argumentation of the applicant can be followed and it can be assumed that SCD patients between 16 to 18 years have similar manifestations of SCD as young adults. Additionally, it is agreed that early treatment of SCD is essential for adolescent patients to avoid chronic complications. The ongoing phase III study A2301 intends to include at least 48 SCD patients from the age of 12 years onwards; these data are considered important in the CMA context. Of the enrolled patients, about 60% received concomitant HU therapy at baseline and about 60% of the recruited patients had 2 to 4 VOCs, whereas 37.4% had 5 to 10 VOCs in the preceding 12 months. Overall, the demographic characteristics are well balanced across treatment groups and the recruited population seems to represent a real world SCD population. Additionally, the applicant has contextualised the representativeness of the study population to EU population adequately. Especially the use of HU/HC and treatment for pain management are expected to be quite similar in US and in Europe. Thus, the patient population in the pivotal study is expected to be treated in a comparable way and to be representative also with regard to EU SCD patients population. Medicinal product no longer authorised

The primary efficacy endpoint was the annual rate of sickle cell related pain crises (SCPC or VOC) . Evaluation of the annual rate of SCPC as primary efficacy outcome is considered clinically relevant and endorsed. For consistency reasons, all crisis events identified by investigators were independently adjudicated by a central review committee (CRC) to determine whether reported sickle cell crises meet the criteria for the primary efficacy outcome. There was a significant discrepancy between VOCs evaluation by the CRC and by the

<div style=\"page-break-after: always\"></div>

investigator. For example, 64.6% of the recorded VOC events in the 5mg/kg crizanlizumab arm were adjudicated as VOCs by the CRC compared with a rate of confirmed VOCs of  81.6% in the placebo arm. An at least twofold higher number of SCPC events in the crizanlizumab treatment groups were adjudicated as 'not SCPC' compared with the placebo group. The lower concordance rate in the 5 mg/kg crizanlizumab arm that mainly occurred within the adjudication category 'Same SCPC event as other recorded SCPC event' (2 week rule; duplicated) is driven by one patient who had 37 crises over 6 months thus entering this category multiple times. Exclusion of this patient increased the overall concordance rate from 64.6% to 77.6% in the 5mg/kg arm compared to 81.6% in the placebo arm. The applicant suggested to exclude outlier patient from the final efficacy analysis due to the fact that this patient violated the protocol inclusion criteria by having more than 10 crises per year at baseline (30 uncomplicated VOC leading to healthcare visit between 26-Nov-2012 and 09-Dec-2013). Furthermore, the frequency and pattern of VOCs reported for this patient is more reflective of chronic pain rather than acute pain episodes due to vaso-occlusion as defined per protocol. It is agreed that analyses should focus on results excluding this outlier patient when using investigator-based VOC counts. Critical findings related to the adjudication process as well as the documentation of this process were identified during the GCP inspection, and inspectors did not recommend accepting these data due to remaining uncertainties. In particular, a major uncertainty pertains to the 2-week rule (VOCs that occurred within 14 days were not counted as a separate event) as this timeframe was not (pre)defined in the study protocol and it cannot be followed whether it was consistently applied during the entire study. Although central adjudication by independent experts is in principle endorsed, the investigators´ diagnosis as well as the subjective patient´s evaluation of pain are considered also important due to the direct and personal link to the disease. According to the GCP inspectors, the two inspected investigator sites worked fairly well in compliance with GCP and the data collected at the sites are considered credible. Analyses using the investigator identified VOC rate are thus considered acceptable for the benefit-risk evaluation. Analyses employing the investigator-adjudicated VOC c ount as well as negative binomial regression and imputation scheme M6 ('jump to reference') have been provided for the primary efficacy endpoint as well as other important endpoints for a better understanding of crizanlizumab´s benefit. The key secondary efficacy endpoint is the annualised rate of days hospitalised. This endpoint is considered clinically meaningful since VOCs are the leading cause of emergency visits, however, duration of hospitalisation might be influenced by other factors, e.g. the insurance status of the patients. The other secondary endpoints including time to first and second SCPC, annual rate of uncomplicated SCPC, annual rate of ACS and a brief pain inventory questionnaire are supported. Separate analyses of uncomplicated SCPC and ACS have been provided. The applicant clarified that no case of hepatic and splenic sequestration was reported during the course of study A2201, and priapism was only reported in one patient (1.5%) in the placebo arm. No robust conclusions on the effect of crizanlizumab on the rate of these events can be drawn based on the limited number of cases. Since milder VOCs are often managed at home by oral analgesics, comparative assessment of analgesics and antiemetic usage (dose and duration) is considered of clinical relevance. The applicant provided comparative tables showing the incidences for analgesics and antiemetics use. However, interpretation of these results is hampered since dose, duration and reasons for use were not consistently collected throughout the study. Medicinal product no longer authorised

## Efficacy data and additional analyses

Of the 198 patients randomised, 192 received treatment and 125 patients completed the study: 64.2% (43/67) in the 5 mg/kg crizanlizumab group, 68.2% (45/66) in the 2.5 mg/kg crizanlizumab group and 63.1% (41/65)

<div style=\"page-break-after: always\"></div>

in the placebo group. The most commonly reported reasons for study drug discontinuation was 'withdrawal by the patient/caregiver/legal guardian', 'lost to follow up' and 'others'. Although the number of patients who discontinued the study prematurely was comparable across the treatment groups, a more critical discussion on the timing, pattern, reasons for and possible implications of missing values on efficacy assessment was requested. It cannot be readily assumed that the probability of discontinuation does not depend on disease status or (lack of) efficacy of treatment. The applicant provided data showing the probability of treatment discontinuation against time for the ITT population separately for the two doses and the placebo group. Time to discontinuation seem similar between treatment groups, if slightly higher for the two dose groups. In the pre-specified primary efficacy analysis, the median annual rate of SCPC after 52 weeks of treatment was 1.63 in the 5 mg/kg crizanlizumab group, 2.01 in the 2.5 mg/kg and 2.98 in the placebo group. The difference between the 5 mg/kg crizanlizumab arm and placebo arm was found to be statistically significant. However, there are uncertainties with regards to the analysis of the primary efficacy endpoint: The handling of missing data is considered critical. The imputation using simple annualisation is questioned; patients will not continue receiving treatment upon study withdrawal and thus the assumption that the SCPC rate will remain constant is questionable and not substantiated. The applicant provided the primary analysis based on the requested negative binomial regression model with the additional imputation methods (i) by pain crises data prior to randomisation (M5) and (ii) reference based multiple imputation (M6). Both methods lead to reduced effect sizes: with M5 the rate ratio is 0.72 [0.54, 0.95], whereas the most conservative method M6 even leads to a non-significant result (0.74 [0.54, 1.03]). A n analysis based on the 'jump to reference' imputation for all subjects who discontinued in the treatment group is considered most appropriate because reliable reasons for discontinuation are difficult to ascertain. Furthermore, the pre-specified primary efficacy analysis according to the SAP presents the p-value corresponding to the primary analysis in the ITT population, together with the standard median as well as oneor two-sample Hodges-Lehmann (HL) estimates. The definition of the metric and respective estimate to be considered for interpreting clinical relevance is not obvious. For the study planning, a relative reduction of 40% in the number of VOCs was considered clinically relevant, and the applicant interprets the results such that the 5 mg/kg treatment led to a 45% reduction considering the ratio of the standard median of 1.63 VOCs in 5 mg/kg crizanlizumab group compared to 2.98 VOCs in placebo. The applicant provided a discussion on the appropriateness of the reported estimate. However, the claimed similarity of the shape of the distribution of annual rate of VOC leading to healthcare visit between treatment and placebo arm cannot be followed. Medicinal product no longer authorised

The negative binomial regression model is seen as a more appropriate analysis method for count data, especially as it does not need the location shift assumption. The negative binomial regression model is particularly useful as it respects the rate based (count divided by exposure) character and provides effect estimates and confidence intervals that can be easily interpreted. As sensitivity analysis, a negative binomial regression analysis using simple annualisation for the missing data was performed: a relative reduction of predicted number of VOCs leading to healthcare visits of 35% was observed (ratio active versus placebo: 0.65, 95% CI [0.47, 0.90]). The applicant further provided the requested re-analyses using the investigator data, negative binomial regression analysis and imputation method M6 (without one outlier patient as discussed above). The re-analysis showed a reduction of the predicted number of VOCs leading to healthcare visits of 26% for crizanlizumab 5 mg/kg vs. placebo (RR=0.74, 95% CI [0.52, 1.06]). Using investigator reported VOCs (one outlier patient excluded) instead of CRC-adjudicated VOCs affected the results only marginally (0.74 [0.54, 1.03]). The lack of significance of the primary endpoint under the most conservative imputation method could be due to low power

<div style=\"page-break-after: always\"></div>

as the trial was originally planned to detect a 40% reduction in SCPC with approximately 90% power, using Wilcoxon's rank sum test (α=0.05), only considering a 15% dropout rate. The applicant provided subgroup analyses for genotype, frequency of prior VOCs and HU use. Re-analyses of the primary endpoint for the individual genotypes (HbSS, HbSC) as well as for alternative groupings based on clinical severity (HbSS together with HbSß0-thalassemia as well as HbSC together with HbSß+-thalassemia) using investigator data, negative binomial regression and imputation method M6 indicate a favourable trend of crizanlizumab over placebo across all genotypes. However, the data need to be interpreted with caution, because patients with HbSB0 thalassemia or HbSB+ thalassemia were underrepresented in the study. Subgroup analysis by gender and ethnicity were conducted post-CSR. Patients with a lower number of previous SCPCs (2-4) did not show a beneficial effect from crizanlizumab when the annual rate of SCPCs by hydroxyurea use was categorised by history of pain crises. The treatment effect seems lower for older than for younger patients for both treatment groups. In conclusion, there could be an effect of crisis history and age on the treatment effect, but both effects seem minor. The applicant conducted a post-hoc analysis of the proportion of VOC-free patients. Patients were considered VOC-free if they completed the study with an annualised rate of VOC leading to healthcare visit of '0'. Overall, the proportion of VOC free patients was more than 3-fold higher in the crizanlizumab 5 mg/kg arm compared with the placebo arm. Similar differences are seen across subgroups according to HU use, number of VOCs at baseline and genotype. The median annual rates of days hospitalised were 4.00 in the 5 mg/kg crizanlizumab group, 6.87 days in the 2.5 mg/kg crizanlizumab group and 6.87 days in the placebo group. The point estimate of the HL estimate of the absolute difference between medians is 0.00 days for both doses of crizanlizumab. The lack of statistical significance was explained by the fact that the analysis included all hospitalisation days rather than hospitalisation days due only to SCPC. The applicant provided a re-analysis showing the annual rate of days hospitalised due to VOC using the investigator reported VOCs, negative binomial regression and imputation method M6. The provided re-analysis showed a 28% reduction of the predicted number of days hospitalised due to VOC on crizanlizumab 5 mg/kg compared to placebo (RR=0.72, 95% CI=[0.36, 1.45]). Although not statistically significant, the results show a positive numerical trend in favour of crizanlizumab 5 mg/kg over placebo. The main secondary efficacy endpoints related to VOC (VOC-free, time to first VOC and annualised rate of uncomplicated VOCs) were also re-analysed using investigator rather than adjudicated crisis. The OR of number of VOC-free patients completing the 1 year study period is 3.05 (1.00, 9.25), i.e. the odds to be VOC-free during 1 year increase by a factor of 3 with 20% of patients in the crizanlizumab group and 8% of patients in the placebo group being VOC free during the 1 year study period. The hazard ratio of first VOC is 0.54 (0.36, 0.81), i.e. the hazard rate of first VOCs is significantly reduced with a difference in time to first VOC of 2.63 months. The risk ratio of annual rate of uncomplicated VOC is 0.72 (0.49, 1.05), i.e. the risk of uncomplicated VOC is reduced by 28% corresponding to on average 1.4 VOCs per year. Medicinal product no longer authorised

While a comparison of the annual rates of uncomplicated SCPC events in the 5 mg/kg crizanlizumab group versus placebo showed a reduction, no treatment differences were observed in the annual rates of acute chest syndrome. According to the individual efficacy response data, ACS occurred more often in patients treated with crizanlizumab (both doses) than on placebo, despite the fact that more patients in the placebo group had a medical history of ACS. The applicant clarified that more patients in the crizanlizumab 5 mg/kg arm (13/67; 19.4%) had at least one ACS in the year before randomisation compared with placebo (5/65; 7.7%) while

<div style=\"page-break-after: always\"></div>

post-baseline, the values were similar between crizanlizumab 5 mg/kg arm (10/67; 14.9%) and placebo arm (11/65; 16.9%). No statistically significant differences between the 5.0 mg/kg arm or the 2.5 mg/kg arm compared with the placebo arm were found in the PROs. 2.5.4. Conclusions on the clinical efficacy Efficacy of crizanlizumab was evaluated in one phase II study in patients with sickle cell disease. In the original primary analysis, 5 mg/kg crizanlizumab treatment led to a 45% reduction of the annual rate of sickle cell related pain crises (CRC-adjudicated), considering the ratio of the standard median of 1.63 VOCs in 5 mg/kg crizanlizumab group and 2.98 VOCs in the placebo group. Following the GCP inspection, evaluation of the treatment effect of crizanlizumab based primarily on the CRC-adjudicated data was not considered sufficiently robust. As data collected at the study sites were considered credible, analyses using the investigator-based VOC rate are acceptable for the benefit-risk evaluation. Supplementary analyses taking into account the issues regarding statistical methodology and crisis adjudication show a beneficial effect on the risk of SCPC occurrence in the 5 mg/kg crizanlizumab compared to placebo. The use of investigator reported VOCs (excluding one outlier patient) instead of CRC-adjudicated VOCs affected the results only marginally. Under the most conservative imputation method, statistical significance could no longer be reached. However, all treatment effect estimates for the primary and secondary endpoints are systematically in favour of crizanlizumab and the observed favourable trends for the 5 mg/kg crizanlizumab dose are of a magnitude considered clinically relevant for SCD patients.: (RR=0.74, 95% CI=0.52, 1.06). Furthermore, preliminary efficacy data from the ongoing study A2202 conducted with the to-be commercialised product SEG101 showed comparable results between study A2202 and study A2201 conducted with the Reprixys-manufactured product (SelG1). The CHMP considers the following measures necessary to address the missing efficacy data in the context of a conditional MA: · In order to confirm the efficacy and safety of crizanlizumab, the MAH should submit the results of the primary analysis of a phase III CSEG101 A2301 study of crizanlizumab with or without hydroxyurea/hydroxycarbamide in adolescent and adult sickle cell disease patients with vaso-occlusive crises. · In order to confirm the efficacy and safety, the MAH should submit the final results of the phase II CSEG101 A2202 study of crizanlizumab with or without hydroxyurea/hydroxycarbamide in sickle cell disease patients with vaso occlusive crisis. 2.6. Clinical safety Medicinal product no longer authorised

The safety database consists of data from four clinical studies: A2201 and A2202 in SCD patients and A2101 and A2102 in healthy volunteers.

Study A2101 in healthy volunteers was a placebo controlled double blind dose ascending study to assess safety, PK, PD at different dose level from 0.2 -8 mg/kg (0.2, 0.5, 1, 5, 8 mg/kg).

<div style=\"page-break-after: always\"></div>

Study A2102 was a randomised parallel comparability study in healthy volunteers to study safety and PK/PD comparability of the two formulations SelG1 and SEG101. The main dose was the dose intended for marketing authorisation - 5 mg/kg. A small exploratory arm was also performed with a dose of 7.5 mg/kg. For the higher dose no data was nor is planned to be submitted for this procedure. Study A2201 also referred to as 'registration study' was a randomised, double-blind, placebo-controlled study in SCD patients to assess efficacy and safety of 2.5 and 5 mg/kg. This is the pivotal study for this procedure. Study A2202 is an ongoing open label study in SCD patients to assess PK/PD and safety for the new formulation SEG101 (5 mg/kg) with a small exploratory arm of 7.5 mg/kg (not intended for this procedure). Study A2201 finished on 23. March 2016 and study A2202 was initiated on 19. Dec 2017. The inclusion/exclusion criteria do not prevent a re-enrolment of patients. The applicant clarified that 8 patients in the ongoing study A2202 were already enrolled in study A2201. Three received placebo in the previous study and five received Crizanlizumab SelG1. Since all patients have been tested negative for ADAs at the beginning of study A2202 it is agreed that no impact on immunogenicity results are expected. However, the five patients previously in the verum groups represent 11% of the study population of study A2202. This could bias the results because a favourable effect (efficacy or safety) is assumed since a negative experience would not lead the patient to participate in a similar study. A review confirmed that all five had indeed rather mild safety profiles. It could also be observed that these patients experienced infections and hypokalaemia only in study A2202. Further comparison of laboratory observations between studies showed comparable data. No conclusions can be drawn based on this very limited dataset but this finding adds to the existing uncertainty of increased infections in study A2202. The applicant acknowledged the potential bias and clarified that for the ongoing phase 3 study A2301 patients are excluded that participated in prior studies of crizanlizumab. The applicant presented the data as pooled safety data of patients who received at least 1 infusion of crizanlizumab at a dose of 2.5 mg/kg (N=64) or 5 mg/kg (N=111). Although in general a combined presentation of safety data is preferable, the shorter treatment duration of patients in study A2202 as initially presented hampered direct comparisons between the studies. Furthermore, different versions of crizanlizumab were used in these studies, whose comparability was questioned but observed differences might be attributed to different assays used (See PK/PD section). Therefore, the data were evaluated separately. Crizanlizumab has been authorised in the US in 2019. Therefore, only very limited post marketing data is available. At the time of submission of the application for marketing authorisation, two studies with crizanlizumab were ongoing: A2202 and B2201. Safety data for A2202 was included in the initial submission until the cut-off date: 19-Oct-2018. With the responses to the D120 LoQ an update was submitted containing data up to the first of March 2019. As response to the D180 LoQ another update was submitted with the cut-off date of 04-Oct-2019. Medicinal product no longer authorised

B2201 is a study in paediatric patients and part of the paediatric investigation plan submitted by the applicant. Submission of the data is not intended for assessment as part of this application procedure. Until the 15th January 2019 only one patient was treated. No SAEs were reported for this patient (see special populations).

Further, a phase III confirmatory Study A2301 is planned to provide the comprehensive data required for the conditional marketing approval. It is a Phase III, multicentre, placebo-controlled, double blind clinical study in adolescent and adult (age ≥ 12 years) SCD patients to assess efficacy and safety of 5 and 7.5 mg/kg in 240

<div style=\"page-break-after: always\"></div>

patients of which at least 48 are adolescents. The study has started to enrol patients in 2019 and results of the primary analysis are planned to be available in 2025. Immunogenicity Crizanlizumab is a monoclonal antibody and hence exhibits a potential for immunogenicity. Antibody formation has been tested in all four studies. This data is discussed in the respective section on immunogenicity. Other adverse events of interest P-selectin is expressed on the surface of activated endothelial cells and activated thrombocytes. It is involved in the response to inflammation via initial recruitment of leukocytes and in the aggregation of platelets during vascular injury. Therefore, inhibition of P-selectin might have an effect on the innate immune response against infection and on haemostasis. These are AEs of special interest and are discussed further in the respective sections. Furthermore, injection site reactions have been monitored throughout the studies and are discussed in the respective sections below. Different crizanlizumab versions Crizanlizumab was first developed by Reprixys Pharmaceuticals and acquired by Novartis in 2016. Novartis has since changed the production process of the product resulting in a new version, SEG101. Clinical studies A2101 and A2201 used the Reprixys-manufactured crizanlizumab SelG1. SEG101 is used in the ongoing study A2202 and is planned to be used in all future development and as the commercial product. A comparative study A2102 was performed with both versions. SEG101 exhibits 28% higher exposure compared with SelG1 and some concerns were initially raised about the comparability of the PD. Reanalyses of samples from study A2201 however indicate that the observed differences in PD are attributable to the used assays. Consequently, both versions are considered comparable (please refer to the PK/PD section for more details). In the ongoing study A2202, almost 100% P-selectin inhibition has been observed with SEG101. The clinical implications of 100% inhibition are currently unknown, in particular for long-term treatment. In the presented studies some minor differences of safety profiles have been identified as discussed below. The safety data available for SEG101 are limited and more comprehensive data is required which will be generate in the confirmatory phase III study. Patient exposure In study A2201 patients were exposed to the intended dose of crizanlizumab (5.0 mg/kg) for 43.8 weeks (mean) ranging from 4 up to 57 weeks. Similar exposure times have been achieved for the 2.5 mg/kg treatment (46.3 weeks (4-57)) and the placebo arm (43.7 weeks (4-58)). In study A2202, the initial submission included only data for a mean exposure time of 18.5 weeks ranging from 0-40 weeks was reported. Two updates were provided including data for 35.4 weeks (6-58) and 64.7 weeks (6-90). Since the study is still ongoing and different versions were used in the studies, results are assessed separately. Given the exposure times in both studies, no information is available for long-term use. The applicant plans to address this in the ongoing study A2301, which includes a 1 year placebo controlled treatment followed by another 4 years as single arm study. Medicinal product no longer authorised

The resulting safety dataset of patients receiving crizanlizumab is considered to be 64 patients receiving 2.5 mg/kg, 66 patients receiving 5.0 mg/kg SelGI and 45 patients receiving 5.0 mg/kg SEG101. 62 patients received placebo.

<div style=\"page-break-after: always\"></div>

95 healthy volunteers received different doses of crizanlizumab ranging from 0.2 mg/kg to 8 mg/kg. 69 received the intended dose of 5 mg/kg (41 SelGI (8 in A2101; 33 in A2102); 28 SEG101 in A2102). In study A2201, 23 patients (34.8%) receiving the intended 5 mg/kg dose discontinued prematurely from the study. This rate is comparable to the rates in the lower dose (29.7%) and the placebo arms (33.9%). So far, only five (11.1%) of the patients in study A2202 discontinued. The applicant provided an overview of discontinuations compared to treatment time and time on study drug. Overall, the data is comparable between studies and between treatment arms. The duration of exposure has been presented as mean, median and min-max values. Upon request, an overview of the number of patients on study drug per week was provided. No trends for discontinuations after a certain treatment time have been observed. SCD requires life-long treatment, which is intended to be provided with crizanlizumab. The provided evidence submitted for this application should therefore fulfil the requirements specified in guideline ICH E1 for long-term use. This guidance recommends a minimum requirement of 100 patients being studied for a minimum of one year for new medicinal products. A total of 33 patients have been exposed to crizanlizumab 5.0 mg/kg for at least 54 weeks. Additional 27 patients received 2.5 mg/kg for the same duration. The applicant plans to collect more comprehensive data in the planned phase III study A2301 (240 patients randomised 1:1:1: 5, 7.5 mg/kg and placebo). In study A2202 so far eight patients (17.8%) experienced at least one dose interruption during their treatment. Only two were recorded as due to an AE (4.4%), the others were either due to a decision from the patient or the investigator. In study A2201 no information about dose interruptions in general and their reasons were recorded. However, the number of patients with dose interruptions due to an AE is similar (5 patients (7.6%)). Demographics and Baseline Characteristics Overall the treatment arms seem well balanced in respect to the presented characteristics (age, age category, sex, race, ethnicity, BMI, SCD type, HU/HC usage, number of VOC). Age Paediatric population The safety database for paediatric patients is very limited. In total only 6 patients were younger than 18 years at baseline, thereof only 3 received the intended dose of 5 mg/kg (2 in A2201, 1 in A2202). Further, the treatment of the patient in study A2202 is still ongoing. Of the other patients, two received placebo and one 2.5 mg/kg crizanlizumab. Elderly population Only one patient was at least 65 years old. This patient is recruited in the ongoing study A2202. Race/Ethnicity Medicinal product no longer authorised

The majority of patients -93% - are Black or African American. Between treatment groups and studies these percentages are comparable. This imbalance can be explained by the prevalence of SCD worldwide: In ethnicities other than Black or African American it is rather low. No differences between ethnicities are known that would result in altered pathophysiological processes relevant to SCD. The included population does reflect the population suffering from sickle cell disease in Europe (Hickman et al 1999, Gulbis et al 2006, Modell et al 2007, Roberts et al 2007, Colombatti et al 2016).

<div style=\"page-break-after: always\"></div>

## BMI

<!-- image -->

The BMI is balanced between groups in A2201. It is slightly higher in study A2202. No information on body weight was given. An additional analysis of the impact of bodyweight on clearance showed comparable results overweight categories (please refer to the PK section of this report). Sickle cell disease type SCD is a group of genetic mutations consisting of genotypes with different disease characteristics and severities. In the two studies A2201 and A2202 about 65% of the patients were diagnosed with sickle cell disease type HbSS. Other types included in the studies were HbSC (18%), HbSβ+ -thalassaemia (5%), HbSβ0 -thalassaemia (6%) and 6 patients with other diagnoses (3%). This ratio corresponds with the estimated population in Europe (Hickman et al 1999, Saraf et al 2014). Patients with different genotypes are well balanced between treatment groups in study A2201 and in study A2202. Concomitant medications All patients received at least one concomitant medication for an unknown duration. The most frequent concomitant medication was folic acid (73.7%) a recommended supplement in the treatment of sickle cell patients. It is used at a similar frequency in study A2202 (77.8%). Other frequent medications are for the treatment of pain and the alimentary tract. The use of concomitant medication was overall comparable, except for some ATC classes which seem more frequent in patients receiving crizanlizumab in both studies compared to placebo: Nervous system (A2202: 100%, A2201: 5mg/kg: 97%, placebo: 90%), Respiratory system (A2202: 91%, A2201: 5mg/kg: 85%, placebo: 81%), Cardiovascular system (A2202: 87%, A2201: 5mg/kg: 79%, placebo: 68%). No information concerning the reasons and duration of these medications is available. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 9: Concomitant medications by ATC class in SUSTAIN and A2202 studies

|                                                                 | Study A2202 crizanlizumab 5 mg/kg   | Study A2201 authorised   | Study A2201 authorised       | Study A2201 authorised   | Study A2201 authorised   |
|-----------------------------------------------------------------|-------------------------------------|--------------------------|------------------------------|--------------------------|--------------------------|
|                                                                 |                                     | 5 mg/kg                  | Crizanlizumab 2.5 mg/kg N=64 | Placebo N=62             | All subjects N=192       |
| ATC class                                                       | N=45                                | N=66                     |                              |                          |                          |
|                                                                 | n (%)                               | n (%)                    | n (%)                        | n (%)                    | n (%)                    |
| Subjects with at least one medication                           | 45 (100)                            | 66 (100)                 | 64 (100)                     | 62 (100)                 | 192 (100)                |
| Nervous system                                                  | 45 ( 100)                           | 64 (97.0)                | 61 (95.3)                    | 56 (90.3)                | 181 (94.3)               |
| Musculo-skeletal system                                         | 40 ( 88.9)                          | 61 (92.4)                | 61 (95.3)                    | 57 (91.9)                | 179 (93.2)               |
| Blood and blood forming organs                                  | 44 ( 97.8)                          | 59 (89.4)                | 61 (95.3)                    | 57 (91.9)                | 177 (92.2)               |
| Various                                                         | 42 ( 93.3)                          | 59 (89.4)                | 60 (93.8)                    | 55 (88.7)                | 174 (90.6)               |
| Alimentary tract and metabolism                                 | 43 ( 95.6)                          | 57 (86.4)                | 56 (87.5)                    | 53 (85.5)                | 166 (86.5)               |
| Respiratory system                                              | 41 ( 91.1)                          | 56 (84.8)                | 59 (92.2)                    | 50 (80.6)                | 165 (85.9)               |
| Sensory organs                                                  | 38 ( 84.4)                          | 56 (84.8)                | 52 (81.3)                    | 52 (83.9)                | 160 (83.3)               |
| Cardiovascular system                                           | 39 ( 86.7)                          | 52 (78.8)                | 55 (85.9)                    | 42 (67.7)                | 149 (77.6)               |
| Dermatologicals                                                 | 40 ( 88.9)                          | 50 (75.8)                | 55 (85.9)                    | 51 (82.3)                | 156 (81.3)               |
| Genito urinary system and sex hormones                          | 31 ( 68.9)                          | 51 (77.3) longer         | 50 (78.1)                    | 39 (62.9)                | 140 (72.9)               |
| Antineoplastic and immuno-modulating agents                     | 35 ( 77.8)                          | 45 (68.2) no             | 43 (67.2)                    | 43 (69.4)                | 131 (68.2)               |
| Anti-infectives for systemic use                                | 26 ( 57.8)                          | 42 (63.6)                | 43 (67.2)                    | 38 (61.3)                | 123 (64.1)               |
| Antiparasitic products, insecticides and repellents             | 22 ( 48.9)                          | 24 (36.4)                | 23 (35.9)                    | 27 (43.5)                | 74 (38.5)                |
| Systemic hormonal preparations, excl. sex hormones and insulins | 7 ( 15.6)                           | 12 (18.2)                | 14 (21.9)                    | 16 (25.8)                | 42 (21.9)                |

Similarly, although the study protocol prohibited the use of heparin, 18.2% of all patients in study A2201 received heparin as concomitant medication. Analysis of the duration of heparin intake shows that in the majority these were of short duration and had no impact on safety. However, the data set is limited.

Concomitant medications starting on or after the start of study treatment but not more than 105 days after end of treatment or starting prior to and continuing after the start of study treatment are summarised. A medication can be included in more than one ATC class. According to the study protocols, patients were supposed to continue their usual therapy with Hydroxyurea/hydroxycarbamide. HU/HC dose regimen was stable in most patients while on study. Dose modification/interruption of HU/HC, from start to end of study treatment, was only observed in 6 patients in the placebo group and 4 patients in crizanlizumab 5mg/kg group. The rationale for dose reduction/interruption of HU/HC was not collected in the CRF. However, the very low number of patients and the balance between treatment arms does not suggest any negative impact of crizanlizumab on patient's capacity to continue their usual HU regimen. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Number of VOC

The majority of patients (~60%) experienced less than 5 VOC reported in the last 12 months prior to their inclusion in the respective study. This is similar in all treatment arms and in study A2202. An additional comparison of AEs between patients experiencing different number of VOCs at baseline (&lt; 5 VOC or at least 5 VOC at baseline) showed only small differences in the rates of AEs. Adverse events The rates of AEs are high in study A2201, but also well balanced between the treatment and placebo groups ( 5mg/kg: 86.4%, 2.5 mg/kg: 87.5% and placebo: 88.7%). This also applies for rates of AEs with grade ≥3 ( 5 mg/kg: 18.2%; 2.5 mg/kg: 20.3%; placebo: 19.4%). The AE rate in the ongoing study A2202 is slightly higher (93.3%) but the rate of AEs at the preferred term level was overall similar and no concerns are raised. However, the rate of AEs with grade ≥3 is higher (40.0%). Treatment related events occurred more often in the verum arms with higher rates for the higher dose (5mg/kg: 40.9%, 2.5 mg/kg: 32.8%, placebo: 24.2%; A2202: 22.2%). Serious adverse events are balanced between arms (5mg/kg: 25.8%, 2.5 mg/kg: 31.3%, placebo: 27.4%; A2202: 24.4%%), whereas treatment related SAEs are more frequent in the verum arms (5mg/kg: 9.1%, 2.5 mg/kg: 7.8%, placebo: 3.2%; A2202: 0). AEs leading to discontinuations are rare and seem less frequent in the verum groups. AEs leading to dose interruptions occurred at similar rates between treatment arms in study A2201 (5mg/kg: 7.6%, 2.5 mg/kg: 9.4%, placebo: 6.5%; A2202: 13.3%). AEs of at least grate 3 are, however, more frequent in the verum arms (5 mg/kg: 3.0%; 2.5 mg/kg: 6.3%; placebo: 1.6%; A2202: 6.7%) without an observable relation to dose. Rates of AEs requiring additional therapy are high but well balanced between groups (5mg/kg: 71.2%, 2.5 mg/kg: 68.8%, placebo: 64.5%; A2202: 84.4%). Overall, in study A2202 an increase in severity of AEs has been observed compared to study A2201 (grade ≥3 AEs: 40.0% vs. 18.2%, grade ≥3 SAEs: 20.0% vs. 10.6% and grade ≥3 AEs requiring additional therapy: 35.6% vs. 9.1%). The applicant claims that these observations are due to different grading systems applied between the two trials. Although the argumentation can be followed, these observations have to be further discussed when data from the phase III trial becomes available. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 10: overview of adverse events in study A2202 and study A2201 (safety set)

<!-- image -->

The analysis of adverse events is based on the number of patients experiencing at least one event in a certain category, and the corresponding crude incidence rate is calculated by dividing this by the total number of subjects in each treatment arm. Upon request, exposure-adjusted incidence rate were submitted. The exposure-adjusted incidence rates of some events like headache were higher in study A2202, but the number of events was low and no clinically significant differences were observed. Further, no differences for AESIs were identified. In addition an overview of the timing of AEs was submitted. No trends in timing of the events or relation to discontinuations or the administration of crizanlizumab was observed. Common adverse events The most common SOC of AE was Infections and Infestations and was well balanced between treatment arms in study A2201 (5mg/kg: 51.5%, 2.5 mg/kg: 45.3%%, placebo: 53.2%). Higher incidence rates in the crizanlizumab 5 mg/kg treatment arm were observed for the following SOC. The events were typically mild or moderate. The results are presented below for study A2201 (5mg/kg vs placebo). Results for study A2202 are presented in the table below. - General disorders and administration site conditions: 24 (36.4%) vs 18 (29.0%) Medicinal product no longer authorised

|    | longer   |
|----|----------|
| no |          |

- Musculoskeletal and connective tissue disorders: 27 (40.9%) 18 (29.0%)
- Gastrointestinal disorders: 26 (39.4%) vs 15 (24.2%)
- Nervous system disorders: 21 (31.8%) vs 15 (24.2%)
- Injury, poisoning and procedural complications: 10 (15.2%) vs 3 (4.8%)

<div style=\"page-break-after: always\"></div>

| no      | no   | no   |
|---------|------|------|
| product |      |      |

Table 11: AEs by SOC (safety set)

<!-- image -->

•

- •

Fatigue: 7.6% vs. 3.2% (4.4% absolute difference)

- •

Back pain: 15.2% vs. 11.3% (3.9% absolute difference)

- •

- Pyrexia: 10.6% vs. 6.5% (3.9% absolute difference)

- Pruritus: 7.6% vs. 4.8% (2.8% absolute difference)

- Musculoskeletal pain: 12.1% vs. 9.7% (2.4% absolute difference)

No AE was reported in more than 20% of the patients in the 5mg/kg group. The most common AE is headache which is balanced between treatment arms and so far also similar in study A2202. Other AEs that occurred frequently (in ≥15% of SCD patients) are back pain, nausea (both a bit more common in the verum arm), arthralgia (more common in the verum arm) and pain in extremities (balanced between treatment arms). AEs that occurred a higher rate in the 5mg/kg treatment arm compared to placebo are: Arthralgia: 18.2% vs. 8.1% (10.1% absolute difference) · Diarrhoea: 10.6% vs. 3.2% (7.4% absolute difference) · Nausea: 18.2% vs. 11.3% (6.9% absolute difference) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | product   |
|-----------|-----------|
| Medicinal |           |

For general disorders and administrative site conditions, fatigue and pyrexia were more common in crizanlizumab-treated patients as compared to placebo. The frequency of events seems to be higher in study A2202, taking into account the difference in follow-up time at the time of data cut-off, but this comparison is pending until further data is available. In general, the presented rates in study A2202 are currently lower as expected for an ongoing study. Exceptions are higher rates for pyrexia ( 34.6) %, A2201: 5mg/kg 10.6%, placebo: 6.5%) and hypokalaemia (13.3%, A2201: 5mg/kg 1.5%, placebo: 8.1%). In musculoskeletal and connective tissue disorders SOC, almost all preferred terms were reported more commonly in crizanlizumab-treated patients: arthralgia, back pain, musculoskeletal chest pain, musculoskeletal pain, myalgia and pain in extremity were all more common. Only osteonecrosis was more common in placebo group (4 patients). The applicant presented a table illustrating all AEs occurring in at least 5% of the patients in the safety pool.  The safety pool combined data from study A2201 and the ongoing study A2202. As the rates in study A2202 are generally lower, as expected for an ongoing study, their inclusion reduce the rate in the safety pool compared to study A2201. Therefore applying a 5% threshold will potentially exclude AEs that occurred with a higher rate in study A2201 but have not yet occurred in study A2202. The data in the presented list is considered underestimated and the Rapporteur extended the table to include all AEs that occurred in study A2201 in at least 5% of the patients in the verum groups. Table 12: Common AEs (at least 5% in the safety pool) by preferred term (safety set) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Extension to Table above:

|                     | Study A2201 Placebo   | Study A2201 2.5 mg/kg SelG1   | Study A2201 5.0 mg/kg SelG1   | Study A2202 5.0 mg/kg SEG101 authorised   |
|---------------------|-----------------------|-------------------------------|-------------------------------|-------------------------------------------|
| Pneumonia           | 3 ( 4.8%)             | 5 ( 7.8%)                     | 4 ( 6.1%)                     | 1 (2.2%)                                  |
| Chest pain          | 1 ( 1.6%)             | 7 ( 10.9%)                    | 1 ( 1.5%)                     | 4 (8.9%)                                  |
| Abdominal pain      | 1 ( 1.6%)             | 3 ( 4.7%)                     | 4 ( 6.1%)                     | 0                                         |
| Myalgia             | 0                     | 2 ( 3.1%)                     | 5 ( 7.6%)                     | 0                                         |
| Oropharyngeal pain  | 1 ( 1.6%)             | 3 ( 4.7%)                     | 4 ( 6.1%)                     | 0                                         |
| Post-traumatic pain | 0                     | 0                             | 0                             | 3 (6.7%)                                  |
| Joint swelling      | 0                     | 0                             | 0                             | 3 (6.7%)                                  |

<!-- image -->

<!-- image -->

Adverse events considered related to crizanlizumab Treatment related AEs occurred at higher rates in the 5mg/kg treatment group than for placebo (27 (40.9%) vs. 15 (24.2%). Most event were only reported for one patient. Drug related AEs, which occurred in at least two patients receiving 5 mg/kg of crizanlizumab, are nausea, fatigue, pyrexia, arthralgia, pain in extremity, headache, dizziness, somnolence and epistaxis. The applicant performed an additional analysis of all AEs to identify adverse drug reactions. Table 13: Adverse drug Reactions (safety set) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Adverse events of special interest

<!-- image -->

|            |    | longer   |
|------------|----|----------|
|            | no |          |
| Infections |    |          |

Serious event of infections and infestations are less frequent in the verum group (8 (12.1%), placebo: 10 (16.1%), A2202: 5 (11.1%)). Most events were single occurrences and in line with the underlying disease or concomitant medication.

The applicant provided separate analyses for AEs of special interest based on the method of action of crizanlizumab. This includes infections, infusion-related reactions, effect on haemostasis and immunogenicity (see section 'Immunogenicity'). Further, the potential fo r drug-induced liver injury and the prolongation of the QT interval were analysed (see section 'Laboratory findings' of this report ). Table 14: Overview of adverse events of special interest in study A2202 and Study A2201 (safety set) Infections The overall rates of infections are balanced in study A2201 between patients receiving crizanlizumab and placebo (5mg/kg: 53.0%, 2.5mg/kg: 45.3% and placebo 53.2%). The rates for grade ≥ 3 events are a bit higher in the verum arm, but the number of patients is very small (5mg/kg: 4 (6.1%); 2.5mg/kg: 3 (4.7%), placebo: 2 (3.2%)). In study A2202 the overall rate of infections is similar (22 (44.4%); grade ≥ 3: 5 (11.1%)). An increased rate of pyrexia was observed in study A2202 (20.0%, A2201: 5mg/kg: 10.6%, 2.5mg/kg: 9.4%, placebo: 6.5%). Most events occurred in the context of infections. Drug related infection events were also more common in the verum arms of A2201, but again with very low numbers and all only reported by one patient (5mg/kg:6 (9.1%), 2.5mg/kg: 4 (6.3%), placebo: 2 (3.2%), A2202: 0). Medicinal product no longer authorised

Infection AEs in patients with chronic / recurrent infections were presented with information on medical history, nature, severity, causality and outcome of the on-treatment infection.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Infusion-related reactions

The applicant conducted a search for infusion-related reactions based on two strategies: 1) A broad list of search terms based SMQ terms related to anaphylactic reactions/conditions and angioedema. 2) A second search focussed on more severe terms. The search criteria seem reasonable and the method to identify respective reactions is acceptable. Adverse events related to infusion-related reactions were more frequent in the crizanlizumab arms in study A2201 (5mg/kg: 23 (34.8%); 2.5mg/kg: 20 (31.3%); placebo: 13 (21.0%)). In study A2202 the overall rate is comparable (14 patients, 31.1%). The majority of AEs were mild or moderate and transient in nature. The most common AEs were headache and nausea. Both AEs are adequately reflected in the SmPC together with infusion site reaction and infusion related reaction. One serious AE of 'systemic inflammatory response syndrome' was reported. The event occurred 28 days after the last infusion. Therefore, a relation to the infusion is unlikely. One patient presented with bradycardia during infusion. The detailed description of the event is not consistent with an IRR, and other factors are more likely to explain the symptoms. Effect on haemostasis: haemorrhage P-selectin is essential in initial platelet recruitment and aggregation in areas of vascular injury, and thus adverse effects on primary haemostasis could be expected to occur. The applicant searched AEs for a potential effect on the haemostatic system. In study A2201 the rates of events of potential effect on haemostasis are higher for the 5mg/kg group than for placebo (5 mg/kg: 11 (16.7%), placebo: 8 (12.9%), A2022: 5 (11.1%)). The majority are reported changes in laboratory values, but the majority of bleeding events occurred in the verum group. Additionally, the only event of intracranial haemorrhage (SAE, grade 4, hospitalisation) was reported in the 2.5 mg/kg group and lead to study drug discontinuation. Data on possible bleeding complications related to traumas or surgical procedures, or minor bleeds and bruising, could be used to estimate bleeding tendency. Related events like tendency to bruise, epistaxis, gastrointestinal bleeds and menorrhagia were rare, and no clear difference between treatment groups was evident. Some of the patients underwent surgical procedures or experienced traumas during the study, but no information on possible complications or bleeds were described. No information is available for patients with an increased risk for bleeding at baseline. The use of anticoagulant medications was not allowed apart from aspirin, and very few patients were exposed to anticoagulants for over two weeks. The applicant will address this issue in the confirmatory trial A2301, where prophylactic doses of anticoagulants is allowed, and detailed information on anticoagulant medication use will be collected. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

<!-- image -->

<!-- image -->

Serious adverse events The rates for SAEs are balanced between groups in study A2201: 5 mg/kg: 17 (25.8%), placebo: 17 (27.4%). So far, eleven patients (24.4%) experienced SAEs in study A2202. Most SAEs were only reported by one patient. The only SAEs reported in more than a single patient in the 5 mg/kg arm were: Pneumonia (3 (4.5%), placebo: 3 (4.8%); A2202: 0) and Pyrexia (2 (3.0%), placebo: 1 (1.6%); A2202: 0). Serious adverse events considered related to study drug are reported in more patients in the crizanlizumab groups of study A2201 but generally low (5mg/kg: 6 (9.1%); 2.5 mg/kg: 5 (7.8%); placebo: 2 (3.2%)). No events have been reported in study A2202 so far. The majority of events were reported by one patient each. The reported events in the narratives as related to study drug were (occurrences &gt; 1 are indicated): -5mg/kg: cellulitis (infectious in origin), pyrexia (2), tooth infection, lower respiratory tract infection, pneumonia, atypical pneumonia, hypotension, bradycardia, deep vein thrombosis -Placebo: pyrexia, sickle cell anaemia with crisis, right ventricular failure, neutrophil count decreased, gamma glutamyl transferase increased Most events were single occurrences and in line with the underlying disease or concomitant medication. Deaths No deaths were reported in studies in healthy volunteers (A2101, A2102) . In study A2202, one death was reported of a patient who received 3 doses of 7.5mg/kg . The death was judged as not related to the treatment. No relation to administration of crizanlizumab was observed given the provided narrative. Although bleeding was observed while she was treated in the hospital, this event is more likely attributed to aspirin use than to alter hemostasis in this patient: aPTT, PT/INR and platelet counts were low to normal and stable at all laboratory evaluations from baseline until her last visit. In study A2201 five patients died during the treatment period. Two patients received 5 mg/kg, one patient 2.5 mg/kg and two placebo. No death was judged as related to treatment. The provided detailed narratives include patients' medical history and concomitant medicati on. All deaths are consistent with common causes of death in the SCD patient population. No correlation with HU use or other medication was observed. Overall, the deaths were rare, balanced between treatment arms and the assessment that none were considered treatment related can be followed. Laboratory findings Blood samples were taken during the Screening Phase, at day 1, at day 14, day 28 and every 4 weeks thereafter prior to and following administration of study drug during the 52-week Treatment Phase, and during the Follow-Up Evaluation Phase (Week 58). Medicinal product no longer authorised

## Haematology

No clinically relevant changes in haematology parameters have been observed in healthy volunteers.

<div style=\"page-break-after: always\"></div>

Almost all patients showed decreased values for haemoglobin, balanced between placebo and treatment groups (5mg/kg: 97.0%, placebo: 96.8%) and of neutrophils (balanced between placebo and treatment groups (5mg/kg: 30.3%, placebo: 35.5%). In the treatment arms, more patients showed decreased platelets (5mg/kg: 18.2%, placebo: 9.7%; A2202: 24.4%). This data might be influenced by technical problems with automated platelet counts. Data from study A2301 where a solution for the technical problem has been implemented, is required to address this issue. INR abnormalities were similar across study groups. Abnormal aPTT values were reported for 38.7% of patients in placebo group, and 50.0% patients in crizanlizumab 5mg/kg group. There was no difference in the frequency of grade 3 aPTT increase or PT/INR between the arms. Moreover, analysis of time-profiles for aPTT and INR showed no time-dependent effects during treatment or compared to baseline. Biochemistry In study A2201 no unexpected biochemistry abnormalities have been observed. All observed values were balanced between placebo and the treatment groups except for more patients in the 5mg/kg group with decreased glucose (27 patients, 40.9%; placebo: 15 patients, 24.2%). All events have been of grade 1 or 2. Nevertheless, this might be of interest for diabetic patients. Further assessment of the data from study A2202 and the upcoming phase 3 study are needed. It was further noted that in study A2202 -which is still ongoing -several abnormalities have been observed which were not seen in study A2201 (see table below). Some have also been of grade 3 or 4: Amylase increase (2 patients (4.4%)), Triglycerides increase (2 (4.4%)), Creatine kinase increase (2 (4.4%)), Triacylglycerol lipase increase (3 (6.7%), all cases). These abnormalities have also been observed in study A2102 for both versions (see Table below). This could indicate an effect of a higher P-selectin inhibition and needs to be addressed when more data becomes available. Medicinal product no longer authorised

| Parameter                       |   A2201 SCD Placebo N=62 Medicinal |   A2201 SCD 5mg/kg SelG1 N=66 | A2202 (ongoing *Data submitted at D180) SCD 5mg/kg SEG101 N=45   | A2102 HV 5mg/kg SEG101 N=28   | A2102 HV 5mg/kg SelG1 N=33   |
|---------------------------------|------------------------------------|-------------------------------|------------------------------------------------------------------|-------------------------------|------------------------------|
| Amylase increase                |                                  0 |                             0 | 13 ( 28.9)                                                       | 2 (7.7%)                      | 8 (25.8%)                    |
| Triglycerides increase          |                                  0 |                             0 | 8 (17.8%)                                                        | 2 (7.4%)                      | 4 (12.5%)                    |
| Creatine kinase increase        |                                  0 |                             0 | 7 (15.6%)                                                        | 14 (56.0%)                    | 14 (53.8%)                   |
| Magnesium increase              |                                  0 |                             0 | 5 (11.1%)                                                        | 10 (38.5%)                    | 9 (36.0%)                    |
| Triacylglycerol lipase increase |                                  0 |                             0 | 3 (6.7%)                                                         | 5 (17.9%)                     | 6 (20.0%)                    |

<div style=\"page-break-after: always\"></div>

## Hepatic safety

<!-- image -->

| no   |
|------|

Significant hepatic insufficiency was an exclusion criterion. Hepatic insufficiency is not expected to influence the pharmacokinetics of a monoclonal antibody, and no safety issues related to altered crizanlizumab exposure are expected in patients with hepatic insufficiency. However, liver function also plays a role in haemostasis.

The applicant defined the criteria for potential drug induced liver injuries (DILI) as ALT&gt; 3xULN &amp; DBILI &gt; 2xULN &amp; ALP &lt; 2xULN and provided eDISH plots to illustrate the results. The applicant states that none of the patients had a pattern of on-treatment parameters fulfilling these criteria. Vital signs, physical findings, and other observations related to safety Changes in blood pressure and pulse rate have been observed in patients (A2201, A2202) and in healthy volunteers (A2102). The observations did not indicate a consistent pattern and were regarded as not clinically significant. An effect of crizanlizumab can, however, not be excluded at the moment. Electrocardiograms Overall changes in ECG have been observed but were similar between treatment groups and placebo in study A2201 and were not clinically significant. Similar observations have been made in study A2202. An increased rate of hypokalaemia has been observed in the ongoing study A2202 (13.3%, A2201: 5mg/kg 1.5%, placebo: 8.1%). Although hypokalaemia also occurred in the placebo group, events of grade 2 and 3 only occurred in study A2202. Safety in special populations Data presented in these sections represent the data cut-off of 1-Mar-2019 for study A2202. Updated tables for the most recent data cut-off 4-Oct-2019 have not been provided by the applicant. However, the data are very similar in general and do not change the conclusions presented in this section. Renal and hepatic impaired patients No data has been provided concerning renal and hepatic impaired patients. Only three patients with severe renal impairment were included in study A2201. The applicant plans an additional study in the post marketing setting in SCD patients with chronic kidney disease due to sickle cell nephropathy (A2203). Medicinal product no longer authorised

Although no clear indication of adverse effects related to regulation of haemostasis have been identified, minor alterations in coagulation parameters were observed, and the role of hepatic function in safety of crizanlizumab is thus insufficiently characterised .

<div style=\"page-break-after: always\"></div>

## Gender

<!-- image -->

| Medicinal   |
|-------------|

Table 15: Overview of adverse events by gender (safety set) The safety pool contained 59 female and 52 male patients. Overall, the rates of AEs and SAEs are comparable between gender. This is also the case for AEs leading to discontinuation, AEs leading to dose interruption and AEs requiring additional therapy. The only differences (min 5% difference) between women and men were observed for headache and urinary tract infections -both increased for women. However, the reported rates are similar to the rates observed in the placebo arm of study A2201. No effect on dose was observed for these events. The data does not indicate differences in the safety profile between gender. Ethnicity Table 16: Overview of adverse events by ethnicity (safety set) Medicinal product no longer authorised

*. pooled ams of 5 mg/kg crizanlizumab from Study A2201 + Study A2202. Only Hispanic or Latino vs. Not Hispanic or Latino is presented in this table, the category \"Other\"ethnicity ispresented inthesourcetable.#.Onlydose interuption wereauthorized(adjustment/reductionof thedosewerenot authorized).

<div style=\"page-break-after: always\"></div>

The safety pool was presented by 'Hispanic/Latino' or not.

The non-clinical data showed a much higher rate of foetal and infant losses for crizanlizumab (50%) as compared to 12.5% in control groups.

In the presented safety data, similar rates for AEs and SAEs are observed between both ethnicities. The rates are increased for Hispanic/Latino patients for AEs ≥ Grade 3. However, these observed differences can be attributed to the small sample size. Eleven patients were recorded with Unknown Ethnicities. This subgroup has been excluded from the original analysis since it might contain an unknown mixture of Hispanic and Not Hispanic subjects. Age category (paediatric and elderly patients) Paediatric population The intended indication includes paediatric patients ≥ 16 years of age. In the four studies presented for this MAA only 6 patients were younger than 18 years at baseline. This includes only three patients with the intended dose of 5mg/kg (2 placebo, 1 crizanlizumab 2.5 mg/kg). A potential benefit for paediatric patients is acknowledged as patients with SCD are burdened from an early age. Sickle cell disease manifests already from an age of about 6 months and early treatment initiation is essential to prevent organ dysfunction and damage to bone and joints. The ongoing study B2201 is an ongoing open label, single arms study to establish appropriate dosing and to collect safety data in paediatric patients aged 6 months to &lt; 18 years receiving crizanlizumab for 2 years (sequential design in descending age groups: 12-18 years, 6-12 years, 6 month -6 years). The study is part of the agreed paediatric investigation plan PIP (EMEA-002141-PIP01-17). The applicant plans to enrol paediatric patients starting from an age of 12 years in the ongoing phase III study A2301 (at least 48 patients). This data will allow a more comprehensive assessment of the safety profile in paediatric patients. However, this data will not be available before 2025. Elderly population Only one patient was ≥ 65 years old at baseline ( 65 years). The applicant did not provide the requested table due to the lack of data in the elderly population. This is acceptable for this MAA as the definition of an elderly population (&gt;65 years) is not particularly relevant for patients with SDC as life expectancy is decreased to 42 53 years for men and 48 - 58 years for women (Platt et al 1994, Wierenga et al 2001, Lanzkron et al 2013). Concomitant HU/HC use Hydroxyurea is the only approved medicinal product for prevention of vaso-occlusive crises in SCD patients and is commonly used. Both patients on HU/HC, and patients not using HU were included in the clinical studies. Comparison of safety profiles between these populations did not reveal relevant differences. Use in pregnancy and lactation, effect on fertility Medicinal product no longer authorised

No specific clinical studies have been performed, but six cases of pregnancy were reported among subjects receiving crizanlizumab (study A2201: 2 in the 5 mg/kg arm and 1 each in the 2.5 mg/kg and placebo arms; and 2 cases in Study A2202). All patients discontinued the study drug as soon as the pregnancy test was positive

<div style=\"page-break-after: always\"></div>

(test every 4 weeks at treatment visit). Only very limited information is available regarding the pregnancies in patients exposed to crizanlizumab. The provided narratives report one abortion, two unknown outcomes and two cases of pre-eclampsia and premature delivery in the treatment groups, which is common in SCD patients. A normal pregnancy was described in the patient in the placebo group. Lactation: There are no data regarding the presence of crizanlizumab in human milk, the effect on the breastfed child or the effects of crizanlizumab on milk production. It is unknown whether crizanlizumab is transferred into human milk. Because many medicinal products, including antibodies, can be transferred into human milk, a risk to newborns cannot be excluded. Infertility: No data on the effects of crizanlizumab on fertility in humans is available. No effects on fertility were observed in non-clinical studies. Overdose No cases of overdose have been reported in the clinical studies. The potential for an overdose is considered rather low as crizanlizumab is administered at clinical sites by medical personnel only. The maximum dose administered to healthy volunteers was 8mg/kg twice two weeks apart. The maximum dose in SCD patients is 7.5mg/kg in the ongoing study A2202. Drug abuse No potential for drug abuse is identified. Adakveo is administered at clinical sites by medical personnel. Withdrawal and rebound No studies have been performed to assess withdrawal and rebound effects of crizanlizumab. Since crizanlizumab is slowly cleared from the patient's body, no abrupt changes in concentration are expected. P -selectin level are similar before and after treatment and no AEs or laboratory parameters have been identified that might indicate a withdrawal or rebound effect. Based on the provided data, the risk for withdrawal and rebound effects are considered benign. Effects on ability to drive or operate machinery or impairment of mental ability Adverse events judged to be related to study drug are reported for crizanlizumab that could influence the ability to drive or operate machinery. In healthy volunteers, dizziness and 'feeling abnormal' were reported by one patient receiving 5mg/kg SEG101. In patients Fatigue, Dizziness and Somnolence were also reported as related to study drug. The applicant is asked to add respective wording according to the respective guideline to the SmPC (see attached documents). Adverse events in healthy volunteers in study A2102 (comparative study: SEG101 and SelG1) Medicinal product no longer authorised

The rate of patients with AEs was comparable between both groups (SEG101 35.7%; SelG1 36.4%). Most AEs occurred only in one subject except for headache, viral upper respiratory tract infection and paraesthesia. Headache and paraesthesia were balanced between groups (headache: SEG101: 2 subjects (7.1%); SelG1: 2 subjects (6.1%); paraesthesia: SEG101: 1 subject (3.6%); SelG1: 1 subject (3.0%)). Viral upper respiratory

<div style=\"page-break-after: always\"></div>

tract infection, however, occurred on in the SEG101 treatment arm in three subjects (10.7%). As P-selectin is also involved in immune response this finding is of special interest. AEs in relation to study drug were only identified for SEG101: one subject grade 1 dizziness and feeling abnormal on Day 3 that resolved the following day, and one subject reported grade 1 headache on Day 2 that resolved the same day. Although the events are rare, their relation to the study drug requires an inclusion in the SmPC. The applicant is invited to provide respective wording (see attached documents). Changes in laboratory values have been identified for both versions that have otherwise only been found in study A2202. A connection to 100% P-Selectin inhibition can currently not be ruled out. Immunological events Anti-crizanlizumab antibodies were measured in all four clinical studies. As discussed in the pharmacology section two different assays were used. One for studies A2101 and A2201 (both with SelG1) and the new assay developed by Novartis for A2102 and A2202 (both including the new version SEG101). While improvement of the methods is appreciated, the data from the registration study (A2201) might underestimate ADA frequencies. The applicant reanalysed the respective data. Overall, low rates of ADAs were reported. In studies A2101 and A2201 (measured with the old assay) the majority of reported ADA positive patients had pre-existing ADAs (A2101: 3 HV ADA positive (2 pre-existing; A2201: 10 positive (8 pre-existing). In study A2102, two HVs tested positive for ADA. In study A2202 no ADA positive results have been reported so far. Novartis has committed to developing a neutralizing antibody assay and using the assay to assess the neutralizing potential of anti-drug antibody (ADA)-positive samples from study A2301. Safety related to drug-drug interactions and other interactions No drug interactions have been investigated by the applicant considering that crizanlizumab is not metabolised via the cytochrome P450 enzymes. Hydroxyurea/hydroxycarbamide (HU/HC) is the only approved medicinal product for prevention of VOCs in sickle cell patients. Therefore, information on tolerability of concomitant HU/HC use is an important aspect or safety evaluation. Similar safety profiles have been observed for the concomitant use of HU/HC and patients without HU/HC. No other concomitant medication has been analysed for an effect on the safety profile of crizanlizumab. No effect of concomitant medication with HU/HC was found on the PK profile of crizanlizumab. This was however only studied as part of the popPK analysis, which has some limitations (see also PK section). Concomitant use of hydroxyurea needs to be considered from various perspectives. Possible changes in HU tolerance, and possible contribution to the therapeutic effects observed, need to be taken into account. Dose modification/interruption of HU/HC, from start to end of study treatment, was only observed in a few patients (placebo: 6, 2.5mg/kg: 6 and 5mg/kg: 4). Medicinal product no longer authorised

As discussed in context of potential effects on haemostasis, the potential effect of concomitant anticoagulant medication and increased bleeding risk has to be addressed with data gathered in the phase 3 study A2301.

<div style=\"page-break-after: always\"></div>

## Discontinuation due to adverse events

<!-- image -->

The number of patients who discontinued in total is similar between treatment arms in study A2201 (5mg/kg: 34.8%, placebo 33.9%). In study A2202 the rate is lower (13.3%). The reasons for discontinuation were similar between treatment groups. Table 17: Disposition of patients (safety set) Only six patients discontinued their treatment due to AEs (3 placebo, one in each treatment arm of study A2201 and one in study A2202). The adverse events that led to the discontinuations in the treatment groups were sickle cell anaemia with VOC, bradycardia and intracranial haemorrhage (2.5 mg/kg). All are consistent with the underlying disease but also represent AEs of special interest. Therefore, a connection with the study drug cannot be ruled out at the moment but more data from the phase 3 study will become available. The most common reason for discontinuation in the treatment groups was 'patient decision' and 'others' (5mg/kg each: 7 patients, 10.6%; placebo: 5 patients, 8.1% and 3 patients 4.8%). Post marketing experience Very limited post marketing data is available. Crizanlizumab has been authorised in the US in 2019. Novartis has received a limited number of post-marketing reports of infusion-related reactions including severe pain, sometimes requiring hospitalisation. The mechanism and relation to the underlying disease and/or treatment is unclear at this time and is being investigated. Infusionrelated reactions are included in the 'Warning and precautions' of the proposed label. In addition, section 'Adverse reactions' of the proposed label includes infusion related reactions and specific pain events such as back pain, arthralgia, abdominal pain, musculoskeletal chest pain, myalgia and oropharyngeal pain as adverse drug reactions. Medicinal product no longer authorised

| longer   |
|----------|

Novartis is evaluating all available data from all sources, actively gathering additional data to better understand and characterize these cases and assess if additional measures are needed.

Meanwhile, Novartis is working on setting up a dedicated crizanlizumab webpage, which will be directed to Healthcare Professionals and is planned to contain post-marketing safety information.

<div style=\"page-break-after: always\"></div>

<!-- image -->

During the clinical development, studies have been performed with different versions of crizanlizumab. Although comparability between both versions (SelG1 and SEG101) was supposed to be demonstrated in study A2102, comparability was initially not sufficiently established based on the observed higher exposure and uncertainties concerning the PD marker (%inhibition of P-selectin). A reanalysis of data from study A2201 indicates that the observed differences can be attributed to the different assays used in the studies. Information about the efficacy of SEG101 is presently limited, since the only study investigating SEG101 is still ongoing and efficacy was only a secondary endpoint. Initially, the safety profiles of both versions could not be adequately compared, with only preliminary safety data available for study A2202. After two updates, safety data for an exposure of 64.7 weeks (6-90) is available for SEG101. But the study is performed without a placebo arm and indirect comparison with study A2201 is hampered due to different exposure times (A2201: 46.3 weeks). However, overall the results obtained in study A2202 seem to confirm the results of study A2201. Some differences have been observed but

Novartis committed to provide the results of the internal assessment and all relevant documentation as soon as available. 2.6.1. Discussion on clinical safety The safety database comes from four clinical studies: A2201 (randomised, double-blind, placebo controlled) and A2202 (open label, single arm, ongoing) in SCD patients; A2101 (placebo controlled double blind dose ascending study) and A2102 (randomised, parallel, comparability study) in healthy volunteers. A Phase III multicentre, placebo-controlled, double blind confirmatory Study A2301 is planned to provide the comprehensive data required for a full approval. This study started to enrol patients in H2 2019. The results of the primary analysis are expected in 2025. The study is designed to provide controlled treatment data over one year and long-term data, which is currently lacking, over a period of 5 years. However, it is not clear if the study will provide sufficient data given the previously observed drop-out rate. The applicant implemented several measures to prevent early discontinuations, which seem reasonable, but the effect is unknown so far. Although the ethnicity proportion (93% Black/African American) does not correspond to the overall European population, it does reflect the population suffering from sickle cell disease in Europe (Hickman et al 1999, Gulbis et al 2006, Modell et al 2007, Roberts et al 2007, Colombatti et al 2016). The population included in the clinical developmental programme is considered representative for the intended target population and thus suitable to assess crizanlizumab safety in the intended indication. Although the number of patients aged 16 to 18 years is too limited to reliably conclude on the safety of crizanlizumab in this age group (6 patients; 3 received the intended dose of 5 mg/kg), an extrapolation from older patients is acceptable given the mode of action of crizanlizumab and P-selectin, similar disease manifestations and comparable PK. In the context of a CMA and the planned enrolment of at least 48 adolescents in study A2301, it is agreed that the indication of crizanlizumab can include 16-18 years old SCD patients. The indication has been restricted to patients with recurrent VOCs since currently only data for patients with a history of 2 to 10 SCPCs within the preceding 12 months is available, and an extrapolation to the general population of SCD patients is currently not considered possible, especially since a trend to higher P-selectin level has been observed in patients with a higher number of VOCs. Although comparable safety profiles were observed in the presented studies, the small sample size and the lack of long-term data hampers further conclusions. Further, some concerns regarding efficacy have to be addressed (please refer to the efficacy section for further details). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

do not raise further concerns. The remaining uncertainties could be addressed with data from the confirmatory phase III study which is a specific obligation to the marketing authorisation. The safety database consists of 111 patients receiving the intended dose (66 SelG1; 45 SEG101) and additional 64 patients receiving 2.5 mg/kg SelG1. Further, 95 healthy volunteers received different doses of crizanlizumab ranging from 0.2 mg/kg to 8 mg/kg. 69 HV received the intended dose of 5 mg/kg (41 SelG1; 28 SEG101) but only as single dose. Further, a small exploratory arm for 7.5 mg/kg of 10 patients is included in study A2202. Concomitant medication is very common in SCD patients. Some ATC classes are more frequent in patients receiving crizanlizumab compared to placebo (nervous, respiratory and cardiovascular system). No concerns are raised at this point since this is consistent with the underlying condition which is also reflected in the high rate in the placebo group, Further information also for long term effects will be gathered in the phase 3 study A2301. Only limited drug-drug interaction potential is expected due to the degradation by proteolytic catabolism. Therefore, no interaction studies have been performed which is acceptable. Further, detailed analyses of concomitant use of HU/HC did not reveal any influence. However, some uncertainties remain concerning anticoagulants. This will be further investigated in the phase 3 study A2301. None of the deaths was judged as related to treatment and all deaths are consistent with common causes of death in the SCD patient population. In study A2201 five patients died during the treatment period (5 mg/kg: 2; 2.5 mg/kg: 1; placebo: 2). In study A2202, one death has been reported in the 7.5 mg/kg group. Rates of drug related serious adverse events are very low but more frequent in the verum groups. Although the events correspond with adverse events of special interest (infections, effect on haemostasis), they are also consistent with complications of the underlying disease. Treatment  emergent  adverse  events  were  mostly  balanced  between  treatment  groups.  Gastrointestinal disorders, musculoskeletal and connective tissue disorders, and general disorders, like pyrexia, were more common in crizanlizumab-treated patients. However, the majority of the AEs were mild and resolved by the end of the study. Crizanlizumab's target P-selectin has been shown to play a role in muscle repair. Therefore, an effect  observed  as  an  increase  in  musculoskeletal  and  connective  tissue  disorders  could  be  attributed  to crizanlizumab. Additional analysis of these events that occurred consistently more common in crizanlizumab-treated  patients  than  in  the  placebo  group  were  requested.  Further,  additionally  laboratory values related to muscle damage (CK increased, Mg increased) have also been observed. However, no relation between these events and time on treatment or time since last infusion was observed. Many events were confounded by mild traumas and pre-existing conditions. Further, no musculoskeletal events were connected with altered laboratory findings. However, no long term data is not yet available. Overall an increase in severity of AEs has been observed in study A2202 (grade ≥3 AEs: 40.0% vs. 18.2%, grade ≥3 SAEs: 20.0% vs. 10.6% and grade ≥3 AEs requiring additional therapy: 35.6% vs. 9.1%). The applicant claims that these observations are due to different grading systems applied between the two trials. Although the argumentation can be followed, these observations have to be further discussed when data from the phase III trial becomes available. Medicinal product no longer authorised

The inhibition of P-selection might have an effect on the innate immune response against infections and on haemostasis. Further AEs of special interest were identified as infusion related reactions, the potential for immunogenicity, for drug-induced liver injury and QT prolongation:

<div style=\"page-break-after: always\"></div>

## Infections :

•

- Abnormal aPTT values were reported more frequently in patients treated with crizanlizumab compared to placebo. No time-dependent effects during treatment or compared to baseline were observed. The applicant has suggested that heparin (flush) received by several patients would explain the difference. This is unlikely to explain the differences, as heparin treatment was more common in the placebo group (24.6%) as compared to crizanlizumab 5mg/kg group (11.9%). When interpreted in context of similar rate of bleeding events observed, these increases do not appear to have clinical significance. However,

· Overall rates of infections are balanced between placebo and crizanlizumab treatment arms. However, higher rates of severe infections and a higher rate of pyrexia were observed while treated with crizanlizumab compared to placebo. Based on the presented data a direct association with crizanlizumab administration seems unlikely. However, the increased frequency of pyrexia and infections in general needs further clarification requiring further data, which could be generated in the planned phase 3 study. · The vaccination status could influence the infection incidences. Unfortunately, this could not be clarified since no information about the vaccination status has been collected in the presented studies. In the phase 3 study A2301 inclusion criteria have been implemented that require that patients are up-to-date in terms of immunisations as per local requirements. · A potential influence on infection rates generated by patients with a history of splenectomy who have a higher risk for infections has not been observed. · Patients with chronic or recurrent infections experienced more infection AEs than patients with no medical history of infections, but there was no apparent difference in nature and severity of the events. Infection AEs were more frequent in this sub-population, but the number of patients and events is too low to draw any conclusions. However, types of infections, their severity or outcome did not raise any specific concerns. Close monitoring of infection events in ongoing and future clinical studies is planned. Effect on the haemostatic system : · Higher rates for events related to a potential effect on the haemostatic system have been found for Crizanlizumab with the majority being reported changes in laboratory values. However, the majority of reported bleeding events occurred in the verum group. Based on the provided data the risk for increased bleeding events seems limited but further data is required especially for long term use before a definite conclusion can be drawn. This will be addressed in more detail in study A2301. · Decreased platelets have been observed in patients receiving crizanlizumab. These results can currently not be assessed since some interference with automated platelet counts has been observed during the studies. A solution for this interference was suggested but has so far not been implemented in the current studies. In the ongoing phase 3 study A2301 appropriate analyses will be performed. Those interferences are also reflected in section 4.4 of the SmPC. According to the applicant, the interference can be explained with an ex-vivo test showing that the clumping is dependent on the presence of crizanlizumab and EDTA. This need to be further substantiated with reliable data from study A2301. · Very limited information is available on bleeding risk in patients who have an increased risk for bleeding at baseline. Patients on any anticoagulation medication besides aspirin were excluded from the study, as were patients with severe hepatic dysfunction, potentially impairing haemostasis. Overall, very limited information is available on concomitant use of crizanlizumab and anticoagulants, in particular longer exposure to anticoagulants. Effect on haemostasis (haemorrhage) is included as an important potential risk in the RMP and will be addressed in trial A2301. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

The intended indication inc ludes paediatric patients ≥ 16 years of age. In the four studies presented for this MAA, only 6 patients were younger than 18 years at baseline. This includes only three patients with the intended dose of 5mg/kg (2 placebo, 1 crizanlizumab 2.5 mg/kg). Although the number of patients aged 16 to 18 years is too limited to reliably conclude on the safety of crizanlizumab in this age group, an extrapolation from older patients is acceptable given the mode of action of crizanlizumab and P-selectin, similar disease manifestations these findings emphasize the need to further characterise the risk in patients at higher risk of bleeding. This will be addressed in study A2301. Infusion-related reactions were more frequent for crizanlizumab than placebo. The most frequently reported adverse drug reactions (≥10% of patients) in the Adakveo 5 mg/kg group were arthralgia, nausea, back pain, pyrexia and abdominal pain, which are adequately reflected in the section 4.8 of the SmPC together with the general terms infusion site reaction and infusion related reaction. The formation of ADAs seems minimal but no data is available for long term treatment but will be gathered in study A2301. No indication of potential drug induced liver injury has been observed. However, no long-term data is available but will be gathered in study A2301. Changes in ECG have been observed but were similar between treatment groups and placebo, transient and were not clinically significant. An increased rate of hypokalemia in study A2202 has been observed but seems not to have clinical implications so far. Further, a relation to the treatment with crizanlizumab is unlikely but cannot be ruled out. In the ongoing study A2202 and study A2301, laboratory parameters including electrolytes and EKG will be monitored which is currently considered as a sufficient method. Abnormal laboratory values have only been observed in patients and HV receiving SEG101. No explanation for the higher rates of laboratory abnormalities could be presented by the applicant. However, it is acknowledged, that none of the laboratory abnormalities observed in Study A2102 or A2202 were reported as AE. A comparison of laboratory results obtained in study A2201 cannot be made since in study A2201 these parameters were not measured. The applicant emphasised that biochemical laboratory abnormalities are commonly observed in SCD patients. A potential difference between treatment and placebo cannot be assessed with the current data. However, in the ongoing study A2202 and study A2301 (including placebo arm), laboratory parameters will be monitored. This is currently considered as sufficient method to address this uncertainty, since no further assessment can be made and no AEs have been reported related to the abnormal values. Based on the limited data and non-clinical findings of foetal and infant loss, further data is required to assess potential risks related to pregnancy (please refer also to the non-clinical section). The applicant proposed the PRIM (PRegnancy outcomes Intensive Monitoring) programme to monitor pregnacies in study A2301 and during the treatment with crizanlizumab. It is included in the RMP and the SmPC. This is considered an acceptable measure to gather more data. No data exists for renally and hepatically impaired patients. Although hepatic and renal impairment is common in SCD patients, no influence of Crizanlizumab is expected as it is degraded by proteolytic catabolism. A potential influence of hepatic insufficiency on haemostasis and a subsequent effect in combination with crizanlizumab treatment, however, cannot be ruled out. Additional PK analyses are requested to clarify potential dose adjustments for renal impaired patients. Assessment of paediatric data on clinical safety Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

and comparable PK. In the context of a conditional MA and the planned enrolment of at least 48 adolescents in study A2301, it is agreed to include 16-18 year old SCD patients in the indication. In addition, study B2201 will gather further data in the paediatric population in the post marketing. Additional safety data needed in the context of a conditional MA The data from the presented studies did not reveal critical findings, but safety is not comprehensively characterised due to paucity of data. There is no experience with Crizanlizumab treatment beyond one year but long-term data will be collected in study A2301. It is planned that this phase III study will generate data on crizanlizumab treatment for up to 5 years, albeit data will be uncontrolled after 1 year (please also refer to section 3.7.3). The critical issues to be addressed are long-term safety (&gt;1 year) and potential systemic effects of the 100% P-selectin inhibition in the long term. There were no notable differences in safety profiles between patients on HU / without HU, demonstrating the tolerability of crizanlizumab as an add-on therapy. Direct comparisons of safety profiles between HU and crizanlizumab (between patients on HU in placebo group, n=39, and patients not using HU in crizanlizumab 5mg/kg group, n=42) have not been performed, and might not produce relevant comparative evidence due to low number of patients. Additional data would be generated in study A2301 since a placebo arm is implemented for one year. Further, the applicant committed to collect information why patients do not take or stopped taking HU/HC. The CHMP considers the following measures necessary to address the missing safety data in the context of a conditional MA: · In order to confirm the efficacy and safety of crizanlizumab, the MAH should submit the results of the primary analysis of a phase III CSEG101 A2301 study of crizanlizumab with or without hydroxyurea/hydroxycarbamide in adolescent and adult sickle cell disease patients with vaso-occlusive crises. · In order to confirm the efficacy and safety of crizanlizumab, the MAH should submit the final results of the phase II CSEG101 A2202 study of crizanlizumab with or without hydroxyurea/hydroxycarbamide in sickle cell disease patients with vaso occlusive crisis. 2.6.2. Conclusions on the clinical safety Overall, the safety data is very limited. Especially for the crizanlizumab version SEG101 intended for marketing, the safety data is only presented from one ongoing study in 45 patients and a very limited dataset of 28 healthy volunteers administered a single dose. However, the safety data generated in study A2201 with SelG1 seems overall comparable to study A2202. Some minor differences have been observed but do not raise concerns. Moreover, concerns on the comparability of the two antibodies have been largely resolved. Data from clinical studies did not show critical findings, but in view of the sparse data, the safety profile of crizanlizumab cannot be considered sufficiently characterised especially concerning long-term exposure. This will however be addressed with the confirmatory phase III study. Medicinal product no longer authorised

The measures outlined in the previous section (' Additional safety data needed in the context of a conditional MA ') and discussed in more detail in section 3.7.3., are considered necessary by the CHMP in order to confirm the safety of crizanlizumab in the context of a conditional marketing authorisation.

<div style=\"page-break-after: always\"></div>

## 2.7. Risk Management Plan

| Important identified risks   | • Infusion-related reactions                                                                       |
|------------------------------|----------------------------------------------------------------------------------------------------|
| Important potential risks    | • Effects on haemostasis (haemorrhage) • Immunogenicity related clinical consequences • Infections |
| Missing information          | • Long-term safety • Use in pregnant and breast-feeding women                                      |

<!-- image -->

| Study/Status                                                                                                                                                                                                                                                                                                                 | Summary of objectives                                                     | Safety concerns addressed                                                                                                                             | Milestones           | Due dates           |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|---------------------|
| Category 2 (safety)                                                                                                                                                                                                                                                                                                          | Category 2 (safety)                                                       | Category 2 (safety)                                                                                                                                   | Category 2 (safety)  | Category 2 (safety) |
| Study CSEG101A2202 : A phase II, multicenter, open-label study to assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/ Hydroxycarbamide, in sickle cell patients with vaso-occlusive crisis. (Ongoing)                                                                                                       | To assess PK/PD and safety of crizanlizumab over the study period product | • Infusion-related reactions • Effects on haemostasis (haemorrhage) • Immunogenicity related clinical consequences • Infections • Long-term safety no | Annual status update | With annual renewal |
|                                                                                                                                                                                                                                                                                                                              | To assess PK/PD and safety of crizanlizumab over the study period product | • Infusion-related reactions • Effects on haemostasis (haemorrhage) • Immunogenicity related clinical consequences • Infections • Long-term safety no | Final analysis CSR   | 31-Dec-2025         |
| Category 3                                                                                                                                                                                                                                                                                                                   |                                                                           |                                                                                                                                                       |                      |                     |
| Study CSEG101A2301 (STAND ): A phase III, Multicenter, Randomised, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Vaso-Occlusive Crises (Ongoing) Medicinal | To assess efficacy, safety of two doses of crizanlizumab vs placebo       | • Infusion-related reactions • Effects on haemostasis (haemorrhage) • Immunogenicity related clinical consequences • Infections • Long-term safety    | Annual status update | With annual renewal |
| Study CSEG101A2301 (STAND ): A phase III, Multicenter, Randomised, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Vaso-Occlusive Crises (Ongoing) Medicinal | To assess efficacy, safety of two doses of crizanlizumab vs placebo       | • Infusion-related reactions • Effects on haemostasis (haemorrhage) • Immunogenicity related clinical consequences • Infections • Long-term safety    | Final analysis CSR   | 31-Dec-2029         |

<!-- image -->

Safety concerns Table 18: Summary of safety concerns Pharmacovigilance plan Table 19: Ongoing and planned additional pharmacovigilance activities Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Study/Status                                                                                                 | Summary of objectives                                                                                                                                                                                                                                                  | Safety concerns addressed                       | Milestones                                                                                  | Due dates                                                                                                                   |
|--------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|---------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|
| Crizanlizumab Pregnancy outcomes Intensive Monitoring (PRIM) ; enhanced pharmacovigilance program) (Planned) | Estimate the proportion of pregnancies resulting in fetal loss (intrauterine death resulting in stillbirth, spontaneous abortion, or induced termination), among pregnant women exposed to crizanlizumab within 105 days prior to LMP or at any time during pregnancy. | • Use in pregnant and breast-feeding women      | Interim update                                                                              | Each PSUR Will be provided with PSUR when defined criteria have been met (N=500 prospective pregnancy with known authorised |
| Crizanlizumab Pregnancy outcomes Intensive Monitoring (PRIM) ; enhanced pharmacovigilance program) (Planned) | Estimate the proportion of pregnancies resulting in fetal loss (intrauterine death resulting in stillbirth, spontaneous abortion, or induced termination), among pregnant women exposed to crizanlizumab within 105 days prior to LMP or at any time during pregnancy. | • Use in pregnant and breast-feeding women      | Final programme update                                                                      | cases pregnancy outcome are available or a maximum of 10 years after EU marketing authorisation, whichever occurs first)    |
| SCD registry study (Planned)                                                                                 | In-depth feasibility analysis to use existing SCD registries, electronic health records and/or specific pregnancy registries to further investigate; 'use ' in pregnancy', 'long - term safety' and other safety concerns                                              | • Use in pregnancy • Long-term safety no longer | Submission of the feasibility outcome report                                                | Jan-2021,will be submitted with the PSUR                                                                                    |
| SCD registry study (Planned)                                                                                 | In-depth feasibility analysis to use existing SCD registries, electronic health records and/or specific pregnancy registries to further investigate; 'use ' in pregnancy', 'long - term safety' and other safety concerns                                              | • Use in pregnancy • Long-term safety no longer | Submission of registry study protocol or alternative proposal as Post-authorisation measure | Sep-2021                                                                                                                    |

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Risk minimisation measures

| Safety concern                               | Risk minimisation measures                                                                                                            |
|----------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|
| Infusion-related reactions                   | Routine risk minimisation measures: SmPC Section 4.4 and Section 4.8 Additional risk minimisation measures: None authorised           |
| Effects on haemostasis (haemorrhage)         | Routine risk minimisation measures: None Additional risk minimisation measures: None                                                  |
| Immunogenicity related clinical consequences | Routine risk minimisation measures: SmPC Section 4.8 (Undesirable effects) Additional risk minimisation measures: None longer         |
| Infections                                   | Routine risk minimisation measures: None Additional risk minimisation measures: None no                                               |
| Long-term safety                             | Routine risk minimisation measures: None Additional risk minimisation measures: None product                                          |
| Use in pregnant and breast-feeding women     | Routine risk minimisation measures: SmPC Section 4.6 (Fertility, pregnancy and lactation) Additional risk minimisation measures: None |

Table 20: Summary of risk minimisation activities Conclusion The CHMP and PRAC considered that the risk management plan version 1.3 is acceptable. 2.8. Pharmacovigilance Medicinal product no longer authorised

## Pharmacovigilance system

The  CHMP  considered  that  the  pharmacovigilance  system  summary  submitted  by  the  applicant  fulfils  the

<div style=\"page-break-after: always\"></div>

requirements of Article 8(3) of Directive 2001/83/EC.

<!-- image -->

Periodic Safety Update Reports submission requirements The requirements for submission of periodic safety update reports for this medicinal product are set out in the Annex II, Section C of the CHMP Opinion. The applicant did request alignment of the PSUR cycle with the international birth date (IBD). The IBD is 15.11.2019. The new EURD list entry will therefore use the IBD to determine the forthcoming Data Lock Points. 2.9. New Active Substance The CHMP, based on the available data, considers crizanlizumab to be a new active substance as it is not a constituent of a medicinal product previously authorised within the European Union. 2.10. Significance of paediatric studies A Paediatric Investigation Plan (PIP) was accepted by PDCO (EMEA-002141-PIP01-17-M01). A partial compliance check was adopted on 29 th  May 2019. Development in children 6 months - 18 years of age was deferred and respective additional studies (not included in this submission) are included in the key elements. A waiver was granted for children from birth to less than 6 months of age. One clinical study was initiated with Group 1 (12 to &lt; 18 years) and is ongoing (completion deferred): Study B2201 is a multicentre, single-arm, open-label study to confirm and to establish appropriate dosing and to collect safety data in paediatric patients aged 6 months to &lt; 18 years receiving crizanlizumab for 2 years. It is conducted in a sequential design in descending age groups. Group 1: 12 to &lt; 18 years, Group 2: 6 to &lt; 12 years, and Group 3: 6 months to &lt; 6 years. In the planned clinical study A2301 the inclusion of at least 48 SCD patients between 12 and 18 years randomised (1:1:1) over all three treatment arms is planned. Study A2301 is planned to generate the comprehensive data required as commitment for the conditional marketing authorisation. This study is not part of the PIP. 2.11. Product information 2.11.1. User consultation The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use. 2.11.2. Additional monitoring Medicinal product no longer authorised

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Adakveo (crizanlizumab) is included in the additional monitoring list as it contains a new active substance which, on 1 January 2011, was not contained in any medicinal product authorised in the EU.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Therefore, the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle. 3. Benefit-Risk Balance 3.1. Therapeutic Context 3.1.1. Disease or condition The applicant applied for the following indication: 'for the prevention of vaso -occlusive crises in sickle cell disease patients aged 16 years and over'. The CHMP agreed with the following indicati on: ' Adakveo is indicated for the prevention of recurrent vaso occlusive crises (VOCs) in sickle cell disease patients aged 16 years and older. It can be given as an add on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate. ' 3.1.2. Available therapies and unmet medical need The treatment of clinical manifestations consists mainly of the management of pain episodes (hydration, anti-inflammatory agents, pain medication, massage etc.). Fever and suspected infection are treated with appropriate antibiotics. Life-threatening or severe complications (e.g., severe acute chest syndrome or stroke) often require red blood cell transfusions. Blood transfusions are usually combined with iron chelators, which are necessary in patients with long-term anaemias such as sickle cell disease. Splenectomy may be necessary for splenic sequestration. Hydroxycarbamide (=Hydroxyurea) is approved in the EU since 2007 for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults, adolescents and children older than 2 years suffering from symptomatic Sickle Cell Syndrome (Siklos). The only curative option is haematopoietic stem cell transplantation, which is however only an option for selected patients, mainly children and adolescents with a haploidentical donor. Although the best results are obtained with a matched sibling donor, matched unrelated and haploidentical donors are alternative methods used recently but are not the standard of care. Crizanlizumab will address an unmet need by providing an alternative treatment option besides current preventive SoC (i.e., hydroxyurea) and by reducing the requirement for on-demand symptomatic pain management. 3.1.3. Main clinical studies Medicinal product no longer authorised

The evidence of efficacy submitted in this CMA comes from a single-phase II study. Study A2201 was a multicentre, randomised, double blind, parallel-group, placebo-controlled study evaluating the efficacy of two doses of crizanlizumab, with or without concomitant hydroxyurea, in SCD patients aged 16 to 63 years (n=198). Patients with any sickle cell disease genotype (including HbSS, HbSC, HbSß0 thalassaemia and HbSß+

<div style=\"page-break-after: always\"></div>

thalassaemia) and a history of 2-10 vaso-occlusive crises (VOCs) in the previous year were randomised in a 1:1:1 ratio to 5 mg/kg crizanlizumab, 2.5 mg/kg crizanlizumab or placebo. Randomisation was stratified by hydroxyurea use (yes, no) and the number of VOCs in the year preceding study start (2-4 or 5-10). The study consisted of a 30-day screening period, a 52-week treatment period and a follow-up evaluation phase for a maximum total duration of 58 weeks. The primary endpoint was the annual rate of sickle cell related pain crises (SCPC). The key secondary efficacy endpoint was the annual rate of days hospitalised. 3.2. Favourable effects From a quality perspective, an appropriately designed manufacturing process and adequate control strategy is in place ensuring consistent quality of Crizanlizumab drug substance and drug product. Pre-specified Analyses: The pre-specified efficacy analyses were performed on CRC-adjudicated data using the Hodges-Lehmann (HL) estimate as well as simple annualisation for imputation of missing data. In the primary efficacy analysis, crizanlizumab 5 mg/kg led to a 45.3% lower median annual rate of VOC leading to a healthcare visit compared to placebo, considering the ratio of the standard median of 1.63 VOCs in the 5 mg/kg crizanlizumab group compared with 2.98 VOCs in the placebo group. The point estimate of the two-sample HL estimator was -1.01 (95% CI [-2.00, 0.00]). The difference was statistically significant using a stratified Wilcoxon Rank Sum Test (p=0.010). For the 2.5 mg/kg crizanlizumab group, no significant reduction of VOCs was found, but the medians were consistently lower than in the placebo group (e.g. standard median 2.01 VOCs in 2.5 mg/kg crizanlizumab group compared to 2.98 VOCs in placebo). In patients receiving concomitant HU therapy, the median annual rate of SCPC was reduced by 32.1% considering the ratio of a standard median of 2.43 VOCs in 5 mg/kg group compared to 3.58 VOCs in placebo. In patients not receiving HU, crizanlizumab 5 mg/kg led to a 50% lower median annual rate of VOC leading to a healthcare visit compared to placebo, considering the ratio of the standard median of 1.00 VOCs in the 5 mg/kg crizanlizumab group compared with 2.00 VOCs in the placebo group. Comparison of the median annual rates of uncomplicated SCPC in the 5 mg/kg crizanlizumab arm versus placebo showed a 62.9% reduction with active treatment (1.08 VOCs in the 5 mg/kg crizanlizumab group compared to 2.91 VOCs in placebo). The point estimate of the two-sample HL estimator was -1.00 (95% CI [-1.98, 0.00]) (p=0.015). Medicinal product no longer authorised

Treatment with 5 mg/kg crizanlizumab was associated with increased median time to first and second VOC leading to healthcare visit compared to placebo. The median time from randomisation to the first VOC was 4.07 months in the 5 mg/kg crizanlizumab group compared with 1.38 months in the placebo group (p=0.001; hazard ratio 0.495). The median time to the second SCPC was 10.32 months in the 5 mg/kg crizanlizumab arm compared with 5.09 months on placebo (p= 0.022). The difference in median time to first or second VOC for the 2.5 mg/kg crizanlizumab group versus placebo was 2.2 months to first and 9.20 months to second VOC in favour of crizanlizumab but did not reach statistical significance.

Supplementary Analyses:

<div style=\"page-break-after: always\"></div>

The negative binomial regression analysis using CRC-adjudicated data showed that the predicted number of VOCs leading to healthcare visits on crizanlizumab 5mg/kg was 2.43 compared to 3.75 on placebo, resulting in a 35% reduction. The median annual rates of days hospitalised due to VOC were 2.01 days in the 5 mg/kg crizanlizumab group and 5.83 days in the placebo group. However, the Hodges-Lehmann median absolute difference between the crizanlizumab 5 mg/kg arm and the placebo arm was 0.00 days hospitalised per year (95% CI: -3.00, 0.00; Wilcoxon rank sum test: p=0.716)). Additional supplementary analyses employing the investigator identified VOC rate as well as negative binomial regression (when applicable) and imputation method M6 ('jump to reference') were provided for the primary efficacy endpoint as well as important other endpoints: The predicted number of VOC leading to healthcare visits on crizanlizumab 5mg/kg was 3.62 compared to 4.95, resulting in a 26% reduction (RR=0.74, 95% CI=[0.52, 1.06]). The predicted number of days hospitalised due to VOC were 17.31 days in the 5 mg/kg crizanlizumab group and 24.41 days in the placebo group, resulting in a 28% reduction (RR=0.72, 95% CI=[0.36, 1.45]). The risk ratio of annual rate of uncomplicated VOC is 0.72 (0.49, 1.05), i.e. the risk of uncomplicated VOC is reduced by 28% corresponding to on average 1.4 VOCs per year. The odds ratio of number of VOC-free patients completing the 1 year study period is 3.05 (1.00, 9.25), i.e. the odds to be VOC-free during 1 year increase by a factor of 3 with 20% of patients in the crizanlizumab group and 8% of patients in the placebo group being VOC free during the 1 year study period. Patients were considered VOC-free if they completed the study with an annualis ed rate of VOC leading to healthcare visit of '0'. The hazard ratio of time to first VOC is 0.54 (0.36, 0.81), i.e. the hazard rate of time to first VOCs is significantly reduced with a difference in time to first VOC of 2.63 months. Analyses of the primary endpoint for the individual genotypes (HbSS, HbSC) as well as for alternative groupings based on clinical severity (HbSS together with HbSß0-thalassemia as well as HbSC together with HbSß+-thalassemia) indicate a favourable trend of crizanlizumab over placebo across all genotypes. Preliminary efficacy data from study A2202 conducted with the to-be commercialised product (Novartis-manufactured crizanlizumab SEG101) showed a median reduction from baseline of 0.97 VOCs leading to healthcare visit by investigator. These preliminary efficacy data show an effect of comparable magnitude as the results obtained in study A2201 where a median reduction from baseline of 1 VOC per year (per investigator) was reported in the crizanlizumab 5 mg/kg arm versus 0 in the placebo arm. 3.3. Uncertainties and limitations about favourable effects Medicinal product no longer authorised

On the quality level, analytical differences are evident between the product used in the pivotal clinical phase 2 study A2201 and product manufactured according to the intended commercial manufacturing process. However, a direct impact of these differences in product quality on PK, efficacy and safety is rather unlikely. Of note, the design of the comparability studies and the indirect bridging approach results in some uncertainty. Efficacy data with the to-be commercialised product SEG101 is currently being collected (as a secondary endpoint) in the single arm study A2202. Preliminary data of study A2202 have been provided and so far seem comparable to study A2201 (SelG1). Comprehensive data is intended to be generated in the phase 3 study A2301 with SEG101.

<div style=\"page-break-after: always\"></div>

The non-clinical primary pharmacodynamics documentation is mostly limited to in vitro target binding of SelG1 and SEG101 as well as an in vitro assay supporting the inhibitory effect of crizanlizumab on neutrophil rolling. No functional models have been employed to substantiate the prevention of vaso-occlusion by crizanlizumab and thus, the proposed mode of action. The clinical data generated in SCD patients is limited, and in particular, data with the to-be marketed SEG101 is sparse; only preliminary PK/PD- and safety results from the ongoing study A2202 are available. The single pivotal study was performed with the earlier version SelG1 and extrapolation of efficacy results is thus essential. However, comparability between both versions was not firmly established in the initial submission dossier. The comparability study A2102 conducted in healthy volunteers showed an about 30% higher exposure for SEG101 vs. SelG1. Reliability of the comparative PD result was questioned since %P-selectin inhibition is lower in SCD patients than in healthy subjects and the chosen PD marker %P-selectin inhibition over 29 days seems rather insensitive for showing differences. Upon request, the applicant re-analysed samples from the initial registration study A2201 with the new Novartis PD assay and compared the results with the original results of study A2201. The reanalysis suggests that the observed differences in %P-selectin inhibition between SelG1 and SEG101 can most likely be attributed to differences between the different assays used in the different studies (A2201: Reprixys PD assay; A2202 and A2102: the new Navigate assay). Due to the critical findings of the GCP inspection of the pivotal phase II study, evaluation of the treatment effect of crizanlizumab based primarily on the CRC-adjudicated data is not considered sufficiently robust. The data collected at the sites, however, were found credible. Analyses using the investigator-based VOC rate are thus acceptable for the benefit-risk evaluation. Due to uncertainties regarding the statistical methodology, neither the pre-specified- nor the supplementary analyses provided in the second round of the procedure were suitable to reliably conclude on the magnitude of effect of 5 mg/kg crizanlizumab over placebo. The negative binomial regression model as wel l as the 'jump to reference' imputation (M6) were considered most appropriate to inform on the benefit of crizanlizumab. Additionally, re-analyses showing the effect of crizanlizumab in patients with and without HU/HC treatment were requested for a proper assessment of the therapeutic advantage of crizanlizumab over or in addition to the authorised treatment with HU/HC. 3.4. Unfavourable effects In study A2201, five patients died during the treatment period: two on 5 mg/kg crizanlizumab, one on 2.5 mg/kg and two patients died in the placebo arm. In the ongoing study A2202, one death has been reported in the 7.5 mg/kg treatment group. The investigators judged none of the deaths as drug related and all as consistent with causes of death in the SCD patient population. Rates of drug related serious adverse events were more frequent in the crizanlizumab groups of study A2201 but generally low (5mg/kg: 6 (9.1%); 2.5 mg/kg: 5 (7.8%); placebo: 2 (3.2%)). No drug related SAEs have been reported so far in study A2202. These events include cellulitis (infectious in origin), pyrexia, tooth infection, lower respiratory tract infection, pneumonia, atypical pneumonia, hypotension, bradycardia and deep vein thrombosis. They are consistent with adverse events of special interest (infections and effect on haemostasis). Medicinal product no longer authorised

Musculoskeletal and connective tissue disorders were consistently more commonly reported in crizanlizumab-treated patients, and a dose-response relationship was observed in this SOC class as well. All but two AEs in this class were of CTC grade less than 3.

<div style=\"page-break-after: always\"></div>

The most common adverse drug reactions were the following: oropharyngeal pain, nausea, abdominal pain, diarrhoea, vomiting, pruritus, arthralgia, back pain, myalgia, musculoskeletal chest pain, pyrexia, infusion site reaction, infusion related reaction. AEs of special interest have been identified based on the method of action of crizanlizumab: infections, infusion-related reactions, effects on haemostasis and immunogenicity. Although the overall rates of infections are balanced in study A2201 between arms (5mg/kg: 53.0%, 2.5mg/kg: 45.3% and placebo 53.2%), higher rates for grade ≥ 3 events have been observed in the verum arm (5mg/kg: 4 (6.1%); 2.5mg/kg: 3 (4.7%), placebo: 2 (3.2%)). In study A2202 the overall rate of infections is similar (22 (44.4%); grade ≥ 3: 5 (11.1%)). In the ongoing study A2202, an increased rate of pyrexia was observed compared to study A2201 (20.0%; A2201: 5mg/kg 10.6%, 2.5mg/kg 9.4%, placebo 6.5%). Drug related infection events were more common in the crizanlizumab arms of A2201 (5mg/kg: 6 (9.1%), 2.5mg/kg: 4 (6.3%), placebo: 2 (3.2%), A2202: 0). Adverse events related to infusion related reactions were more frequent in the Crizanlizumab arms in study A2201 (5mg/kg: 23 (34.8%); 2.5mg/kg: 20 (31.3%); placebo: 13 (21.0%)). In study A2202 the overall rate is comparable (14 patients, 31.1%). The majority of AEs were mild or moderate and transient in nature. The most common AEs were headache and nausea. A specific warning has been added in section 4.4 of the SmPC with regards to infusion-related reactions. In addition, infusion-related reactions has been added as an important identified risk in the safety specifications in the RMP. Increased rates for events related to a potential effect on the haemostatic system have been found for 5mg/kg crizanlizumab mostly as reported changes in laboratory values (5 mg/kg: 11 (16.7%), 2.5 mg/kg: 7 (10.9%), placebo: 8 (12.9%), A2022: 5 (11.1%)). An increase was also observed in activated partial thromboplastin time (13 patients 28.9%) and prothrombin intl. normalised ratio (9 (20.0%). Additionally, the only event of intracranial haemorrhage (SAE, grade 4, hospitalisation) was reported in the 2.5 mg/kg group of study A2201. In the crizanlizumab treatment arms, more patients showed decreased platelet counts (5mg/kg: 18.2%, 2.5mg/kg: 20.3%, placebo: 9.7%; A2202: 24.4%). However, this is most likely an artefact seen in vitro only due to platelet clumping in EDTA blood. A specific warning has been added in section 4.4. of the SmPC to mitigate the potential for laboratory test interference, it is recommended to run the test as soon as possible (within 4 hours of blood collection) or use citrate tubes. When needed, platelet counts can be estimated via a peripheral blood smear. In addition, this issue will be further clarified with data gathered in study A2301 since samples will be analysed with an improved method. A potential effect of crizanlizumab on platelet counts can therefore only be assessed when respective data from study A2301 becomes available. Two different versions of crizanlizumab have been used in the presented studies. Differences in the safety profile in HV and SCD patients have been observed between studies with different versions. An increased rate of pyrexia (20.0%) was found in study A2202 for SCD patients on 5mg crizanlizumab SEG101 compared to treatment with the same dose with version SelG1 (A2201: 5mg/kg 10.6%, placebo: 6.5%). Further, several changes in laboratory parameters (e.g. amylase, triglycerides, creatine kinase, magnesium), some of them grade 3 or 4, have only been observed in study A2202. Medicinal product no longer authorised

In the non-clinical toxicology programme, no maternal toxicity or developmental effects were observed, however, a considerable amount of foetal and infant losses occurred in the treatment groups at both dose levels (50% in each of the treatment groups vs. 12.5% in the control group). According to the applicant the cause is 'unclear and likely multifactorial'. Macroscopic evidence for placental infarcts was detected in 4 cases (2 in the

<div style=\"page-break-after: always\"></div>

10 mg/kg and 1 in the 50 mg/kg group). A recommendation regarding the use of crizanlizumab in pregnancy has been included into section 4.6 of the SmPC. In addition, a category 3 PASS  is planned (Crizanlizumab Pregnancy outcomes Intensive Monitoring (PRIM); enhanced pharmacovigilance program)) to estimate the proportion of pregnancies resulting in foetal loss (intrauterine death resulting in stillbirth, spontaneous abortion, or induced termination), among pregnant women exposed to crizanlizumab within 105 days prior to LMP or at any time during pregnancy. 3.5. Uncertainties and limitations about unfavourable effects Crizanlizumab is a first-in-class monoclonal antibody binding to P-selectin, thereby inhibiting interaction with its ligands. P-selectin is an adhesion molecule expressed on activated endothelial cells and platelets, and P-selectin inhibition is intended to reduce cell adhesion and thereby the risk of vaso-occlusive events in SCD. Although adhesion of multiple cells is a key factor in the pathogenesis of vaso-occlusive crises, it is not the only factor leading to VOCs. A direct relation between elevated P-selectin level and VOCs has not been established. It has been described, however, that P-selectin is expressed at higher levels in SCD patients, who are considered to be in a chronic pro-inflammatory state, and that P-selectin plays an essential role in the initial recruitment of leukocytes and the aggregation of platelets to the site of vascular injury during inflammation. The intended target P-selectin belongs to a family of adhesion proteins which are partially, albeit with lower affinity, also bound by the natural ligand of P-selectin, PSGL-1. It has not been addressed experimentally whether crizanlizumab binds unspecifically to other selectins (E- and L-selectin), potentially causing unwanted effects. The impact of a 100% inhibition of P-selectin on the physiological effects of P-selectin is not fully elucidated and potential adverse consequences thereof cannot be excluded. Inhibition of P-selectin might affect the innate immune response against infection and haemostasis. The applicant addressed this by defining AEs of special interest connected to the mode of action of P-selectin. The identified drug-related serious adverse events are consistent with complications of the underlying disease, but also correspond with adverse events of special interest (infections, effect on haemostasis). In the ongoing study A2202, an increased rate of pyrexia was observed compared to study A2201 (20.0%; A2201: 5mg/kg 10.6%, 2.5mg/kg 9.4%, placebo 6.5%). Although overall rates of infections are balanced between placebo and the crizanlizumab treatment arms, more severe infections and a higher rate of pyrexia that have been observed in patients on crizanlizumab. Most events occurred in the context of infections. Based on the presented data a direct association with crizanlizumab administration seems unlikely. However, the increased frequency of pyrexia and infections in general needs further clarification, requiring further data especially for long- term use, which will be generated in the planned phase 3 study and is a specific obligation to the Marketing Authorisation. Medicinal product no longer authorised

Higher rates for events related to a potential effect on the haemostatic system have been found for 5mg/kg crizanlizumab (5 mg/kg: 11 (16.7%), 2.5 mg/kg: 7 (10.9%), placebo: 8 (12.9%), A2022: 5 (11.1%)) mostly as reported changes in laboratory values. The majority of reported bleeding events occurred in the 5 mg/kg crizanlizumab group (5mg/kg: 7; 2.5mg/kg: 3; placebo: 4). Additionally, the only event of intracranial haemorrhage (SAE, grade 4, hospitalisation) was reported in the 2.5 mg/kg group of study A2201 and lead to study drug discontinuation. An increase was also observed in activated partial thromboplastin time (13 patients 28.9%) and prothrombin intl. normalised ratio (9 (20.0%). These parameters could be influenced by inhibition of P-selectin. No relation of the timing of the events with either time on study drug or time after last infusion was observed. Further, neither data is available for long-term use for more than one year nor for patients with an increased bleeding risk, e.g. concomitantly using anticoagulants. Currently a higher risk of effects on the

<div style=\"page-break-after: always\"></div>

haemostatic system cannot be ruled out based on the limited data. Data gathered in the phase 3 study A2301 could help to address this uncertainty. Further,  P-selectin  has  been  shown  to  play  a  role  in  muscle  repair.  Musculoskeletal  and  connective  tissue disorders were consistently more commonly reported in crizanlizumab-treated patients. Additionally laboratory values related to muscle damage (CK increased, Mg increased) have also been observed. However, no relation in terms of types of events, timing of other factors possibly connected to crizanlizumab were observed. Many events were confounded by mild traumas and pre-existing conditions. Further, no musculoskeletal events were connected with altered laboratory findings. However, no long-term data is available, but will be generated in the planned phase III study. In the pivotal study A2201, P-selectin inhibition of around 70% was obtained and only limited data is available from the ongoing single arm study A2202, performed with SEG101 and reaching 100% inhibition in SCD patients. Results of a reanalysis of the samples from the initial pivotal registration study A2201 conducted with the new Novartis assay (Navigate PD assay) indicate that the observed differences in %P-selectin inhibition between SelG1 and SEG101 can most likely be attributed to differences between the historical Reprixys PD assay originally used in study A2201 and the new Navigate assay. Updated safety data from study A2202 show overall comparable safety profiles between both studies, only some minor differences were observed. However, no long-term data over one year exist. The remaining uncertainties regarding the observed differences and the missing long- term data could be addressed with data collected in the planned phase III study. As a monoclonal antibody, crizanlizumab exhibits a potential for immunogenicity and infusion site reactions. Anti-crizanlizumab antibodies have been detected in ten SCD patients (of 175) in study A2201 of which two were treatment induced and eight had pre-existing ADAs. None have been detected in study A2202 so far. In healthy volunteers, three subjects tested positive for ADAs in Study A2101, two of them had pre-existing ADAs. One subject tested positive for treatment induced ADAs, which was transient. In Study A2102, one subject in the SelG1 (5 mg/kg) treatment group and another subject in the exploratory SEG101 7.5 mg/kg arm tested positive for ADA. The data from all four clinical studies so far indicate a low incidence of ADA formation. But no data for long term use is available. However, more data is required especially to assess the respective potential for SEG101. The information with regards to patients with severe renal impairment is very limited with only three subjects included in the registration study A2201. In response to the D180 LooI, the applicant showed that there are no noticeable AUC or trough concentration differences between renal function categories. Although comparable safety profiles between patients with different severities of the disease and patients with different genotypes have been observed, the size of the beneficial effect is still unclear and no long-term data is available. Long-term safety data will be provided as part of the specific obligations to the MA. Due to the very limited clinical data and the identified non-clinical safety signal of increased foetal and infant loss, a potential risk for pregnant patients cannot be ruled out. The applicant implemented a survey programme to ensure that data in relation to pregnancies are collected post marketing. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 3.6. Effects table

<!-- image -->

| Effect                                                | Short Descriptio n                                                                                                                                                                                                                              | Unit                                                                                                                                                                                                                                            | Treatme nt 5 mg/kg                                                                                                                                                                                                                              | Treatment 2.5 mg/kg                                                                                                                                                                                                                             | Control                                                                                                                                                                                                                                         | Uncertainties/ Strength of evidence                                                                                                                                                                                                             | Refere nces                                                                                                                                                                                                                                     |
|-------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                       | Favourable Effects (pre-specified Analyses) The initial submission of the efficacy analyses was performed on CRC-adjudicated data using the Hodges-Lehmann (HL) estimate as well as simple annualisation for imputation of missing data. longer | Favourable Effects (pre-specified Analyses) The initial submission of the efficacy analyses was performed on CRC-adjudicated data using the Hodges-Lehmann (HL) estimate as well as simple annualisation for imputation of missing data. longer | Favourable Effects (pre-specified Analyses) The initial submission of the efficacy analyses was performed on CRC-adjudicated data using the Hodges-Lehmann (HL) estimate as well as simple annualisation for imputation of missing data. longer | Favourable Effects (pre-specified Analyses) The initial submission of the efficacy analyses was performed on CRC-adjudicated data using the Hodges-Lehmann (HL) estimate as well as simple annualisation for imputation of missing data. longer | Favourable Effects (pre-specified Analyses) The initial submission of the efficacy analyses was performed on CRC-adjudicated data using the Hodges-Lehmann (HL) estimate as well as simple annualisation for imputation of missing data. longer | Favourable Effects (pre-specified Analyses) The initial submission of the efficacy analyses was performed on CRC-adjudicated data using the Hodges-Lehmann (HL) estimate as well as simple annualisation for imputation of missing data. longer | Favourable Effects (pre-specified Analyses) The initial submission of the efficacy analyses was performed on CRC-adjudicated data using the Hodges-Lehmann (HL) estimate as well as simple annualisation for imputation of missing data. longer |
| Annual rate of sickle cell related pain crises (SCPC) | Primary Endpoint                                                                                                                                                                                                                                | standard median of vaso-occlus ive crises Hodges-Le hmann median Treatment comparison (versus placebo) product                                                                                                                                  | 1.63 2.00 -1.01                                                                                                                                                                                                                                 | 2.01 2.50 -0.69 no                                                                                                                                                                                                                              | 2.98 3.49                                                                                                                                                                                                                                       | Uncertainties regarding statistical methodology (treatment effect estimate and handling missing data), concomitant medication                                                                                                                   | CSR study A2201                                                                                                                                                                                                                                 |
| Annual rate of days hospitalis ed Medicinal           | Key secondary Endpoint                                                                                                                                                                                                                          | standard median of days Hodges-Le hmann median Treatment comparison (versus placebo)                                                                                                                                                            | 4.00 12.48 0.00                                                                                                                                                                                                                                 | 6.87 9.01 0.00                                                                                                                                                                                                                                  | 6.87 13.00                                                                                                                                                                                                                                      | Uncertainties regarding statistical methodology (treatment effect estimate and handling missing data), concomitant medication                                                                                                                   | CSR study A2201                                                                                                                                                                                                                                 |

Table 21: Effects table for crizanlizumab ; indication: 'For the prevention of vaso occlusive crises in sickle cell disease patient s aged 16 years and over'; (data cut -off: 19-Oct-2018). The following table summarises the pre-specified efficacy results as well as requested re-analyses from the main study. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| Effect                                                          | Short Descriptio n                                                                                                                                                   | Unit                                                                                                                                                                 | Treatme nt                                                                                                                                                           | Treatment 2.5 mg/kg                                                                                                                                                  | Control                                                                                                                                                              | Uncertainties/ Strength of evidence                                                                                                                                  | Refere nces                                                                                                                                                          |
|-----------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Annual rate of uncompli cated SCPC                              | Secondary Endpoint                                                                                                                                                   | standard median of days Hodges-Le hmann median Treatment comparison (versus                                                                                          | 5 mg/kg 1.08 1.97 -1.00                                                                                                                                              | 2.00 2.01 -0.87                                                                                                                                                      | 2.91 3.00                                                                                                                                                            | Uncertainties regarding statistical methodology (treatment effect estimate and handling missing data), concomitant medication authorised                             | CSR study A2201                                                                                                                                                      |
| Time to first and second VOC                                    | Secondary Endpoint                                                                                                                                                   | placebo) Median time from randomisat ion to first VOC (months) Median time from randomisat ion to second VOC (months)                                                | 4.07 10.32                                                                                                                                                           | 2.20 9.20 no longer                                                                                                                                                  | 1.38 5.09                                                                                                                                                            | Uncertainties regarding statistical methodology (handling missing data), concomitant medication                                                                      | CSR study A2201                                                                                                                                                      |
|                                                                 | Favourable Effects (Requested Re-analyses) Re-analyses using investigator data, negative binomial regression and imputation method M6 ('jump to reference'). product | Favourable Effects (Requested Re-analyses) Re-analyses using investigator data, negative binomial regression and imputation method M6 ('jump to reference'). product | Favourable Effects (Requested Re-analyses) Re-analyses using investigator data, negative binomial regression and imputation method M6 ('jump to reference'). product | Favourable Effects (Requested Re-analyses) Re-analyses using investigator data, negative binomial regression and imputation method M6 ('jump to reference'). product | Favourable Effects (Requested Re-analyses) Re-analyses using investigator data, negative binomial regression and imputation method M6 ('jump to reference'). product | Favourable Effects (Requested Re-analyses) Re-analyses using investigator data, negative binomial regression and imputation method M6 ('jump to reference'). product | Favourable Effects (Requested Re-analyses) Re-analyses using investigator data, negative binomial regression and imputation method M6 ('jump to reference'). product |
| Annual rate of sickle cell related pain crises (SCPC) Medicinal | Primary Endpoint                                                                                                                                                     | Mean (±SD) Treatment comparison (versus placebo) RR (95% CI)                                                                                                         | 3.62 (4.122) 0.74 (0.52, 1.06)                                                                                                                                       |                                                                                                                                                                      | 4.95 (5.287)                                                                                                                                                         |                                                                                                                                                                      | D180 Clinical AR                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Effect                                       | Short Descriptio n     | Unit                                                                                         | Treatme nt                 | Treatment 2.5 mg/kg   | Control              | Uncertainties/ Strength of evidence   | Refere nces          |
|----------------------------------------------|------------------------|----------------------------------------------------------------------------------------------|----------------------------|-----------------------|----------------------|---------------------------------------|----------------------|
| Annual rate of days hospitalis ed due to VOC | Key secondary Endpoint | Mean (±SD) Treatment comparison (versus placebo) RR (95% CI)                                 | 17.31 (32.936) 0.72 (0.36, |                       | 24.41 (47.370)       | authorised                            | D180 Clinical AR     |
| Annual rate of uncompli cated SCPC           | Secondary Endpoint     | Mean (±SD) Treatment comparison (versus placebo) RR (95% CI)                                 | 3.39 (3.988) 0.72 (0.49,   | no longer             | 4.79 (5.492)         |                                       | D180 Clinical AR     |
| Time to first and second VOC                 | Secondary Endpoint     | Time to first VOC leading to healthcare visit (months) HR (95% CI) product                   | 3.78 0.54 (0.36, 0.81)     |                       | 1.15                 |                                       | CSR study A2201      |
| VOC-free                                     | Medicinal              | Number of patients who completed 1-year study period with no VOC leading to healthcare visit | 13 (20%)                   |                       | 5 (8%)               |                                       |                      |
| Unfavourable Effects                         | Unfavourable Effects   | Unfavourable Effects                                                                         | Unfavourable Effects       | Unfavourable Effects  | Unfavourable Effects | Unfavourable Effects                  | Unfavourable Effects |
| Death                                        |                        | Patients                                                                                     | 2 +1 7.5mg/kg              | 1                     | 2                    | A2201: RCT A2202: study ongoing       | SCS CSR A2201 A2202  |

<div style=\"page-break-after: always\"></div>

| Effect                            | Short Descriptio n     | Unit         | Treatme nt 5 mg/kg   | Treatment 2.5 mg/kg   | Control   | Uncertainties/ Strength of evidence        | Refere nces         |
|-----------------------------------|------------------------|--------------|----------------------|-----------------------|-----------|--------------------------------------------|---------------------|
| Drug related SAEs                 |                        | Patients (%) | 6 (9.1) 0            | 5 (7.8)               | 2 (3.2)   | A2201: RCT A2202: study ongoing authorised | SCS CSR A2201 A2202 |
| Drug related AEs                  |                        | Patients (%) | 27 (40.9) 10 (22.2)  | 21 (32.8)             | 15 (24.2) | A2201: RCT A2202: study ongoing            | SCS CSR A2201 A2202 |
| Infusion related reactions        | AE of special interest | Patients (%) | 23 (34.8) 14 (31.1)  | 20 (31.3)             | 13 (21.0) | A2201: RCT A2202: study ongoing            | SCS CSR A2201 A2202 |
| Effect on the haemosta tic system | AE of special interest | Patients (%) | 11 (16.7) 5 (11.1)   | 7 (10.9)              | 8 (12.9)  | A2201: RCT A2202: study ongoing            | SCS CSR A2201 A2202 |

Although results of the pre-specified primary and secondary analyses showed favourable effects of treatment with crizanlizumab, the magnitude of the clinical benefit was difficult to assess due to uncertainties regarding the statistical methodology. Additionally, as outlined in the GCP inspection report, evaluation of the treatment effect of crizanlizumab cannot be based primarily on the CRC-adjudicated data that are not considered sufficiently robust. Data collected at the study sites, however, are considered credible and analyses using the investigator-based VOC rate are acceptable for the benefit-risk evaluation. Therefore, taking into account the issues raised on statistical methodology and crises adjudication; re-analyses were provided for a better understanding of the crizanlizumab benefit.

Abbreviations: VOC = vaso-occlusive crises, SAE = serious adverse event, AE= adverse event, CSR = clinical study report, SCS = Summary of clinical safety 3.7. Benefit-risk assessment and discussion 3.7.1. Importance of favourable and unfavourable effects An alternative or add-on treatment to the present standard of care for SCD patients to reduce the rate of VOCs would be valuable, particularly as the current standard of care, Hydroxyurea, is not always well tolerated or accepted by patients and may yield insufficient response. Furthermore, it would be beneficial if intermittent symptomatic therapy of VOCs, such as painkillers or blood transfusions, could be reduced. The endpoints used in the pivotal study for primary (annual rate of VOCs leading to hospitalisation) and secondary analysis (annual rate of days hospitalised, time to first and second VOC, annual rate of uncomplicated VOC, annual rate of acute chest syndrome) are considered relevant outcomes for SCD patients. VOCs are a hallmark of the disease and represent a substantial burden for patients. VOCs increase morbidity and can result in organ failure, stroke and/or death (Bailey et al, 2019; Morgan et al, 2019). SCD patients describe them as excruciating and incapacitating events affecting all aspects of their life. Medicinal product no longer authorised

The provided re-analyses showed a beneficial effect on the risk of SCPC occurrence in the 5 mg/kg crizanlizumab arm compared to placebo. Although statistical significance could not be reached under the most conservative

<div style=\"page-break-after: always\"></div>

imputation method (worst-case scenario), the treatment effect estimate for the primary and secondary endpoints is systematically in favour of the 5mg/kg crizanlizumab dose over placebo. The lack of significance could be explained by the low power as the trial was originally planned to detect a 40% reduction in SCPC with approximately 90% power, using Wilcoxon's rank sum test (α=0.05), and only considered a 15% dropout rate. Further, using investigator data instead of adjudicated data could add some variability. Although power was already low for the significant original primary analysis based on annualised VOC rates, differences in rates decrease even more when using reference-based multiple imputation, which assumes that patients behave like in the reference group after discontinuing the trial. Annualised rates would form a hypothetical estimand, i.e. what would have happened if the patients had stayed in the trial, assuming patients are missing at random. On the other hand, the reference-based imputation for patients who discontinue the trial would form a treatment policy estimand corresponding more to what would be observed in clinical practice. The reported beneficial effects are considered clinically relevant for SCD patients. Efficacy of crizanlizumab was evaluated in one phase II study in patients with sickle cell disease. In the original primary analysis, 5 mg/kg crizanlizumab treatment led to a 45% reduction of the annual rate of sickle cell related pain crises (CRC-adjudicated), considering the ratio of the standard median of 1.63 VOCs in 5 mg/kg crizanlizumab group and 2.98 VOCs in the placebo group. However, although a beneficial effect on the risk of SCPC occurrence has been demonstrated, the results of the pre-specified primary analysis were not considered sufficiently robust to evaluate the magnitude of the treatment effect. According to the requested supplementary analyses, which were considered adequate for the benefit-risk evaluation, crizanlizumab (compared with placebo) reduces the number of VOCs leading to healthcare visits by 26% (3.62 vs. 4.95) and the predicted number of days in hospital due to VOC by 28% (~17 vs. 24 days). The hazard ratio of a time to first VOC is 0.54, with a difference in time to first VOC vs placebo of 2.6 months. Re-analysis of the proportion of patients who remained free of VOC until end of study indicates a favourable effect of crizanlizumab: the proportion of VOC-free patients was 3-times higher in the crizanlizumab 5 mg/kg arm compared with the placebo arm (20% vs 8%). The pivotal study A2201 was not powered to demonstrate differences between subgroups; nonetheless, subgroup analyses consistently suggest therapeutic benefit across all sub-populations. With regards to concomitant HU use, an unmet medical need mainly exists in patients not achieving sufficient therapeutic response with HU or who are unable to tolerate it, while patients not yet on HU, but eligible for HU have an approved and efficacious therapeutic option. Analyses of the primary endpoint for the individual genotypes (HbSS, HbSC) indicate a favourable trend of crizanlizumab over placebo across all genotypes. Medicinal product no longer authorised

Although minor analytical differences are observed between the version used in the pivotal study A2201 -SelG1 - and the version intended for commercialisation -SEG101 -a direct impact of these differences on PK, efficacy and safety is rather unlikely. Re-analysis of the A2201 study samples using the Novartis PD assay support the conclusion that the observed differences in %P-selectin inhibition between SelG1 and SEG101 are most likely attributable to the differences between the historical Reprixys PD assay and the new Navigate assay. Considering this, it is concluded that comparability between SelG1 and SEG101 has been sufficiently established. Preliminary efficacy and safety data from the ongoing study A2202 conducted with the to-be commercialised product SEG101 were provided and showed comparable results between study A2202 and study A2201 conducted with the Reprixys-manufactured product (SelG1). Only some minor differences concerning safety have been observed which could be addressed with more comprehensive data from the planned phase III study.

<div style=\"page-break-after: always\"></div>

From a safety perspective, only few concerns were identified and the majority of frequently observed safety signals appear manageable. A connection of crizanlizumab with AEs of special interest based on the mode of action of its target P-selectin, such as a higher rate of infections and a potential effect on haemostasis, can currently not be ruled out, especially for long term use. For the version intended for marketing -SEG101- safety data is extremely limited, coming from 45 patients treated with crizanlizumab in the ongoing study A2202 and 28 healthy subjects administered a single dose in study A2102. Data generated in study A2201 with the earlier version SelG1 indicate comparable safety results, however. For the full characterisation of the safety of crizanlizumab more comprehensive data are required, which will be generated in the phase III study. Long-term data (&gt;1 year) is missing, which would also be required to assess long-term consequences of an almost 100% inhibition of P-selectin. The open label extension of the phase III study will generate uncontrolled data for up to 5 years on crizanlizumab treatment. However, the number of patients is expected to be even more limited than discussed above. 3.7.2. Balance of benefits and risks The current standard of care for SCD patients is mainly preventive or symptomatic. The only curative treatment is haematopoietic stem cell transplantation, which is only an option for selected patients, mainly children and adolescents. Although the best results are obtained with a matched sibling donor, matched unrelated and haploidentical donors are alternative methods used recently, but are not the standard of care. Currently, the only treatment for a broader SCD population authorised in the EU for the prevention of VOCs is Hydroxyurea (HU; Siklos). However, HU is not well tolerated by some patients; others are not willing to accept the potential adverse events. Crizanlizumab could provide an alternative treatment option to meet the medical need of these SCD patients. The data submitted so far suggest that crizanlizumab has a more favourable safety profile and better tolerability compared with HU. Preventing VOC has the potential to increase life expectancy of SCD patients by reducing organ damage, to reduce the incidence of acute complications and emergency room-/hospitals visits and improve the quality of life. It is reported that SCD patients who experience ≥ 1 to 3 VOCs and ≥ 3 VOCs per year have a 2.7 and 5.7 times higher risk of death than patients with &lt;1 VOC annually (Bailey et al, 2019). Thus, the magnitude of the observed treatment effect on the primary and secondary endpoints is considered clinically relevant for SCD patients. The submitted re-analyses taking into account the issues raised on statistical methodology and crises adjudication are adequate to assess the clinical benefit of crizanlizumab. Although statistical significance could not be reached under the most conservative method (worst-case scenario), the treatment effect estimates for the primary and secondary endpoints are systematically in favour of crizanlizumab over placebo. The lack of significance could be explained by the conservative, reference-based imputation for around a third of patients who discontinue before the end of the trial. Considering the totality of evidence, efficacy has been established. Medicinal product no longer authorised

In the pivotal study, endpoints were appropriately chosen to allow assessment of the label claim. However, the major therapeutic advantage of crizanlizumab in patients not receiving HU/HC had been questioned. The applicant restricted the indication to patients with recurrent VOCs and proposed the following indication: 'Adakveo is indicated for the prevention of recurrent vaso -occlusive crises in sickle cell disease patients aged 16 years or older. It can be given as an add-on therapy to hydroxyurea/ hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC i s inappropriate or inadequate.'

The revised indication as add-on to HU or in case of intolerance to- or inappropriateness of HU is acceptable. The

<div style=\"page-break-after: always\"></div>

population in study A2201 reflects the claimed indication as investigators agreed that for the enrolled patients who did not receive HU/HC treatment, HU/HC was either inappropriate or they were identified as inadequately responding to HU/HC prior to study entry; thus, only a few subjects, if any, were truly HU/HC naïve. The applicant committed to document the reasons why HU is not used by a patient in the proposed confirmatory phase III study. Being able to offer an add-on modality to HU for patients who still experience VOCs or (mono-)therapy in patients for whom HU/HC is inappropriate or inadequate will provide a new treatment option to achieve a meaningful reduction of VOCs for patients who currently have no satisfactory treatment. Although the clinical data for subjects below the age of 18 years is limited (6 patients overall, 3 of them receiving 5mg/kg), an extrapolation from older patients is acceptable given the mode of action of crizanlizumab, similar disease manifestations and comparable PK. In the context of a CMA and the planned enrolment of at least 48 adolescents in study A2301, it is agreed that the indication of crizanlizumab includes SCD patients aged 16-18 years. Overall, the safety profile of crizanlizumab observed so far raises few concerns. Some uncertainties related to the intended 100% inhibition of the target P-selectin remain (i.e. long-term systemic effects, a higher risk of infections and a potential effect on haemostasis) but could be addressed and further investigated in the confirmatory phase III study. The applicant plans to generate comprehensive safety and efficacy data in the phase III study A2301 that started in 2019 (see discussion on CMA below). The study also plans for inclusion of 48 adolescents, presently only partly included in the indication (from 16 years onwards). Generation of the missing long-term data is planned in a 5-year open-label phase. 3.7.3. Additional considerations on the benefit-risk balance Conditional marketing authorisation As comprehensive data on the product are not available, a conditional marketing authorisation was requested by the applicant in the initial submission. The product falls within the scope of Article 14-a of Regulation (EC) No 726/2004 concerning conditional marketing authorisations, as it aims at the treatment of a seriously debilitating disease. SCD is debilitating, life-threatening and systemic disease regardless of patient age. It is still associated with decreased life expectancy SCD patients, although the current SoC improved the overall quality of life and life expectancy in the last decades. Further, crizanlizumab was designated as an orphan medicinal product EU/3/12/1034 on 9 Aug 2012 in the following condition:  Treatment of sickle cell disease. Furthermore, the CHMP considers that the product fulfils the requirements for a conditional marketing authorisation: Medicinal product no longer authorised

- The benefit-risk balance is positive, as discussed above.
- It is likely that the applicant will be able to provide comprehensive data.

<div style=\"page-break-after: always\"></div>

The applicant plans to generate comprehensive safety and efficacy data with a phase III study A2301. This multicentre, placebo-controlled, parallel, double blind clinical study in SCD patients 12 years of age and older started in H2 2019; results of the primary analysis are planned to be available in 2025. The design was adapted based on Scientific Advice from the SAWP/CHMP: 240 patients (including at least 48 adolescents) will be randomised 1:1:1 to treatment with crizanlizumab 5 mg/kg, 7.5 mg/kg, or placebo. The study is planned for one year, with an open label extension (5 years on investigational treatment). Stratification factors, inclusion and exclusion criteria are planned to be similar to study A2201. In addition to confirming the efficacy and safety data of crizanlizumab in the 5 mg/kg dose, this study is planned to assess whether a higher dose (7.5 mg/kg) of crizanlizumab could further reduce the frequency of VOCs. The primary objective is to compare the efficacy of crizanlizumab and placebo based on the annualised rate of VOC leading to a healthcare visit, in addition to standard of care. The key secondary objective is to compare the efficacy based on the annualised rate of all VOCs (whether managed at home or leading to healthcare visit). Among other secondary objectives, the study will investigate SCD-related renal damage, the PK/PD of crizanlizumab 5.0 and 7.5 mg/kg and the safety and immunogenicity of crizanlizumab over the study period. Since the study will be performed mainly in countries outside the EU, where crizanlizumab is not marketed yet, the applicant claims that the feasibility to perform the study as a placebo-controlled trial after marketing authorisation is maintained. They expect that enrolment of the 240 patients will take about 2.5 years. There was some doubt whether the envisaged study size/amount of data will ultimately be sufficient for a conclusive assessment. Assuming a similar dropout rate as in study A2201, we could expect additional data for about 55 patients on the 5mg/kg dose (80 enrolled per arm). Considering a lower dropout rate, such as observed in study A2202, about 70 patients would presumably finish the first year of treatment. The applicant implemented measures to reduce early dropout, which seem reasonable, but since they have not been applied in any of the submitted studies, their effectiveness cannot be judged. Concerning long-term data, dropout will certainly occur during the 5-year observation phase, but patients switching from placebo to crizanlizumab after 1 year will contribute additional data. Furthermore, safety data from the 7.5mg/kg crizanlizumab arm will be valuable for addressing remaining uncertainties. Taking all these aspects into account, it can reasonably be assumed that study A2301 will be able to generate comprehensive data. Furthermore, submission of final results from study A2202 is expected (included as a second condition to the MA). · Unmet medical need will be addressed. A significant unmet medical need exists in SCD for more effective and well-tolerated treatments. Current treatment is preventive, symptomatic or not well tolerated/accepted. Further, despite current treatment many patients with SCD still experience VOC. Curative treatment (HSCT) is only an option for selected young patients with a haploidentical donor and is not the standard of care. Thus, there remains a significant unmet medical need in this patient population. Crizanlizumab exhibits a new mode of action compared to existing treatments offering an alternative to HU or add-on treatment option. Medicinal product no longer authorised

HU represents the current SOC. It is approved in all EU Member States for 'the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults, adolescents and children older than 2 years suffering from symptomatic Sickle Cell Syndrome'. Thus, evidence was requested that crizanlizumab provides 'a major therapeutic advantage' over HU in the initially sought indication 'prevention of VOC'. The applicant

<div style=\"page-break-after: always\"></div>

restricted the indication to 'add -on therapy or as monotherapy in patients for whom HU/HC is inappropriate or inadequate'. It is acknowledged that for patients already taking HU ('add -on') representing the majority of patients in the phase II study, no other authorised medicinal products are available. For patients for whom HU/HC is inappropriate or inadequate, no authorised treatments are currently available either. Therefore, unmet medical need exists in the population targeted by the modified indication. · The benefits to public health of the immediate availability outweigh the risks inherent in the fact that additional data are still required. SCD patients have a high unmet medical need and few therapeutic options. Therefore, an immediate availability of treatment alternatives has the potential to reduce the immediate disease burden (VOCs) and has the potential to reduce the incidence of acute complications and consequently extend life expectancy and quality of life for patients with SCD. A conditional marketing authorisation would enable SCD patients to get access to crizanlizumab well in advance compared to when the drug would become available to them after submission of the phase III data from study A2301 (results of the primary analysis are planned to be available in 2025). Crizanlizumab has a favourable safety profile and the sole important identified risk for crizanlizumab of infusion-related reaction can be adequately addressed via routine risk minimisation measure (i.e. appropriate labelling). Therefore, making crizanlizumab available to patients while collection of comprehensive efficacy and safety will be ongoing in the controlled phase 3 study A2301 is not expected to represent a risk to public health. Given the limited treatment options, a high unmet medical need in SCD patients, the debilitating nature of the disease, the observed favourable treatment effects and the observed safety profile, it can be concluded that immediate availability of the drug will outweigh the risks inherent in the fact that additional data are still required. 3.8. Conclusions The overall B/R of Adakveo is positive. 4. Recommendations Outcome Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Adakveo is favourable in the following indication: ' Adakveo is indicated for the prevention of recurrent vaso occlusive crises (VOCs) in sickle cell disease patients aged 16 years and older. It can be given as an add on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate. ' The CHMP therefore recommends the granting of the conditional marketing authorisation subject to the following conditions: Medicinal product no longer authorised

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

<div style=\"page-break-after: always\"></div>

## Other conditions and requirements of the marketing authorisation

| Description                                                                                                                                                                                                                                                                                                     | Due date                                              |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|
| In order to further confirm the efficacy and safety of crizanlizumab, the MAH should submit the results of the primary analysis of a phase III CSEG101A2301 study of crizanlizumab with or without hydroxyurea/hydroxycarbamide in adolescent and adult sickle cell disease patients with vaso-occlusive crises | Clinical study report primary analysis: December 2025 |
| In order to further confirm the efficacy and safety of crizanlizumab, the MAH should submit the final results of the phase II CSEG101A2202 study of crizanlizumab with or without hydroxyurea/hydroxycarbamide in sickle cell disease patients with vaso-occlusive crisis                                       | Clinical study report: December 2025                  |

<!-- image -->

Periodic Safety Update Reports The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. Conditions or restrictions with regard to the safe and effective use of the medicinal product Risk Management Plan (RMP) The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP. An updated RMP should be submitted: · At the request of the European Medicines Agency; · Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached. Additional risk minimisation measures None. Specific obligation to complete post-authorisation measures for the conditional marketing authorisation This being a conditional marketing authorisation and pursuant to Article 14-a of Regulation (EC) No 726/2004, the MAH shall complete, within the stated timeframe, the following measures: Description In order to further confirm the efficacy and safety of crizanlizumab, the MAH should submit the results of the primary analysis of a phase III CSEG101A2301 study of crizanlizumab with or without hydroxyurea/hydroxycarbamide in adolescent and adult sickle cell disease patients with vaso-occlusive crises Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

Conditions or restrictions with regards to the safe and effective use of the medicinal product to be implemented by the Member States Not applicable. New active substance status Based on the CHMP review of the available data, the CHMP considers that crizanlizumab is a new active substance as it is not a constituent of a medicinal product previously authorised within the European Union. Paediatric data Furthermore, the CHMP reviewed the available paediatric data of studies subject to the agreed Paediatric Investigation Plan P/0060/2019 and the results of these studies are reflected in the Summary of Product Characteristics (SmPC) and, as appropriate, the Package Leaflet. Medicinal product no longer authorised